sbfm_10q.htm

0001354488-14-004103.txt : 20140812 0001354488-14-004103.hdr.sgml : 20140812 20140812172635 ACCESSION NUMBER: 0001354488-14-004103 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140812 DATE AS OF CHANGE: 20140812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52898 FILM NUMBER: 141035082 BUSINESS ADDRESS: STREET 1: 469 JEAN-TALON WEST STREET 2: 3RD FLOOR CITY: MONTREAL STATE: A8 ZIP: H3N 1R4 BUSINESS PHONE: 514-764-9698 MAIL ADDRESS: STREET 1: 469 JEAN-TALON WEST STREET 2: 3RD FLOOR CITY: MONTREAL STATE: A8 ZIP: H3N 1R4 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 10-Q 1 sbfm_10q.htm QUARTERLY REPORT sbfm_10q.htm

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

Quarterly Report Under

the Securities Exchange Act of 1934

For Quarter Ended: June 30, 2014

Commission File Number: 000-52898

SUNSHINE BIOPHARMA INC.

(Exact name of small business issuer as specified in its charter)

Colorado		20-5566275
(State of other jurisdiction of incorporation)		(IRS Employer ID No.)

469 Jean-Talon West

3rd Floor

Montreal, Quebec, Canada H3N 1R4

(Address of principal executive offices)

(514) 764-9698

(Issuer’s Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o

Non-accelerated filer	o	Smaller reporting company	þ
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes þ No

The number of shares of the registrant’s only class of common stock issued and outstanding as of August 12, 2014, was 68,270,961 shares.

TABLE OF CONTENTS

PART I.

FINANCIAL INFORMATION

		Page No.

Item 1.	Financial Statements	3
	Consolidated Balance Sheet as of June 30, 2014 (unaudited)	3
	Unaudited Statement of Operations for the Six Month Period Ended June 30, 2014	4
	Unaudited Consolidated Statement of Cash Flows for the for the Six Month Periods Ended June 30, 2014 and 2013	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation.	11
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	17
Item 4.	Controls and Procedures.	18

	PART II
	OTHER INFORMATION

Item 1.	Legal Proceedings	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	19
	Signatures	19

Sunshine Biopharma, Inc.
Balance Sheet

	Unaudited			Audited
	June 30,			December 31,
	2014			2013
ASSETS

Current Assets:

Cash and cash equivalents	$	38,411		$	31,240
Prepaid expenses		5,640			-

Total Current Assets		44,051			31,240


TOTAL ASSETS	$	44,051		$	31,240

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:

Current portion of note payable		282,500			12,500
Accounts payable		93,874			23,809
Interest payable		5,898			2,641

TOTAL LIABILITIES		382,272			38,950


SHAREHOLDERS' EQUITY

Preferred stock, $0.10 par value per share;
Authorized 5,000,000 Shares; Issued
and outstanding -0- shares.		-			-

Common Stock, $0.001 per share;
Authorized 200,000,000 Shares; Issued
and outstanding 65,965,728 and 60,299,061 at
June 30, 2014 and December 31, 2013 respectively		65,966			60,299

Capital paid in excess of par value		6,409,606			5,426,140

Accumulated other comprehesive (Loss)		-			-

(Deficit) accumulated during the development stage		(6,813,793	)		(5,494,149	)

TOTAL SHAREHOLDERS' EQUITY		(338,221	)		(7,710	)

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	44,051		$	31,240

See Accompanying Notes To These Financial Statements.

Sunshine Biopharma, Inc.
Unaudited Statement Of Operations


	Unaudited			Unaudited
	3 Months			3 Months
	Ended			Ended
	June 30,			June 30,
	2014			2013

Revenue:	$	-		$	-

General & Administrative Expenses

Accounting		32,020			1,620
Financial Consulting		60,000			64,500
Legal		169,405			75,000
Licenses & fees		70,000			5,655
Office		7,983			5,665
Public relations		100,000			-
Research & development		323,000			-
Stock Transfer Fee		3,105			153

Total G & A		765,513			152,593

(Loss) from operations	$	(765,513	)	$	(152,593	)

Other (expense) interest		(52,875	)		(375	)

Net (loss)	$	(818,388	)	$	(152,968	)

Basic (Loss) per common share		(0.01	)		(0.00	)

Weighted Average Common Shares Outstanding		65,468,255			56,564,063

See Accompanying Notes To These Financial Statements.

Sunshine Biopharma, Inc.
Unaudited Statement Of Operations


	Unaudited			Unaudited
	6 Months			6 Months
	Ended			Ended
	June 30,			June 30,
	2014			2013

Revenue:	$	-		$	-

General & Administrative Expenses

Research and Development		323,000			23,400
Accounting		37,200			5,400
Consulting		326,000			684,610
Legal		214,777			24,689
Licenses		153,333			325,000
Office		12,889			8,279
Merger Cost		-			-
Public Relations		100,000			-
Stock Transfer Fee		4,188			1,606
Writedown of intangible assets		-			-

Total G & A		1,171,387			1,072,984

(Loss) from operations		(1,171,387	)		(1,072,984	)

Other (expense):
Interest expense		(148,257	)		(5,705	)
Beneficial conversion feature		-			(548,951	)

Total Other (Expense)		(148,257	)		(554,656	)

Net (loss)	$	(1,319,644	)	$	(1,627,640	)

Basic (Loss) per common share	$	(0.02	)	$	(0.03	)

Weighted Average Common Shares Outstanding		63,309,853			54,248,411

See Accompanying Notes To These Financial Statements.

Sunshine Biopharma, Inc.
Unaudited Statement Of Cash Flows


	Unaudited			Unaudited
	6 Months			6 Months
	Ended			Ended
	June 30,			June 30,
	2014			2013
Cash Flows From Operating Activities:


Net (Loss)	$	(1,319,644	)	$	(1,627,640	)

Adjustments to reconcile net loss to net cash used in
operating activities:

Stock issued for licenses, services, and other assets		860,800			636,310
Stock issued for payment interest on notes payable		75,000			5,086
Stock issued for payment of expenses		43,333
Beneficial conversion feature on note conversion		-			548,951
(Increase) Decrease in prepaid expenses		(5,640	)		(2,030	)
Increase (Decrease) in Accounts Payable		70,065			(302	)
Increase in interest payable		3,257			619

Net Cash Flows (used) in operations		(272,829	)		(439,006	)

Cash Flows From Investing Activities:


Net Cash Flows (used) in Investing activities		-			-

Cash Flows From Financing Activities:

Proceed from note payable		160,000			463,000
Note payable used to pay expenses		60,000			-
Note payable used to pay origionation fees		50,000			-
Sale of common stock		10,000			-

Net Cash Flows provided by financing activities		280,000			463,000


Net Increase (Decrease) In Cash and cash equivalents		7,171			23,994
Cash and cash equivalents at beginning of period		31,240			132,638

Cash and cash equivalents at end of period	$	38,411		$	156,632

Supplementary Disclosure Of Cash Flow Information:	$	-

Stock issued for services, licenses and other assets	$	593,400		$	576,310
Stock issued for note conversions	$	-		$	513,000
Stock issued for net deficit of MWBS	$	-		$	-
Stock issued for interest	$	170,000		$	-
Stock issued for payment of expenses	$	43,333		$	-
Loan proceeds used to pay expenses	$	40,000		$	-
Cash paid for interest	$	-		$	-

See Accompanying Notes To These Financial Statements.

Sunshine Biopharma, Inc.

Notes To Unaudited Financial Statements

For The Six Month Interim Period Ended June 30, 2014

Note 1 – Nature of Operations/Activities

Mountain West Business Solutions, Inc. (“MWBS”) was incorporated August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009 MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. The financial statements represent the activity of Sunshine Etopo, Inc. from August 17, 2009 (inception) through October 15, 2009, and the consolidated activity of Sunshine Etopo, Inc. and Sunshine Biopharma Inc. from October 15, 2009 forward. Sunshine Etopo, Inc. and Sunshine Biopharma Inc. are hereinafter referred to collectively as the "Company". The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.

During the last six month period the Company has continued to raise money through stock sales and borrowings.

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s current technology before another company develops a similar technology and drug.

Note 2 – Unaudited Financial Information

The unaudited financial information included for the six month interim period ended June 30, 2014 was taken from the books and records without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations for the six month interim period ended June 30, 2014 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2014.

Note 3 – Notes Payable

The Company had outstanding loans of $12,500 accruing interest at a rate of 12% and $100,000 accruing interest at 10%. At June 30, 2014 and December 31, 2013 accrued interest was $5,898 and $2,641, respectively.

Sunshine Biopharma, Inc.

Notes To Unaudited Financial Statements

For The Six Month Interim Period Ended June 30, 2014

Note 4 – Issuance of Common Stock

During the six months ended June 30, 2014 the Company issued 5,666,667 shares of $0.001 par value Common Stock as follows:

In January 2014 the Company issued 200,000 shares of $0.001 par value Common Stock for cash of $40,000 or $0.20 per share and was paid directly to an affiliated company for licensing rights.

In January 2014 the Company issued 600,000 shares of $0.001 par value Common Stock for R&D services valued at $96,000 or $0.16 per share.

In February 2014 the Company issued 66,667 shares of $0.001 par value Common Stock for cash of $13,333 or $0.20 per share and $3,333 was paid directly to an affiliated company for licensing rights.

In March 2014 the Company issued 10,000 shares of $0.001 par value Common Stock for services valued at $1,400 or $0.14 per share.

In March 2014 the Company issued 1,000,000 shares of $0.001 par value Common Stock for services valued at $170,000 or $0.17 per share.

On March 27, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for origination fee valued at $75,000 or $0.15 per share as part of a convertible note payable for $100,000.

On April 14, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for services valued at $100,000 or $0.20 per share.

On April 17, 2014 the Company issued 1,700,000 shares of $0.001 par value Common Stock for services valued at $323,000 or $0.19 per share.

Sunshine Biopharma, Inc.

Notes To Unaudited Financial Statements

For The Six Month Interim Period Ended June 30, 2014

Note 4 – Issuance of Common Stock (Continued)

On April 25, 2014 the Company issued 400,000 shares of $0.001 par value Common Stock for services valued at $60,000 or $0.15 per share.

On May 15, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for services valued at $80,000 or $0.16 per share.

On June 12, 2014 the Company issued 190,000 shares of $0.001 par value Common Stock for services valued at $30,400 or $0.16 per share.

Note 5 – Convertible Notes

March 27, 2014 the Company issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $100,000 plus 500,000 Common shares (paid) and $20,000 (unpaid) for origination fee. This Convertible Note accrues interest at the rate of 10% per annum and is convertible at the option of the Holder into shares of the Company’s Common Stock at $0.20 per share on or before September 27, 2014. Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon Conversion, the stock may be valued at either the book value or the market value of the bonds.

May 7, 2014 the Company issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $500,000. The note proceeds are payable on an as needed basis. During the quarter ended June 30, 2014 $100,000 was disbursed. This Convertible Note accrues interest at the rate of 10% per annum beginning in three months from the date issued and is convertible at the option of the Holder into shares of the Company’s Common Stock at $0.20 per share on or before September 27, 2014.

Sunshine Biopharma, Inc.

Notes To Unaudited Financial Statements

For The Six Month Interim Period Ended June 30, 2014

Note 5 – Convertible Notes (Continued)

Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon Conversion, the stock may be valued at either the book value or the market value of the bonds.

Note 6 – Financial Statements

For a complete set of footnotes, reference is made to the Company’s Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission and the audited financial statements included therein.

PART I.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

Overview and History

We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.” During our fiscal year ended July 31, 2009 our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies. Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation (“SBI”), in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock (the “Agreement”). As a result of this transaction our officers and directors resigned their positions with us and were replaced by our current management. Following completion of this transaction we changed our name to “Sunshine Biopharma, Inc.”. On December 21, 2011, Advanomics Corporation, a privately held Canadian company (“Advanomics”), and our licensor, exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.

Our principal place of business is located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada H3N 1R4. Our phone number is (514) 764-9698 and our website address is www.sunshinebiopharma.com.

We have not been subject to any bankruptcy, receivership or similar proceeding.

Results Of Operations

Comparison of Results of Operations for the six months ended June 30, 2014 and 2013

For the six months ended June 30, 2014 and 2013 we did not generate any revenues.

General and administrative expenses during the six month period ended June 30, 2014 were $1,171,387, compared to general and administrative expense of $1,072,984 incurred during the six month period ended June 30, 2013, an increase of $98,403. This relatively modest increase is the net result of an increase in the cost of some operations and a decrease in others. The operations which saw a decrease in cost include (i) consulting fees of $326,000 incurred during the 2014 period compared to $684,610 incurred during the similar period in 2013; and (ii) license fees of $153,333 payable to Advanomics Corporation were incurred during the six months period of 2014 compared to $325,000 incurred in the same period of 2013. Expenses which increased in the six months period ended June 30, 2014 compared to the same period of 2013 include (i) $323,000 in research and development costs in the six months ended June 30, 2014, compared to $23,400 during the similar period in 2013; (ii) $214,777 in legal fees incurred during the six months ended June 30, 2014, compared to $24,6894 during the six months ended June 30, 2013, primarily as a result of our attempts to re-domicile into Canada, several registration statements we filed with the SEC and the cost of defending against litigation; and (iii) $100,000 in public relations costs incurred during the six months ended June 30, 2014, compared to nil for the similar period in 2013. Most of our other expenses remained relatively constant during the six months ended June 30, 2014 compared to the similar period in 2013.

We also incurred $148,257 in interest expense during the six months ended June 30, 2014, compared to $5,705 in interest expense during the similar period in 2013. Finally, in the six months ended June 30, 2013 we incurred $548,951 in costs associated with a beneficial conversion feature to our then outstanding convertible debentures. No such costs were incurred in 2014.

As a result, we incurred a net loss of $1,319,644 (approximately $0.02 per share) for the six month period ended June 30, 2014, compared to a net loss of $1,627,640 (approximately $0.03 per share) during the six month period ended June 30, 2013.

Comparison of Results of Operations for the three months ended June 30, 2014 and 2013

For the three months ended June 30, 2014 and 2013 we did not generate any revenues.

General and administrative expenses during the three month period ended June 30, 2014 were $765,513, compared to general and administrative expense of $152,593 incurred during the three month period ended June 30, 2013, an increase of $612,920. This increase is attributable increased costs across the board, including (i) $323,000 in research and development (R&D) activities undertaken during the three months ended June 30, 2014, compared to no costs associated with R&D during the similar period in 2013; (ii) increase in legal fees of approximately $94,405 arising from the filing of registration statements with the SEC during this period, as well as the costs of defending litigation brought against us; and (iii) increase of approximately $30,000 in accounting fees, $65,000 in licensing fees, and $100,000 in public relations costs. We also incurred $52,875 in interest expense during the three months ended June 30, 2014, compared to $375 in interest expense during the similar period in 2013.

As a result, we incurred a net loss of $818,388 (approximately $0.01 per share) for the three month period ended June 30, 2014, compared to a net loss of $152,968 (less than $0.01 per share) during the three month period ended June 30, 2013.

Because we did not generate any revenues since our inception, following is our Plan of Operation.

Plan of Operation

We are currently a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The preclinical studies for our lead compound, Adva-27a, a multi-purpose antitumor compound, were successfully completed in late 2011. We are now continuing our clinical development of Adva-27a by conducting the next sequence of steps comprised of Good Manufacturing Practice (“GMP”) manufacturing, Investigational New Drug (“IND”)-enabling studies, regulatory filing and Phase I clinical trials. We plan to conduct our Phase I clinical trials for Adva-27a at the Jewish General Hospital, Montreal, Canada, one of McGill University’s Hospital Centers. The planned indication will be pancreatic cancer in parallel to multidrug resistant breast cancer as Adva-27a has shown a positive effect on both of these cancer types for which there is currently little or no treatment options available. See “Clinical Trials” below.

We have licensed our technology on an exclusive basis from Advanomics Corporation, and we are planning to initiate our own research and development program as soon as practicable once financing is in place. There are no assurances that we will obtain the financing necessary to allow us to implement this aspect of our business plan, or to enter clinical trials. See Part I, Item 2, Management's Discussion and Analysis of Financial Condition-Liquidity and Capital Resources below.

Carbon-Difluoride Platform Technology

Many therapeutically important compounds contain diester bonds that link different parts of the molecule together. Diester bonds are naturally unstable often leading to suboptimal performance when the molecule is administered to patients. Diester bonds have specific six-dimensional, as well as electrostatic properties that cannot be easily mimicked by other bonds. Bonds that do not mimic the diester bond correctly invariably render the compound inactive. In collaboration with Institut National des Sciences Appliquées de Rouen in France (“INSA”), Advanomics Corporation has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a diester isostere. An isostere is a different chemical structure that mimics the properties of the original. In the body, Carbon-Difluoride compounds are resistant to metabolic degradation but recognized similarly to the diester compounds (see Figure 1).

Figure 1

While no assurances can be provided, we are planning to expand our product line through acquisitions and/or in-licensing as well as in-house research and development.

Our Lead Compound (Adva-27a)

Our initial drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. If we are successful in our current financing efforts, Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast cancer in mid to late 2015 (see “Clinical Development Path” and “Clinical Trials” below). Etoposide, which is also a derivative of Podophyllotoxin, is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Like Etoposide, Adva-27a is a Topoisomerase II inhibitor; however, unlike Etoposide and other anti-tumor drugs currently in use, Adva-27a is able to destroy multidrug resistant cancer cells. Adva-27a is a new chemical entity and has been shown to have distinct and more desirable biological properties compared to Etoposide. Most notably, Adva-27a is very effective against multidrug resistant breast cancer cells while Etoposide has no activity against this aggressive form of cancer (see Figure 2). In other side-by-side studies against Etoposide as a reference, Adva-27a showed markedly improved cell killing activity in various other cancer types, particularly prostate, colon and lung cancer (see Table 1). Our preclinical studies to date have shown that:

●	Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
-		Breast Cancer Cells (MCF-7/MDR)

-	Small Cell Lung Cancer Cells (H69AR)
-	Uterine Cancer (MES-SA/Dx5)

●	Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.

●	Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.

●	Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.

●	Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).

●	Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.

●	Adva-27a does not inhibit tubulin assembly.

These and other preclinical data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The manuscript entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” appeared in print in the October 2012 issue of the journal [ANTICANCER RESEARCH 32: 4423-4432 (2012)]. A copy of the full manuscript as it appeared in the journal is available on our website at www.sunshinebiopharma.com.

Figure 2

Table 1

Clinical Development Path

The early stage preclinical studies for our lead compound, Adva-27a, were successfully completed in late 2011 and the results have recently been published [ANTICANCER RESEARCH 32: 4423-4432 (2012)]. We are now continuing our clinical development program of Adva-27a by conducting the next sequence of steps comprised of the following:

●	GMP Manufacturing of 1 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials
●	IND-Enabling Studies
●	Regulatory Filing (Fast-Track Status Anticipated)
●	Phase I Clinical Trials (Multidrug Resistant Breast Cancer Indication)

Clinical Trials

Adva-27a’s initial indication will be pancreatic cancer and multidrug resistant breast cancer for which there are currently little or no treatment options. In June 2011 we concluded an agreement with McGill University’s Jewish General Hospital in Montreal, Canada to conduct Phase I clinical trials for this indication. All aspects of the planned clinical trials in Canada will employ U.S. Food and Drug Administration (“FDA”) standards at all levels. As a result of the Dutchess Agreement described below, we now anticipate that Phase I clinical trials will commence in mid to late 2015 and we estimate that it will take 18 months to complete, at which time we, together with our licensor, expect to file for limited marketing approval with the regulatory authorities in Canada and the FDA in the U.S. See “Marketing,” below.

Marketing

According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. Given the terminal and limited treatment options available for the multidrug resistant breast cancer indication we are planning to study, we anticipate being granted limited marketing approval (“compassionate-use”) for our Adva-27a following receipt of funding and a successful Phase I clinical trial. There are no assurances that either will occur. Such limited approval will allow us to make the drug available to various hospitals and health care centers for experimental therapy and/or “compassionate-use”, thereby generating some revenues in the near-term.

We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to buyout or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant capital in order to manufacture and market our new drug.

Intellectual Property

We are the exclusive licensee for the U.S. territory of Advanomics Corporation’s Adva-27a which is covered by international patent applications filed on April 27, 2007 (PCT/FR2007/000697). These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation. On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and compositions.

Our Lead Anti-Cancer Compound, Adva-27a, in 3D

Subsequent Events

On July 25, 2014, we formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. While no assurances can be provided, we anticipate that Sunshine Biopharma Canada will soon rent office and warehouse space, secure a pharmaceutical establishment and export license from Health Canada and proceed to signing manufacturing, marketing, sales and distribution contracts for various generic pharmaceuticals and biomedical products. This new effort broadens our business scope and provides us with the opportunity to generate revenues in the near to mid-term. We anticipate revenues to be generated through the export of generic pharmaceuticals overseas. In addition to revenue generation, we anticipate that as a result of these activities, Sunshine Biopharma Canada will then be well positioned for the marketing and distribution of Adva-27a, our flagship oncology drug candidate currently being developed for the treatment of pancreatic cancer and multidrug resistant breast cancer, provided that Adva-27A is approved for such marketing and distribution, of which there can be no assurance.

In addition, on August 7, 2014, we elected to issue our initial put notice to Dutchess, wherein we requested that Dutchess purchase 930,233 shares of our Common Stock for $100,000. Upon receipt of these funds we intend to utilize the proceeds from the sale of these shares to repay debt. We anticipate that the proceeds from the next put notice shall be utilized to commence IND studies on our Adva-27a drug.

Government Regulations

Our existing and proposed business operations are subject to extensive and frequently changing federal, state, provincial and local laws and regulations. We will be subject to significant regulations in the U.S. in order to obtain the approval of the FDA to offer our product on the market. The approximate procedure for obtaining FDA approval involves an initial filing of an IND application following which the FDA would give the go ahead with Phase I clinical (human) trials. As a result of the Dutchess Agreement described below, we now anticipate that this process will commence in mid to late 2015 and we estimate that this procedure will take 18 months to complete. Following completion of Phase I, the results are filed with the FDA and a request is made to proceed to Phase II. Similarly, following completion of Phase II the data are filed with the FDA and a request is made to proceed to Phase III. Following completion of Phase III, a request is made for marketing approval. Depending on various issues and considerations, the FDA could provide limited marketing approval on a humanitarian basis if the drug treats terminally ill patients with limited treatment options available. As of the date of this Report we have not made any filings with the FDA or other regulatory bodies in other jurisdictions. We have however had extensive discussions with clinicians at the McGill University’s Jewish General Hospital in Montreal where we plan to undertake our Phase I study for multidrug resistant breast cancer they believe that Health Canada is likely to grant us a so-called fast-track process on the basis of the terminal nature of the cancer which we will be treating. There are no assurances this will occur.

Liquidity and Capital Resources

As of June 30, 2014, we had cash or cash equivalents of $38,411.

Net cash used in operating activities was $272,829 during the six month period ended June 30, 2014, compared to $439,006 for the six month period ended June 30, 2013. The decrease is primarily due to a beneficial conversion charge of $548,951 incurred during the six months ended June 30, 2013 which we did not incur during the similar period in 2014. However, stock issued for services, stock issued for payment of interest on notes payable, and stock issued for payment of expenses all increased significantly during the 6 months ended June 30, 2014. We anticipate that overhead costs in current operations will increase in the future once our research and development activities discussed above increase.

Cash flows from financing activities were $280,000 for the six month periods ended June 30, 2014, compared to $463,000 during the six months ended June 30, 2013. Cash flows used by investing activities were $0 for the six month periods ended June 30, 2014 and 2013.

In June 2012, we conducted a private placement of our Common Stock for the purposes of supporting our working capital whereby we sold 250,000 shares at a price of $0.20 per share and received proceeds of approximately $50,000 therefrom.

Between July and October 2012, we conducted a private placement of our Common Stock to fund our drug development program whereby we sold 1,410,000 shares of our Common Stock at a price of $0.25 per share and received proceeds of approximately $352,500 therefrom.

In December 2012, we commenced a private offering of Convertible Notes. We issued nine Convertible Notes to six accredited investors (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $513,000. These notes accrued interest at the rate of 6% per annum and were convertible at our option into shares of our Common Stock at $0.20 per share on or before June 30, 2013. We elected to convert these notes with interest accrued thereon and issued an aggregate of 2,590,426 shares of Common Stock to these investors. The Convertible Notes were considered to have a beneficial conversion feature and under ASC 470-20-25-10 the beneficial conversion feature was calculated to be $548,951 in total based on the issuance date and the share price on that date. This amount was booked to interest expense and Additional Paid in Capital for the period as all of the Convertible Notes were converted by June 30, 2013.

During the six months ended June 30, 2014 we conducted a private placement of our Common Stock for the purposes of supporting our working capital whereby we sold 266,667 shares at a price of $0.20 per share and received proceeds of approximately $53,333 therefrom.

On March 27, 2014, we issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $100,000 plus 500,000 Common shares (paid) and $20,000 (unpaid) for origination fee. This Convertible Note accrues interest at the rate of 10% per annum and is convertible at the option of the Holder into shares of our Common Stock at $0.20 per share on or before September 27, 2014. Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon conversion the issued stock may be valued at either the book value or the market value of the note.

On May 7, 2014, we issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $500,000. The note proceeds are payable on an as needed basis. During the quarter ended June 30, 2014, $100,000 was disbursed. This Convertible Note accrues interest at the rate of 10% per annum beginning in three months from the date issued and is convertible at the option of the Holder into shares of the Company’s Common Stock at $0.20 per share on or before September 27, 2014. Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon conversion, the stock may be valued at either the book value or the market value of the bonds.

We are not generating revenue from our operations, and our ability to implement our business plan for the future will depend on the future availability of financing. Such financing will be required to enable us to further develop our drug research and development capabilities and continue operations. We estimate that we will require approximately $5 million in debt and/or equity capital to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital. During the six months ended June 30, 2014, we did, on April 23, 2014, enter into an Investment Agreement (the “Investment Agreement”) with Dutchess Opportunity Fund, II, LP (“Dutchess”), for the sale of up to $2.5 million of shares of our Common stock over a three-year commitment period. Under the terms of the Investment Agreement, we may, from time to time and in our sole discretion, issue shares of our Common stock to Dutchess at a price equal to ninety percent (90%) of the lowest daily volume weighted average price during a Trading Day of our Common Stock during the five (5) consecutive Trading Days immediately preceding the Put Notice Date, up to $2.5 million. In connection with the Investment Agreement, we also issued to Dutchess an engagement fee in the form of 400,000 “restricted” shares of our Common Stock.

The amount of each tranche under the Investment Agreement is limited to maximum $100,000 and we may only issue a Put Notice (as defined under the Investment Agreement) ten (10) Trading Days after each prior Put Notice Date. We are not obligated to utilize any of the $2.5 million available under the Investment Agreement and there are no minimum commitments or minimum use penalties.

The Investment Agreement does not impose any restrictions on our operating activities. During the term of the Investment Agreement, Dutchess is prohibited from engaging in any short selling or hedging transactions, either directly or indirectly, related to our Common Stock.

As a material term of the Dutchess Agreement, we were required to register the 400,000 shares of our Common Stock already issued to Dutchess, as well as 13,000,000 additional shares of our Common Stock reserved for issuance upon our drawing down funds pursuant to the Investment Agreement. We filed the registration statement with the SEC on May 22, 2014 and it became effective July 23, 2014. After completing various other procedural requirements we are now in a position to commence the process of drawing down on the $2.5 million financing available under the Investment Agreement to fund our operations and our Adva-27a development program. Despite this agreement there can be no assurances that we will have sufficient capital to complete the implementation of our business plan, as we currently estimate we will need up to $5 million to do so. We expect to raise the additional capital necessary to fully implement our business plan either by the sale of our securities, or through generating revenues as described in Plan of Operation above. There are no assurances that either scenario will be successfully implemented. As of the date of this report we have not reached any agreement with any party that has agreed to provide us with the additional capital we think may be necessary to fully implement our business plan, or whether we will generate sufficient revenues to allow us to do so. Our inability to obtain additional sufficient funds from external sources if and when needed may have a material adverse effect on our plan of operation, results of operations and financial condition.

Our cost to continue operations as they are now conducted is nominal, but these are expected to increase in the near future once we commence Phase I clinical trials. We do not have sufficient funds to cover the anticipated increase in these expenses. We need to raise additional funds in order to continue our existing operations, to initiate research and development activities, and to finance our plans to expand our operations for the next year. If we are successful in raising additional funds, our research and development efforts will continue and expand.

Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the six month period ended June 30, 2014.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures - Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of June 30, 2014, at the reasonable assurance level. We believe that our consolidated financial statements presented in this Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations - Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting - There were no changes in our internal control over financial reporting during the six month period ended June 30, 2014, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are a defendant to one outstanding matter of litigation but believe we have reached a settlement, which requires that we arrange to deliver 650,000 shares of our common stock.. We are not party to any other material legal proceedings, nor have any such actions been threatened against us.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On May 7, 2014, we issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $500,000. The note proceeds are payable on an as needed basis. During the quarter ended June 30, 2014, $100,000 was disbursed. This Convertible Note accrues interest at the rate of 10% per annum beginning in three months from the date issued and is convertible at the option of the Holder into shares of our Common Stock at $0.20 per share on or before September 27, 2014. Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon conversion, the stock may be valued at either the book value or the market value of the bonds.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURE

Not Applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on August 12, 2014.

	SUNSHINE BIOPHARMA, INC.

	By:	s/ Steve Slilaty
		Dr. Steve N. Slilaty,
		Principal Executive Officer


	By:	s/ Camille Sebaaly
		Camille Sebaaly, Principal Financial Officer and
		Principal Accounting Officer

EX-31.1 2 sbfm_ex311.htm CERTIFICATION sbfm_ex311.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Steve N. Slilaty, certify that:

I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 12, 2014	/s/ Steve N. Slilaty
	Steve N. Slilaty, Chief Executive Officer

EX-31.2 3 sbfm_ex312.htm CERTIFICATION sbfm_ex312.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Camille Sebaaly, certify that:

I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 12, 2014

/s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer

EX-32 4 sbfm_ex32.htm CERTIFICATION sbfm_ex32.htm

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-Q for the six month period ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 12, 2014	/s/ Steve N. Slilaty Steve N. Slilaty, Chief Executive Officer

Dated: August 12, 2014	/s/Camille Sebaaly Camille Sebaaly, Chief Financial Officer

GRAPHIC 5 img001.jpg begin 644 img001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W2ZN?LS(` MN[=GC./2J_\`:A_YXC_OO_ZU)JC9>''HW]*\9\3^,->L/$E_:6M]Y<$3X13$ MAP,#U&:QK5HTE>1A7KJBN:1[/_:C?\\1_P!]_P#UJ/[4;_G@/^^S_A7A:^*_ M&3[66ZN")(VF3%JF"BGDYV]!@_E3HO$WC6>S-W'/<-;`%C,MNFT`=3]RL?KD M.S.;^T::^RSW'^U&_P">`_[[_P#K4?VH?^>`_P"^_P#ZU>!_\)WXF7@ZHQ_[ M81__`!-'_">^)1Q_:9/OY,?_`,34_7Z?9D_VG2[,]]_M4_\`/`?]]_\`UJ/[ M5/\`SP'_`'W_`/6KP+_A//$V1_Q-#_WYC_\`B:/^$]\2?]!)O^_,?_Q-'U^G MV8?VG2[,]\_M0_\`/`?]]_\`UJ/[4/\`SQ'_`'W_`/6KP/\`X3SQ+_T$3_WZ MC_\`B:/^$\\2_P#03/\`WYC_`/B:/K]/LP_M2CV?]?,]]_M4_P#/`?\`??\` M]:C^U3_SP'_??_UJ\!'CSQ,/^8H3_P!L8Q_[+2_\)YXESC^TV_[]1G_V6CZ_ M3[,/[3I=F>^_VJ?^>`_[[_\`K4?VJ?\`G@/^^_\`ZU>!'QWXE!_Y";?C!&/_ M`&6C_A._$P_YB9/_`&RC_P#B:/K]/LP_M.EV9[[_`&HW_/$?]]__`%J/[4?_ M`)XC_OO_`.M7@/\`PGGB;_H)G_OQ'_\`$TO_``G?B4Y(U4C_`+81_P#Q-'U^ MGV8_[1I/HSWW^U&_YX#_`+[_`/K4?VHW_/`?]]__`%J\!7QUXF'!U9B?7R(_ M_B:7_A//$V/^0F?^_,?_`,31]?I]F+^TZ79GOO\`:I_YX#_OO_ZU']JG_G@/ M^^__`*U>!?\`"=^)5X.IEO?R8_\`XFC_`(3SQ+G_`)"1_P"_,?\`\31]?I]F M']ITNS/??[4;_G@/^^__`*U']J-_SP'_`'W_`/6KP+_A/?$IZZD5_P"V$?\` M\32?\)YXFS_R%#_WYC_^)H^OT^S#^TZ79GOW]JG_`)X#_OO_`.M1_:I_YX#_ M`+[_`/K5X%_PGGB7H-3/U\F/_P")H'CWQ+_T$S_WYC_^)H^OT^S#^TZ79GOG M]J'_`)X#_OO_`.M1_:A_YXC_`+[_`/K5X'_PGGB;_H)'_OW'_P#$T'QYXFSC M^TS_`-^8_P#XFCZ_3[,/[4H]F>^_VHW_`#P'_??_`-:C^U&_YX#_`+[_`/K5 MX#_PGGB7_H)G_OS'_P#$T?\`">>)O^@F?^_,?_Q-'U^GV8?VG2[,]]_M1O\` MG@/^^_\`ZU']J-_SP'_??_UJ\"_X3SQ-_P!!,_\`?F/_`.)H_P"$\\3?]!,_ M]^8__B:/K]/LP_M.EV9[]_:A_P">(_[[_P#K4?VHW_/$?]]__6KP$^//$V,_ MVH>__+"/_P")I6\>>)@,C4SUZ_9TQ_Z#1]>IOHQ_VE2[,]\_M1O^>`_[[_\` MK4O]J-_SQ'_??_UJ\NU#4->M;+4[A=:D*VUK;S1?+`S;I-N=RA<@)BM;,U>,@NC/3O[4;_`)X# M_OO_`.M1_:C?\\!_WW_]:O`QX]\2@'.I.QQG_41X'X[:0^._$P/_`"%2?4>3 M'_\`$UF\=3ZIF3S&FNC/??[4;_G@/^^__K4O]JM_SQ'_`'W_`/6KP+_A//$V M1_Q,V_[\Q_\`Q-!\>>)0/^0JV`_P"^ M_P#ZU']J-_SP'_??_P!:O`_^$]\2@8_M)B?4PQ__`!-!\>>)>G]ID>_DQ_\` MQ-'U^GV8?VG2[,]].J,/^6(_[[_^M1_:A_YXC_OO_P"M7@/_``G7B?@#5C]? M(C_^)H_X3OQ-G_D+'_OQ'_\`$T?7Z?9FLL9!4U4:=GZ'OO\`:C?\\1_WW_\` M6H_M1O\`G@/^^_\`ZU>!GQWXFZ_VH1[>5'_\32?\)YXF'34\Y]8H^/\`QVCZ M_3[,R_M.EV9[[_:C?\\!_P!]_P#UJ/[4;_G@/^^__K5X'_PG?B;K_:G_`)"C M_P#B:0>/?$P.?[3)'IY,?_Q-'U^GV8?VG2[,]^_M5_\`G@/^^_\`ZU207YFE M6,Q;<]]V>WTKQ[P7XIUK5/$D5K?7QF@:-V*>6B\@<<@`UZM8_P#'XGX_R-=- M*M&I'F1UT*\:T>:)-JG6'Z-_2OG[QEN_X2[5`O\`ST_H*^@M4^]#]&_I7SYX MSQ_PEVI\_P#+7^@KEQ_P(X\S_AKU-NUUO3X[*SAE,#2)I$\32LS!E<[\)P<< MY7MWJ;2]6L8X])O6U:".&RL7AGM&)#,Y#8(7H0=R_E7!*,D>Q`$@$@8'K M[UY_MG:QYGUAVM8VM,LO#UU:I%=ZC>6-X>KO;AH1\W3@[LX[GBK!\&ZE(I?3 MI[/4HQDD6LVY\`X^Z0#Z>W/6N=+*`1D8[\YI4=D.$)7/=3BES1?Q1(YXOXHD M]U9W5A.8;RVE@D'.V12.AP:K9)^[T_.NO\/:YJ&JWG]AZG?2SVE[%)"#.V[: MY!*G)Y/(X&>O%M''7//I69D&">W;O2]L_P_E28SU.*7ON#8.*```CU(/H,BDQ@]/TQ2YW M'DC\2:3ZGXTCW>'H8>KC52Q'PRT^?3\1 M"<]"/^^J4_>SV/J:7!Z@'![A12D%+!SJ495NB\A6.#AF&?9LTF#CVIE(*,>O%!QDX-`AWX?^."DQ['\L4=OX?Q)HX_V?S-`"44=^,?A1 M0`=J#1V-!Z_Y]:``]#^-.^;!P>/][!IIZ=?6EP#_`!GZ4#-:Y\17ERMX)1$! M=P1P28!!")C&/?Y:FN/%.HW%E+`R6ZR2Q+!).L>)'C7HI;]/?%88)'`'7V%' MJ35\[[ENI+N;=CXHOK&R2Q,%G=V:#"07-LK*.@-;;G M!,EE<$8!SGY6R/PXKF^N?E4_CR*"23D\'&.1BFJC12JRZZFQK6F6MG;6%]82 M7$EG>QNR^>@\P,K;3D`D`=,5D,#@?>'X8K>M\WG@>ZC7#/87BSX#8PKC:?PR M%QCU-8!./_UFBHMFA5$KIH#CDMC'^]R:3Y,^_P#]:E'/())]`M&3T9<5F9`< MKUZ?_6H&3P.IQVH`YXY]OPI-V".:`#YAP2>12X..:3<1@Y_,4=\Y'-`!P.G3 M'>E!XYY'UQ^E+_#GG)YQ2`FD?3Y;@Z6.P-52D^:FFTNGF)\O8?-3AQVX[\4F M0QQW'84$;C\P.?<4'SD8.W67_'VGX_R->(_#I2/&$`P?]5)_ M"!VKVZR_X^T_'^1KV,#_``OF=^6_P7ZDVJ?>B^C?TKY]\9_\C=J??][T'T%? M06J_>A^C?TKY]\:''B_4_P#KK_05./\`@7J3F?\`#7J8)4KR`0/0FESG'3_" MCKP1^N*FM%@:]@2Y+"W:11*T?W@N1DKGO7E+4\1*^A$"2`UM-?6WF0J-EZA"MD<,KKP1@@]._6L^Y\':W:1^=':-=P'D2V<@E M4\XXQSU[XJW2DC25&2V,:VN#:W,-Q&^UXI%=2I(.5(8<_45K>*X4BU^6YC&( M+T+=1<<%9!DX^A)'X5BN)%RCAU..5+#/Y5OZDPU'PIIU\0?.LY&LY&')V9#H M3T"\$@<<`'G('WB3G']:FM;.[OW*65 MI/<,`6Q#&6./P'O6:3>QDHM[(KJ%[C/TI"4SSQ]:W+GPGJUE:27%Y';V^%9A M'<7"J[@#)VC.3^'-=??+,-.U(,L`T+^RT-JZA<&;:N,=]V[=D>F*UC2;U9I& MBVFV>:D\\>W'I0!W[\+3&@J,E@N/0DT[*@<;.?7-.$4JCA),@=CQ3/G.=S$^Q& M:9ZF*IJMBYUZBY8MW=_/M\P(!Y`Y]:!R.>?I2#ZC\JGAMWN;B*"'!>5PB`_W MCP!^HHMT,L7F+JQ5&BN6"V2_4A/KT/K02O?)/O6KXBTFWT7419179N)HTQ<$ MQE`C]P,]1[UEY?)X_P#K?C3E'E=CRI1<79B$C'&#],_UHX]"/][_`.M75>%? M"4VM6\VHSP32V4&0L43KOG?^Z/0<\FJS^"/$N]BND2!2>`&7_&M/8SM>QI[" M=KV.>R>VZE^;T?\`(5T'_""^)3UTB3/^^O\`C2_\(-XD_P"@0_\`WTO^-+V< M^Q/LI_RLYWGT/XXI*Z/_`(0;Q+_T"7_[Z7_&D_X0?Q)_T")?^^E_QI>SGV#V M4_Y6<[QT^E';-=(?!7B8H$_LB3`R1RG?\?:FGP-XD_Z!$O\`WTO^-/V<^P>R MG_*SGN*0[>PKMG\!7\GA\3Q6#M7E-A=Z'$(#/*WFVR3QJ\/#-9E\1:A'8Z=.T)F+I(XVIM8Y&"3R>>1U&.>: MITY..Q4J,^38Y3*GA1^)HP.A8#Z9KHAX7MK<9U37M/MQSE+=C3M=Q6MM:('EF M<%NIPH`'4D\4W5M+.D7RP-,LT;QK+%*O`=&`(/Y5?@\0VB->12:0D5A=PK%+ M!!,P^96W!@S9Y[?A4>L27.MQ'5X;816-N(K0('W&,!?E)SV[9JG&/+9;E.,. M6RW,+C/6CU/'%![$9&1GD9H^7OUK$P',<+CC/X\4G)Z>M.'&KE.(G1Q'N*Z::?FFM1I)Z$].U)[8"T\J&^XO&.`._/^>]- M(NCB*>$3G#6;^Y+_`#%(YYY/Z4A9`.0I/UQ_.C`R`#GZ?4JU,14YIN[9M?#DG_A,(,G'[J3UZ8KV^Q_X^T_ M'^1KS6RA*_$RTG6XBF@N;,RV[1PB/;&00%([D;?K7I5CS=H?7/\`(U[&$CRP M:/9P$>6FUYDVJ??A^C?TKY_\:;?^$MU+U\WG\A7T!JG6+Z-_2OGWQF&/BW4^ MP\[T]A48_P"!>IEF?\->IA,`>`/TI,%ATQ^.:!O`X)P?>G$E3G'_`'S\OZUY M)XAT+$ZYX8+L@-_I*`%N29+8D]NGR$\^QYK%M;V[LK@36EU/!(.\;E2.<,,'^=7(]>\,MIUS9OI- MY;+=%2\4$ZE%=22&7>,@X..>,&N0^Z<#J.PXK3T33H]3NIA/*8;:&%Y9Y0!\ MH`XS]6('UI1J2N.%6=]-33/B/2[)Q_97ANR0AB1->.T[>QQP!^9JK<^+]=NH MO+.H20Q@?/ MQYI\U1Z(%*I+1?@8KNSR,SL[,Q)9B>2?4GO4MG/';7T$\T"3Q1N&>-P<..XQ M[]/RI]U975A<&"[MIH903PZ$>V>F<57+CL>>W-0VT]3-N2>J-37]*&FZB3"S M/9SJ)K60G[T9Z?B.A%97;..?:NCTD#6]&?1I23=P,UQ8$`MOXR\?X]?J#Z\\ MX!^0[XQQ3E'JASCUZ"@!O3I],5I1Z#J\VF?;X]/N'M.A<1DY'/..N.O/0<5? MTC2=,DT>34M5NKB.#SS:[8$5O*8KD.^2#CD\8S\IJ?7M=BCGTTZ+J-P[VEHM MO).JM$&VDXX/.<'Z9I^SLKR-(4^51F%%]';6] M8%N)GC2!6GWX^E5M.U_5M+(%I?31J!CRB^Y#QW4\&NHL!%JV MGS>(I[4&YM6$?DZ2!!+GJ9)#Z<<<5K",'(RIQIRD9?C#4K>\^P6*->275BCQ M37%Y&$D<<8!'MSUK!LTMGO[<7K.+4R*)0AR=F><#'I5GQ!J@UG7;G4EB,(F8 M,$+;B.`.N!Z5FDYZC\N,5$YWG\VE)&!9&RC:2 M(1YX.0/O$]<\YSVK&/AC7QP-%O1SU$3?X58T/Q&;&TETR^,LFES`DK$VUX6[ M/&?7/4=*R9+Z\\QPMY<[=QQF4Y_G5R<'J7.5-ZZE[_A%_$&/^0+?]_\`E@U' M_"+Z_P#]`6__`/`9JH?;[W!'VV?O_P`M#_C2_P!H7W.+ZX_[[/\`C47AYF?/ M#S^__@%S_A%M>_Z`U[_X#-2_$MK_P#T!K['_7%A5/[???\`/Y<_]]'_`!IO MVZ]SG[9/GWF8?UHO3\Q\U/S+O_"+Z_\`]`:_Z?\`/%J7_A%M?X_XE%\.O_+% MJH_;;WM>7/3_`)ZG_&E^WWW_`#^W&>W[T^OUHO3\QKGC58%N[0RK`-9,1_M!(.4#_P`)_P![&C34+6'Q!`D:"X;R[Q%.2D^3SC.<-@D=.:YTCL0W;@]JV?#VIQV%S+;WC/\` MV=>1F*Z5>?\`=8#U!(/YU4U;3)M'U*6RFVYC(VONX=>JMQZCG\:TDK^\C224 MES(JP3SVDBRP2212#I)'(5*^O(J:XU.^NXU2[O;B=`=P6:9I`#ZX/>FV%LU_ M?VUK']Z:58QM()^8@5TNJZ.=;UR_O8;O3K2TCE:)9);E4&(P%S@<\@9Z=Z(P M;01A*2.2SD8\P8^E'W>CYKIO[.$Z>P%WJEUJ,HY9+*(*@..FYCR,]Q4:2>$ M9E*366J69_ADCF2;CW&!BCV;[C=+NTCGA[9SZ9Q6MX?U.+3[UX;I!]@NU\FZ M0X)V_P!\<=5/(-77\,V%SG^R?$-E.^&=]1CJ0P/?(P:I[> M<[=WKS71QH/$'A[R\+]OTJ/.>IDM\G(Q_L''/H?:K&F^$I&M+6^GU"S@GEC6 MYM[68[1*H/(,A^4$\>O'I3=-MZ#]C*>V,\UM^(/%NJV'B"]MM,U0 MO:"0E"`C[-P!*JV.`#QP<<5Q9:1R6))8]26/^>].;BH\J-'45+2'Q+J6K'4K M[3;H7=G.890-H9<#(^E;(\46FH'&N:-;7/K<6^8)>2>3MX/Y"N:)`.,<_049 M8GG=C/%9QFT8NM-MW=[G2#2-`U$L^FZVMJQZ0ZD@3G`/^L'R^O85H^'=-NM` MUYX+Q62XN(?+MKJV1;@1,S`;\`]P#[]ZXSD+GD#H&*X]>E=]X82[F\&744$- M_IY@62YCO;?").0N=KG@GH`,9X/M6])J4KV-Z-IRT6J'Z(;X?%$V^H7KWDML MDD(F<8)4`X^G4UZM9?\`'VGX_P`C7B7P]D9_&<+LY=FCDRQ.23@U[99?\?:? MC_(UZ&$=X-^9Z>`ES0D_-EC5/O1?1OZ5\]^,<#QCJAW8_>]OH*^A-5^]#]&_ MI7SYXS*#Q?J8XSYO/?L*SQ_P(SS+^&O4P3@\[C^-*HVC@%O]T4$J"/E/XT`% MB-N!Z]J\D\,<,YSAL#MM%=%I!DU_0Y=$9B]W;DSV(D;&X]'CR3CD:TM$C@N(Y)+=`RINAC^7)!/!PI)SWS6 ML$[7-Z::5[:$K>&;>P4G6]9MK209_P!'@_?R@\9R%X'7N1TJ222/0M#@M_*6 MX>_G6Z9'&`UNC$1AL?WCDX]JKZ#X=O;NYL;^2W3["'$I:0AB\:-"[>)[@_((?+C,"`8V1%057`X'!'_U^M:-)1YDK&G*HPYTK=!Y\9ZE; MQ"+3+:TTN/`S]EA&6/NS9)K#N;V\NYS/(']*:J2ZE*K*UGJ=3;:7I9O(KO1?$L$4Z M-YL4=\AA*D'(!;H?S%=/%X8\GQ2E[-IR>3=VY.]=KQ6=QALL5Y!7(XSQS7EQ M('49S4B331(\:2R(CXWJ&(#?7UJU5BEJBXUHI?";6J^+;S5M.^R3VEHA=D>> M:./:TK+G!8=,\FL(<^X)YI,'`.>,9QFC;D;@O'L>]9RDY,QG-S>H;@0HYXQU MH)+_: M"L<)<8VLH&.,X&2.Y!H_SFBXKBEZGG]*+A<3`SG(_,T=LY[4X;B`1N_`"FGWSGWHN,7/M28R>]&,G\J7( M'!VGZYH$!&,9)(]^*..PP/4$F@8;@`#/I2G*_>)*^AH`1MP`&,?45O6WB=H+ M.W@ETJPNI;>(Q0SW*%BJDG`QT(!)[5B;2B`G`5C@?7K]/3\Z;L(P3[52DXEQ MDXZ';:'XCU+5+YY;N5/L>G6[W?V>)`B!D4A-H`X.YLX/!Q7%-*\C&1R2S$L2 MPVY-;MGFR\$ZA/N`:^N$MEW<@JF7;&.A^[U[$U@#Y1A3U[@UI-OE5S6I)N,4 MP()ZAAZ<4F`,XY!Z]J4A1U`;Z4;?13CZBL3"XGH<]L?K5^QUK5-,8?8K^X@` M.=J.=I/3D=#^-4<_K1S]"*:DUL-2:V.LL/'NHP7:7%Y9V=[(@`$DD(64#H?G M49Z$BL[7-;MM6M[&VL]/^Q6UKY@">=YF=[!NI`Q@YZUB9Z*>2.:-PP,],<"K M]K)JS-'6FURL..><9HP.N['UXI#CK@T?+GIQ69B*&&,$9]\T<$?=7KUS1AFY M#?+1E@2`QQ0`JX`R-N<^M=EKJOJ7@K3M3FCEMI;98X$5IPTI/]*TA/EN:0GRI^9U7P['_%8V^>/W3\8_V:]NLO^/M/ MQ_D:\2^'?_(XP9Z^6_\`Z#7MUE_Q]I^/\C7JX'^&>UEO\)EC5,9B^C?TKR;Q M#X`UC5-=O+VWGM!%,^5$CL#T`Z!3_.O6=4^]%]&_I6?6]6E&HK2.NO0A5C:1 MY$OPQU_&#/IP'L[_`/Q%._X5CK>#NN+`'MB5_P#XFO6\45A]1IG/_9U+L>:: M#\/M8TW7;.]GN;0PP3+(PCD8G`YZ;:Z"'PYJ4,5K!OM/*BM;F!R0-V^0N5P2 MN0/F&<'UXKJZ*TAAH15D:0PE."LCD].\)SV\^BW1_\*NUOK]HL/\`OM__`(FC_A5VMG_EXL?^^W_^ M)KURBCZE3#^SJ1Y'_P`*NUK_`)^;'/\`UT;_`.)H_P"%7ZY_S\V/_?UO_B:] M1_\`"K]QY M&?AEKIZ7%@3WS*__`,30?AAKG7[1I^>W[U\?^@UZY11]2I"_LZEV.`C^'\LD M&CV=P\!LX"[W85VW.['^$XZ8"_K5:#X8,5T\3S*"KN;TQR,=RY^0)QC/KDUZ M1SZG\Z.P'ITJOJE(OZC1[')0>$F@MQ:0ND-I)#<0RP^;O";_`+KJ=HRW`!SV MZ5QY^&&ODC_2=/(_VI&R/_':]=R?4T4/!TY;A+`T9'D1^&.NCA;G3RO^U(_' M_CM+_P`*PUW_`)^=._"1O_B:]YL/\`OXW_`,32'X8Z MZO*W&GD^\C__`!->NYH_$T?4J0?V=2['D?\`PK'7\Y^T:=D^DC__`!%'_"L? M$'_/?3_^_C__`!%>N44?4J0?V=1['D?_``J[7,$FYL`?3S7_`/B:4_"_6\<3 MZ>?K(_\`\37K=%'U&F']G4CR,?##7?\`GXT_';$C?_$T#X8ZZ3AI].Q[2O\` M_$UZY11]1IA_9U+L>?>$O`VJ:'X@BOKJ:U:%$88B=BQR,=U%>DV/_'VGX_R- M5ZL6/_'XGX_R-=%.FJ:M'8ZJ-&%%24B5ED0%BBGDG/./2NKG9U@D:./S'5240$`L0.@SZ],^]<#;:5K\*VT%Q MIUY/9V\OF1V_GVZ*&R2,D')P3ZUA5DU)6/3P%.$H2YVEJM]VK/:_R.BC\46D M5JKSNTLCR2`".$J0J,0QP2>!QDYY["K(\2Z>]W%!#YTQ=4;=%&6"J_W2>_\` MGDUR%SHA\60;+E[FVFA\JY-O$N,F4X_GQG\: MM1>([*>6TB@2>62Z#%%5/N[6"L&]",_I7+7&D:M<>>K:%-A[@W,:M/`P5B"& M&"?F4YJU:0:O975G<#P_*6MX9(MBSVZ*VX@DX!`'2FJDKZ_DR)X/#N-TU?U7 M8T/$^O7&DWME!%I..E5+?3-GYFD<+0E1C%MH M0QB:?="9L1IG"@[6SZ8-5=6\6VUMIMQ-8!YY8[=9@WEED7<,KNQTS61%I^K0 M'*:%=9%M)`VZYA);>VXM][KG/M5>71];:TDMX]*O(XYK=()@+B##[!@')/!Q MZ4_:2M_P&3'!X=2NVK+S7];'H:G*@^HI:BM7D>TB>:$PR%`6C)!*'TR./RJ7 MCCZ_Y_K72GH>).*4FD%%'844R`HHHH`****`"BBB@`JK?7#V\2"(`RRR+&N> M<$]_PJU5+4D>:%8EM7G!.=R2*A0_4U=-7D<^);C3DX_U]PJ275M'(UT5F5=N MUHEVDY/.0:C75HG5-L,K,\ACV+C*D#)[\U0-K MU.@MKJ&2-UTZ9BDC.,S(,D@`_3UKJ]E#?]4>8L36NHQBTO-._P"1;M]2;S'2 M>-@/M#1+(!\HYX!YSFI%U.)L'RY51@=DC`8?'7'/7BL];>Z\[>;&X9#*9MAF MCQNSG)/7\*5+>Y1U_P")?.43/EH9H\(6SDCOZT.E!_\`#H4<572Z_<_\C0@U M.*=E!1X@\?FJTF.5X]_>H9+BZGOI([2XA6-8U<97<&R3W!]J@ABN8_)_XEDC MB.#R-K3(0R\<_H*CDM[QIF>&RGMU*!&6&6,`C/Z=:(TXJ6Z_`J>)K2CJF_1- M/\B8ZNYM//5"7^S&79@8R#C.>G3.<_6G2P74PE)T^8&147(F3C:<@U7)!K;\491J5^9/7[G_D7WU&*-WC MV.TB2"/:`,NQ7/'/\\4W^TXR41(IFE02B1G:9 M`6(&.W0?2D^SW0.]+&X1P[MO66,XW')'-)4Z=[_JAO%XBST=O1^7D:6G3OK%C_Q^)^/\C4&Q9U3[T/T;^E9U:.J?>A^C?TK.H`****`"BBB@`H' M)XSU%%!Y!%'0:T:9R-S!K99;C]\;E@ZC>P.%VGISWJ_=:S=6MQ M/`(5>2'=-M4(PH8Y"2Z;>&SRF3G@DY[ M\5!Z@'\!3VL;1[E+EK6`SH,+*8QN4>QZTWN7.' M/EJVPXSMN54]SZ#N>M=$-(TT6WV<:?:^1OW^7Y*[=WKC&,U,MC:1J%2VA51V M"#UWY0L=1N+B]^QR;5>$/]I(&/XL(0/<9-0BYCBFU MU9I50JX8`L`0#"O/YY].:TK*Q%J\\K2M+-.^YY&`'08`X]L4L^GV=U,DUQ:P M32I]UY(PQ7Z$T:UJ)CU*%Y4B_D@;K@'.0,']>K:V@??NA0^807RH^8CH3 MZU&NG623R3K:0+-*,/((P&8>YH<)7W-(XJENX_AZ&!=:S?6LT82X@FCB:&*; M$6-S,5YR7&.N0`&^M0)J%Y%:.GVB&2&:6ZB"!3YD94R-N)SR.,$8&,CFNB_L M?3-Z/_9]KN10J'R5^4#H!QQBI%TZR25Y5M(!(ZE6<1C+`]03Z4O9SON/ZS14 M;*/X(P(]9OA=)'&JFWA:&%E91N;QZU9K2":W.:O5IU+<:@P@C MC?\`=#(>0KCD\\`U>J">XAMW!=6+L.B(6./4X!XJZ>CV,<1;E3E*VI2BNI8; M=-P4E]Z*,Y_>;S@?K^E(T\SS0%I(POGE-@&&&`1G.>>GZU;"1SR1.C-Y:?O% M`3"[B<9)_.IC;P^:93`F\G[P3+?RYK92BM;'(J4VDE+1>?XE"*YNI4@S)"CR M1>=ED.`,#CK[]:(KQLFY(4(?+,@/100?ZX_6K8CMKE!&T*,J;2%=!@9''7I2 MSVRSQ[,A%;&X#`W#T_\`U4N=6V'[*>CC*_S_`*ZE#S;CS6D=U*LD9"8P1E\9 M_*I1>R[&F>6!4.$F#D$9`YSST]JGGEM$G`E3,A`Y\LG:,\9(!QS4;SV,<\I M:##'Y))/()4\<@MCD?C3NGKRF?)*&\_QZE=;F:63RI"I*2H\11*N0!LCR2>V`/K4<36[S)*'*[,1I$R M[2I/7@@'IBGS)]!JG.FU>5V%]'YDT,>48@,1$[E0W3G(!Z562=D:)XY-D21R MY60;L$'ID'W_`"%:4L,15WC..]4?MLQ MNC&/*7:V!$[$.1Z_YS6E.][HYL3*'+RMD#07$@3SD.2$#8(Y&_GI[4HLC'(& MCC8%9\*=W1-IX_.K+:A#&IW[BLBB+>81(OV=G!\O(7GD)UP",\T^QM7\R$SQMB-7P&/3Y^/TJPFI1"W MA>4-\Z*[80LJY&>2.E3QW,OI3S?0&5H_G)4D;MAVY'49_"A.25D4X4Y/F&5T296028WXQSTZU-+JT?V9I(5D9@`R!HV^8$@9'MS4R7T1D M6-BP86\CG+AP.3R1BHTMI`(Q-:RS M'RU"8;&ULG.?T-7!J5N45\2X8$Y\LY.,=..G-.%_;MO8%L*`V-A&[/IQS1S3 MM$/LZ+^V4X8I+60.MM(55Y1A<'.X@J>3TQBFK93?9W)3$PMXPA8]^=V.?ZU M;.I1[XE57.]RIRI!7`SS3DU"'"!F;+!2S(IPNX<9XI\TUT$J=#^?3_@#-.AD MC$A9'2,E0%*X&>YZFKU5H[Z"6X$8W!RS+DH<9&<@''7BK/Y_C7/.][L[L.HQ MARQ=[?\`#A1114FX58L?^/Q/Q_D:KU8L?^/Q/Q_D:`+.J?>A^C?TK.K1U3[T M/T;^E9U`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!_CDU3DLI)"5-R3`6!V,H)SG.,D\5

U:PE.1R5X4J:6GXBR:4TD*Q>?\HB$>"@)&!VR> M*OP0F)7&[?N=GX&.IK/^V7"QOY*Q[41I#NSSASQU_P!G]:>;F;[0L4JIG>I! M7(PI5O?MMQ3DIO1LSA*A!\R3OH3+9RJ?+2Y86Y8L$"_-@G.,^E--@S'8T^80 MQ<)L&0QSWSR,DU6^VS16\.W8P$<>_*DDYQWZ#]:O6LLLQD=]FQ795"@YX)'K M[4>_%7'%T*C4;:_,C:PWJB^9C;&$'&>A!X_*C[$WF8\\BWW^;Y80$AB<]<^O M-4[6&>1DD2*96\T[IC,2"`QXVY],CI3WOIVM=S^6%GB9T6,G]--[,MVB* M$:$R>7D!LY^O0].E5Y+JZDLEEW1K(]N\B%0WRX"^_7DTW`%/^TRB86[! M&D8@@C/*D9)_,'\Q5P@$D\'T-1*I.+-X4*,U\/YE9;,*L8W\1RO+TQG=N_\` MBJLT45DY-[G5"G&'PA1114EA5BQ_X_$_'^1JO5BQ_P"/Q/Q_D:`+.J?>A^C? MTK.K1U3[T/T;^E9U`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110%@J`V=L9_/,$?FYSOV MC.:GHIIM;$RC&7Q*Y']GAPP\M<,"&&.H)S_6@PQ,^\HI;CG'IG_$U)11S,.2 M/8KM8VKL&:WC)``!*^G2IE14!"J`#DX^M.HHWZ"I:*.9]Q>RI]D01VRQW!E!'RKL10,;1Q_A4]%%#?-N5&"C>P4444B M@HHHH`*L6/\`Q^)^/\C5>K%C_P`?B?C_`"-`%G5/O0_1OZ5FYXZ<@?\`ZOUK M2U3[T/T;^E9WIGH,4`9R:W:2W8@19RK2&)9_(;RF<9RH;UX/MQC.:NK/!(S* MDT;$-L(5P2#@G^E9-KIVIVJK917%LMDKL?.&3*RLQ.S:0`/][)^F>:SK/PQ< MP6^`]G%-#;QQ6[Q(<2.AR)''E/F&.0#JFU"V2[AM?,#3R@D*"#C M"Y.?3M20:E9SS7$:SH&MW*2*[`$8`)/TYZ_X5D6?A^XMM=BNF^RF..6>7S<$ M32>:VUP(_+F3,D8D52PW;#T.WK63I&FW/]@W"73,+JZ#*S2` MA@`NQ-P[':`2/4FLY_"5TUTSB2U6&2W$,^X,PE_<^7@CMR!\RLO`(P!W#H1"(L*O3GU)QU!'>@ M#J(;^VN+J6VBE5GB1'Y##'TQDTW3](O;=].AEDMVMM-#>0R M,=\I*%%W`CY?E8^N3Z4`7YM9MH+UK5DG9D94D>.(LD;-C`)[<'W'/.*L7MY% M86,UW-N,4*%VV#)P!VSWZ5BWNAWMWJ"W*FUAE8QG[3&726(+CY>,>8N0WWL= M>E:>IV4NIZ->665C:X1XU97/`/0Y&,''Y?K0`EMJ]O<-,LB2VLD*AI([E=A" MDD`@G@CY6YSU'-3+J5DUW);"YC,L<2S,,](V)`;]/_K5DZCX<1[/;8D"5I$> M1[N5IF=5S@!Y-Y7&XXP#U[9S65_PA5TME]G,T!811H2FY2QCF=PO3(!#8Z\% M1UH`Z_[7;X0?:(0T@!3+CYL]#UZ<&JLNMZ?%I=YJ8F+VEH9!,4&2NS(88]01 M6"G@UA9S1/\`9O-:V,4?5_*W45;1UE021NKH?NLIR# M^(_G7+W'A.8W]W+:W$/V1Q&T-K*I**PE\QE/'",1^!)X[5KZ183:?;F)_(Q) M)),RQ$@1%CD*H(Z=23QD\X&<4`/BUBTFU%K%#)Y@+*K[#L9E`+*&[D`@]OKZ M)+KEG!>M;2>:I#;/-\MO+W;2^W=W.T$_ACK6,^;/ MN4[8F..%!Q@\_=''>IGL]7N-;^T3?8VMT#"VS*Q,1*X+[=N&;.1][A3QWR`3 M#Q%9-`[A;@.KB,0M"?,9B-PPONH)Z]CG\VKVL6GQ7A,A28JL2*AWNQ_A" MGD'@]>G?'+X7GN9&NIHK`R>>EP;4!C!*P1T9FXZL),]#]Q>O:V^CWO]D0 M:>GE[K81O%,9&3YP6)4%>5`7`!&>,\8!RP+C^(+%/*),VV0A6;RSB(E]F&/\ M)W_+SW]*GL]3COKF:*&"XVPLRF4IA"5.T@'ZY_[Y-8S>'+O^S8+&-[=XP[3& M5]QE@E+LY=#U8_,1SCIDYSBIX-'N;'4YM0AMK(.JS;!;J8VN2[!OGXX(P>>< MY)XY%(#8DNX8KR"T8GS9E9DQT(7&?YTINH5+"218P'\O+L!EL#@?G^AJAJ5I M?OJ%E>V*6TCVZ2HZ3R%!\VWN%;'W3^=9EUX=NY[N2\VV,KRF0&"X!=%#I$"P M&.2/+Q@XR&ZCN`=(;B$.Z&:/>@!9=PR/?Z&F_:[4QJXN8C&[;4<,"&/8#W]J MY&?P5--)UG,Q$C,^YO,.2I7ICMG)S@<"I]2\)374MPUI]EC,ERTD2X( M$8:*-#\N"IY3)4J<_P!X'-`'5":-I3&)$,BC)0,"<=CCTJO'J=G*MRT:^O)7NT;[0)F$^YMY,BD8VY"[03P<\X`P#S6KINC30 M0ZGYT=G%]MQM2W4[$^3;SD_M+I(9(;B-UG02188`LIZ'_`#_^ MJO=ZQ;6=R;=TG=T0/*T<3.(U)(#-@U M`&V9X53<95`&>6(`X&3GGL`33#>6HB\TW$(C!V[S(-N[TS7-W_AF_O1<6XGM MC`\D\J,^=Y:6%HR#Q@`%L\=A[8*:CX3><3_8Q:H&F66->4"$1;" MG'6A@CHH]2M99KF-)!YENY5T/!.%#'`SZ,.:DCNH)&""5#)MW&/<`V./\:YT M^%9B"YE@:Y-P96F$>TE3;F(C@<#/.!Q3#X/9H=@FBCG:9G,\:X<*UMY.`>.0 M<-CI@#O3`ZB.:*52T=$5\R/C+`], M?,N02#SFH?#>A2:-%<>9Y2M+L&V.1V'R@]=P&,YZ`?B>M8]AX.O+:P2WTNNX97/0'Z^M0/JEG'/! M";B/,Z.\;[AL(4J#\V<=76N5U'PM=I:2A$M)`ADV%8SON/,E1CY@X&`!SS\W MMBK8\)M-))+=)9#SHYQY*+\D;2+&!MR.1^[)/`Y8T`=*;B`3&$SQB4+NV%AD M#U(ZTU;VT8@+U[65[FVPBL"0,$[K=HN<+GJW M4DYQCBKK^$XI)`?+M"%%HJCR^@B8EATXSGI^%,#H?M-OB+]_%^^_U7SC#\9X M.>>QIDU];P745O(X5Y8GE4GA=JE023V^^M>#KVX40QSVJPAG9M&B@#._LL_P#/;_QW_P"O1_9?7]]UZ_+_`/7K M1HH`SO[+/_/;_P`=_P#KT?V7_P!-!_WS6C10!F_V5QCS?_'?_KTO]E_]-O\` MQVM&B@#-_LO_`*;>WW?_`*]+_9A!SYW/3.WG^=:-%`&;_9?_`$U'I]VE_LOM MYW'IM_\`KUHT4`9W]E_]-O\`QW_Z]!TPG.9R<^H_^O6C10!F_P!E?]-?_'?_ M`*]*=,)S^^Z_[/\`]>M&B@#._LPYR)L'V7_Z]`TO`P)<#_=_^O6C10!G#2\8 MQ-C`P/E_^O2'2LC!FR/0KQ_.M*B@#._LL_\`/;_QW_Z]']EG&/._\=_^O6C1 M0!F_V7_TU'K]WOZTO]E\8\T?]\UHT4`9W]E\@^=R.^W_`.O2?V7_`--0.W"U MI44`9ITO/67_`,=Z?K2_V7_TT'7/W:T:*`,[^S#Q^^Z=/E_^O1_99_Y[?^._ M_7K1HH`S?[,_Z;>_W?\`Z_M1_961CSN/]W_Z]:5%`&=_9A)R9L\Y^[_]>D_L MOOYHSZE:TJ*`,[^R_P#IM_X[_P#7I#I>W_CO_`->C M^R_^FW_CO_UZT:*`,[^R_P#IH/\`OFC^RS_SV_\`'?\`Z]:-%`&=_9?_`$V_ M-?\`Z]']E\8\[MC[O_UZT:*`,[^RR.DV/HO_`->C^RSS^^Z_[/\`]>M&B@#. M_LP_\]O?[M']E\Y\[G_=_P#KUHT4`9PTO&,3=/\`9_\`KT?V8?\`GM_X[6C1 M0!G?V6?^>W_CO_UZ/[+XQYO'IMK1HH`SO[+Q_P`M?_'?_KU)!8>3,)/,SCMM &J[10!__9 ` end GRAPHIC 6 img002.jpg begin 644 img002.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W._NGM+8R MH@D;?\`]')6A0!G M^?JO_/E9_P#@6W_QNCS]5_Y\K/\`\"V_^-UH44`9_GZK_P`^5G_X%M_\;H\_ M5?\`GRL__`MO_C=:%%`&?Y^J_P#/E9_^!;?_`!NCS]5_Y\K/_P`"V_\`C=:% M%`&?Y^J_\^5G_P"!;?\`QNCS]5_Y\K/_`,"V_P#C=:%%`&?Y^J_\^5G_`.!; M?_&Z//U7_GRL_P#P+;_XW6A10!G^?JO_`#Y6?_@6W_QNCS]5_P"?*S_\"V_^ M-UH44`9_GZK_`,^5G_X%M_\`&Z//U7_GRL__``+;_P"-UH44`9_GZK_SY6?_ M`(%M_P#&Z//U7_GRL_\`P+;_`.-UH44`9_GZK_SY6?\`X%M_\;H\_5?^?*S_ M`/`MO_C=:%%`&?Y^J_\`/E9_^!;?_&Z//U7_`)\K/_P+;_XW6A10!G^?JO\` MSY6?_@6W_P`;H\_5?^?*S_\``MO_`(W6A10!G^?JO_/E9_\`@6W_`,;H\_5? M^?*S_P#`MO\`XW6A10!G^?JO_/E9_P#@6W_QNCS]5_Y\K/\`\"V_^-UH44`9 M_GZK_P`^5G_X%M_\;H\_5?\`GRL__`MO_C=:%%`&?Y^J_P#/E9_^!;?_`!NC MS]5_Y\K/_P`"V_\`C=:%%`&?Y^J_\^5G_P"!;?\`QNCS]5_Y\K/_`,"V_P#C M=:%%`&?Y^J_\^5G_`.!;?_&Z//U7_GRL_P#P+;_XW6A10!G^?JO_`#Y6?_@6 MW_QNCS]5_P"?*S_\"V_^-UH44`9_GZK_`,^5G_X%M_\`&Z//U7_GRL__``+; M_P"-UH44`9_GZK_SY6?_`(%M_P#&Z//U7_GRL_\`P+;_`.-UH44`9_GZK_SY M6?\`X%M_\;H\_5?^?*S_`/`MO_C=:%%`&?Y^J_\`/E9_^!;?_&Z//U7_`)\K M/_P+;_XW6A10!G^?JO\`SY6?_@6W_P`;H\_5?^?*S_\``MO_`(W6A10!G^?J MO_/E9_\`@6W_`,;H\_5?^?*S_P#`MO\`XW6A10!G^?JO_/E9_P#@6W_QNCS] M5_Y\K/\`\"V_^-UH44`9_GZK_P`^5G_X%M_\;H\_5?\`GRL__`MO_C=:%%`& M=#>77V^.VNK:&,O&\BF.8O\`=*@]57^_12S#_B?6O_7K-_Z'%10`:Q_QXI_U M\V__`*.2M"L_6/\`CQ3_`*^;?_T*S+77].NY+Y([ ME5-C.;>8O\H#A0Q`)Z\,*U#UZUYT_@>^N_$37%Y!:3V3:Y)?M'(VX&)K81@% M2",[AT_&@#KE\06#:V^D"4+3\O0>HJM_PEFGKJ<5A<)/ M:RS-,$:X4(A$14,,>O-<"GPWU8Z2T4L-F]W'IEM:VTADR8I([AI#M./ MEPN,$=^*GO\`P'J[W3S_`-GZ=?*;C49/)GEVC$^T(X^4@,,$G]*`.ZN?$^G: M?=M\.M5BM2)8[/4)()]-E3SF_UX@C"2KR#C..,]>]2W?@G6/M\M]]AL;Z% MKV\F&GS2X0B9$5'Y!&Y=I'T)Q0!Z4UW"LZP-/&)6X5-XW$]>GTI9;F&W7=/- M'$A.T%V"@GTYKS"/XX)Y`(X'KWK>\9^'+_ M`%C4+.ZMK2TU&&.VN+=K2[DVJKR!=LH^4@D88=C@\&@#>3Q%:3>)I]"A5Y+N MWA6:8@C9&&SM!YSDX/0'''K56R\:Z/?ZQ_9D,DZSF6:%&DMV5)'B_P!8JL1R M1_0UG>$O"5QH.LW5S=?9YBVGV=LMPJC?(\:,LA/?GY>O7`]*YZP\#ZU!X@DN M/+BB5;R\N/.:\:19(IE8!%BQA#R"6&#QWSB@#TMK^T1!(UU`$+;-WF+@MUQ] M?:GF[@$_V4'&['KCK7E=S\-+J#0]!M[:U@VVUG)!?VL+QIYLLBJ# M)NDC92?EQD@'T-6YO!>O2^)=.F/V:2QL3&%E$JK*\:P&-@[B/>SENIW;<'ID M4`=W>>(=)L6M_M6HVL?VB?[/$3(,-)@G;GL>/P_&HM5\1V6D7,%I,+B:\G5G MCM[:!II"B]6PH.%!(&37"6O@75[?3M/5K"QE33M4CN+:UF9#(8!'L97E"`,< MX()&<*,DXKI]4TO5;3QFGB+3;2&]WV/V*6VDF\EEP^]75B"#W!'T/M0!TB7U MLY*K<)O5/,9"V&5<=2#R!3Q>VK122+#O$NH>)[F_F MCT]$:*[1&A9%!$L&U`<(';:W4L2.A`%))\/=0MQ&]K:6)MHHM/:6R9]L=T\( M82!_EQW4ACG..>*`/3A>VQDB3[3"7E76?=(Q3+=\*?PH`OZ;XHT[5KAX[/[0\2EA]J,#B!R MIPP60C!P0?;@TNI>)].TS[*99&F2Z$IC>`!U_=H7;)!ZX4X]^*X]?"WB0?#^ M;P21(;T)]GC\LM+*SC*J$&26QVJ>R MUJWO+3SW66SPQ!2\B,+C')X;'8CGIS7-W/AK4H](\*SV@@DO]$B5'MVF*)*K M0^6ZJX'![@XK,L/!.JW=]I$FNI'=6MKJ%U="VN;EK@P1O&!$NYA\VUAGVS0! MZ%]NM@\JFXA#1`&0&093/KZ#I^=.>\MXT=GN(E"':Q9P-I]#Z'VKR^+X^26/4/-\F9<",>6!NW$D8ZC'K5 M_5-[+[+NY2VC90"`[9P2<\+QUKSZP^'EXMAH]A>:=IYBT];^-RI!6 M8RKB.3;MX/;GIBM?4O"VI7?@OPUIK06EUSZ5G>(/$VE^&;"*]U2?RH)95B1@I;)//;L`"?P MKS&]\#ZG:IH=BH6*35;B>VU&"WRT<5H\OGE`V!]T`KVSO(%=CXI\*WWB/5[2 M)+N*STRWLI8Q^Z$A>20!"-K<`!`>>HS0!T.M>(+#0K$W5Y+\N5VQH07;2V-@]K#%<'18YQO5'G*M)O!!`P00.OWC0 M!Z9#/%<1++#*DD;?==&!!_$5AQ>,=.FNKRS2*^^V6L(G-LUHXDDC+;=Z*0-P MSZ5B>#O"^K:3;W*W5]+9;[]KE8+?R65T*H"KXC"CE3P@7&/%))`+.?[/-]JC M,6V3`.WYL<@$'\:MZKK-EHMC]LO9=D1944*I9G9CA54#DDDUP=[X+UM?!>GZ M7;"SNKN226?4VD"%GEE5B2C2(P`#$-<,F[MG)P?7%`'36>KVUQ:1SOYMIYC[%CNXS"^[TVMR2?UJR^H6L; M,DEQ$CJ"64N`1@9->?\`B;PWKWB2X>[FTFP8SZ=+8+;S76_[&[-D3J=N"V.P MP>!S4:_#NX?4A^>:`/17O;>,(S7$*J M^"I9P`V>F*/MMOYDD7VB+S8UWNF\;E7U([5XW/X'UF*`/3#J%JH5CH:]8Z9=V5K/+F:\N%@C1,% M@6!(+#.0/E/->=ZC\-;D6.CP6=M$+:'3#9W-M$\<9$S;2TH9T<9)!!88;@8- M7%\#:HGBB&Y-O:7"1ZM'??VA-+FX,0A\LQ8V]B,]<'.>":`.\DUK3X=7@TJ2 M\B2^EC:5(&.&900,@?4CCZ^E6X;F&XW^1-'+L.UMC`X/H<=*Y'Q#X9N[[Q;; M:M:Q0,O]G3V3S-Q)`SD%)5XY*X(P.>?>J_@GPOJ&BZD+J[M+2Q6/3H;%H[5] MPN9$))G;`&"<]\GGDT`=\.E%(N-HQTI:`"BBB@`HHHH`SYO^0]:_]>LW_H<5 M%$W_`"'K7_KUF_\`0XJ*`#6/^/%/^OFW_P#1R5H5GZQ_QXI_U\V__HY*T*`" MBBB@`HHHH`*3`]*6B@!,#-&T>G2EHH`YOQ7XC/AJTLIEMX)7N[M+53/<>2B% M@3N9\'`X]*IP^-K1=<_LJ_A,$BV'V^2ZCS);*F3R)-H&,+G<>,\=16AXH\.G MQ%:V<2W0MWM;M+I&>$2JQ4$;64D9!SZUF77@C[==&6ZU'B;3&TR[2&`1B2,D MD%,']V03[Y]J`+*>.O#S6K3F^=0LD<7EO;R*Y9P3'A2N2&P<-C!^M$GCSPW% M9Q7+:B3'(CMA89&:-4;:[2*%)0*>"6``K`U+P%J9:UNX=4-SJ0O+,OWOI3`I^T+,^]\*3\AR3C&<#L<4` M;&I>,M.BLM4>QN899]/3,CRI)Y"M\IP9%4C.&!PN3R*@O/'%@GB'3]'MF2>6 M:[>VNF*.$B*Q,[8;;M)&`",\;N:H7?PW@N9KS;J#P0SVGV4)!"%)7Y,-(4``TL31N-_7'S$@=L]Z`-[2?$FDZ[( MZ:?/YC(BR8:)D+1L2`Z[@-RG&,CCWK)B\?8&'VC6&TK;YP.,2,F_. M.?NYQ[]:E\)>"[;PLQ,2L$<@MPDFQ3QN;)W=NF![K;>;/'*BR@AC M^Z.W#GY>#]TCO1!X_P##4]K-/%J#&..)9\^1(/,1FV@H",OEOE^7/-9MM\/8 M[:Y\Y]2/_'\EZ8(H!'#E5=3\@)"EMY+,.N.@K-UOXM+I<=KJ6M/UENEOF\J*W-T[-!(H$6_9N&5&1N''YU8A\6Z-<:VFDPW$ MDEV[NB[8)/++(`SCS-NW(!&>>X%9&O>`!JY0Q:I-:%M.73IRD2L9(U8,,?W3 MG.<=1Q65X>\*:YIGCVXU.:"'[-)<7+22O(KCRW`*B(#YD8D+G/8$<\&@#?LO M&27GB35-,:&U@ATUF6=Y[H+,`JAO,\K;_JSG[V[MTJ5?'?AY[=KC[:ZH&C3Y M[>16/F9\LA2N2K=B.M5-7\#)KNM"\U6^,L4< M35;3OAS;V%M!']KC\R"XMIA+';!&<0DE0YR/++ M=!C'&MO(74*^QMXVYC`;@[L<_2LFT\?03WMKILL'F75S!<3K-!%(T`\J0IAB M5SVY;&`1]*0_#U'FMG34W3R;Z2]$B0`3#?+YA59`-])NM.BN+B\C$W^CK*(DD*[YP/+VY M4$JV>"0,8.<5>TWQ1H^KWK6=G=F6549ES&RK*%;:Q1B,.`>"5)%85K\.;2WU M70KP7\K+I=M'`T.P!;AHU98W;T*[FX^GI5CPOX$L_"UT);>2*:..-XH2UN!* MB,P."^?FZ=@,\4`9FJ_$=]+LIK_^ROM%L-5ET^/9+M)CB1C)*>#G!5\+Z"KU M_P#$2SL?$W]FFU:2QCM)+F:^$G"%(_-VA<HZBH[#P5(2T%^RI:VFLW% M];A<,)H94;Y6STP9''_`1ZU%IWPNT^RL;.REOIKF.);I9S(@W3K.@CP3GC:H M`!YZ4`6)_&>K6FAV>IS:!#%'?S6\5M&U]ROFG`,OR?)@$$XW5TRSZ@=($ZVM MH;XJ"81FS/3OMKFY/!-Q>:39Z7J>L_;+&TF@DBC>T4%EB;(#\_- MD8!.!ZXK;/AS3X1+-I]O%97AMS;Q3PI_J@>F!TX//2@#GK7QW=RQ)<7.E00V MXU@:5))'PS7<\C89EC)D+8[EWQGZFG^(/`XU[Q# M;ZG)J%,4F[*'/R[N`W!Z"@"W%XZ\.RO,/[2"^3'+*[R1.B%8S MB3:Q`!VG&0">HZT[PYXKB\1:KK%O;1E8+)H51W1D=]Z;CN5@",5DW'PVM+O3 MH[*;493$B7JG:@!/VE]^>O\`"0,>M;7AWP[/HUYJ-Y=:B][<7YB,C>4(U7RU MV``#V`H`P+'XF1WVD:Q=/I+QW%A*J06WG!C=;G*1E3CC+*PZ'&,UI:;X]T>\ MT*+4+N3[*_V2*ZFAPTGEI(VQ3D#YLGC_``JE!\-+*+4=*O&O)7;3WN&9=@`G M\QV=-P_V&=B*K/\`#$-8QVD6MS1)]C@L[@B!6,JQ2^8I!S\O)(^E`%VV\?Q- MK<&E7.GW`FN=0NK.)H8V=0(>C-@=\\XZ#D\G^%5U`R6]QJ+PM- M'!`LIC*^84!9MF4!(QE@,G.*O1>"1;ZG:WMMJ++-;ZC<7PW0A@RS\/'C/'`X M:LQ_A6(/J*`-\^.?#XOY;$WQ^TP3) M;RKY,F$D9@JKG;@G+#O3+SQSX=T^-Y)[Q_DDEC=8[>1V4Q,%LPR"6%9$!PRAAD$'GU!P1^-3;1Z5#;"1; M6(3;/,"#?L&%SCG`]*GH`3:*,#%+10`4444`%%%%`!1110!GS?\`(>M?^O6; M_P!#BHHF_P"0]:_]>LW_`*'%10`:Q_QXI_U\V_\`Z.2M"L_6/^/%/^OFW_\` M1R5H4`%%%%`!1110`4444`%%%%`"$`TN***`$P,4TC'3/3M3Z:<4`>7Z+\0K M^X\1RVES):-:Q7-\MQ&EN\;6\,!.)-Y;#]@5`R,CM6A'\5M'EL;BY2WN`T0A M=5W1D%)6VHS,&(09'S;L$9%;2^!]%7R?W@#+O/'D6F7U[)T@DM=.O)YI'N4,,3Q$*8`#)\V[:1 MA@003FK.A>,)M;\33V,.G.-/^PV]W%=,R@D2@D;ESGH.P['.!BI[+P-H]DT; M1FZ>16N&,DDY9F,RA9"WKG:/H:MZ9X5T[1]0M[NS-PDD-G'9$&7*R1I]S<.[ M#)Y]S0!Q&I>/]?M=(MM3M8;>:.YU*['ELAR+6`'(&,?,0C')JQJ'Q+N;7Q!? M26T5O<:';6,\R.H/F32QHCD!LX"_O%7IU!K?TOP3;V;H+M_/CMKZYN;-%&W: MLP(9&'0XW-CVIUA\/_#NGV5G91V[/;6L$\"12/N5TF.9-P_BSQSVQ0!D:SX@ M\1:+H>F7U[?Z6C7]Y!$SBT&`(]3W%5H/!>GPK:1R7>I7"6<\<]NEQ=LXB*9V@9[WEO+JZ:STB2*$IY MI9Q'&Y4D]3ENO05&OC^\T;Q+K&G:QY+Z=8PE;>=$*RRRQPI(P;G&6#'``'2N MED\+Q"]\/1P,D>EZ,K&.UQDM($V(<]/E!8_4TFH>!M$U2:62[@DD,M_'J#`R M''FH@1?^`X'([T`2X0R6Y7&P*00K;AR>F?:NON/`VF37$=Q'<7U MK<)=S7BRV\^QA)*,/V/!`Z=JEA\$Z'`;3;;.5M89X55I"WF";'FE\\LS8R2: M`*FB:_JEQXCM;'4H(X?MFDQWRQ+SY,@8+(F[N.5(_*L#1OB%J$_B!X+W[,UK MYM^C1I;O$T8@8[=KL<2,PSE1C&,^M=/H_A-='UQ;L3F2VMM.CT^TC?+,B!BS M%F/7)VCZ*/>HXO`.D1W4DQDO90SS2)%)<$QPO-N\QT7LQW-U]:`,V;XI:=;Z M?:7=QI]Y!]KA>YBBF:.-C`H4^9R_?=PO4^E7YO'^FPZO::69/]6&WC('!*@$\5:N/!>ERQZ:J&Z@>PA^S02PR[7\KC*,3]X':/>HF\": M1_;7]JAKQ;CS//VK<,%\S9Y9?UR5XSVQD8-`&5_PL.:[CT"XTW2'G@U2[:W( M-Q'N0",N.C<-P3SUZ5)'X#TJ-4837K72WHOC=&<^:TH79DGIC;QC%6[_PM97VJC4UFN[2 M[\L122VEP8C,@.0KXZX.<'KSUH`R;WXBZ=IMYJ5K]7+SP1I-W=2WFZ[@NWG6=;B"@"D/B/I1\0C2BDJR^:;=G+(=LP3>4VAMQ`'&[&W)ZUIR7]O->(\I\R6+SSLEDV[=[ M#KN(_#(SC-:.G:+9Z9H4&CPH7LX8?("2'=N3&,'-`',6_BK4-+\,VWB'7Y;0 MP7T<1@M;>(HR/(1L0R,^TC!Y)QC%8VL?$:XGLS=Z,ZQHFG7TCI(@D*3PE`"" M.&7YCR#@@BNF3P#I*Z=_9S3ZC)9)L^SP/=,RVVP[E,?H00,9SQQTXI]SX(TJ M]MA%>/>7!^RSVK223DNZ2D%P<=_E&/2@"71O%4.KZO>Z9';RK-9865I&526P M"<)G=CYAAL;3SS71J!@$@9K"MO"]C:Z[_:V^YENQ$88C-+N$2'&54>F0#[=J MW@,#%`!M'I1M'I2T4`%%%%`!1110`4444`%%%%`!1110!GS?\AZU_P"O6;_T M.*BB;_D/6O\`UZS?^AQ44`&L?\>*?]?-O_Z.2M"L_6/^/%/^OFW_`/1R5H4` M%%%%`!132>:0L0?_`*U`#J6F;CTR`>]`.1F@!JR!V<#JAP?K@'^M256@/[VX M_P"NGK_L+5F@-0I:86P<=\<"E#`\9'YT`.HQ2`Y&>*,T`&!Z48%***`$P#VI M<444`&*3`I:*`$P*,"EHH`,48HHH`3`-&!2T4`)@48%+10`F!1@4M%`"8`I< M444`)@48%+10`8I,"EHH`3`SG'-&!2T4`)@'L*,"EHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`,^;_D/6O_7K-_Z'%11-_P`AZU_Z]9O_`$.*B@`U MC_CQ3_KYM_\`T*?]?-O_Z.2M"@`HHHH`YCQX8!X,U4SWDEH%MW M9)$G\DLX4E5W`@\D=*\[UO4XKO2[%KG4G$"^%S+82QW#*'OQ@?*5/SR`[?EY M/)XZU[-+!%,NV6-77KAAD?E31;0`*!#&`ARN%'RGU'I0!XYX:O=0GUS2);NY MG;Q%)JT\.HV_FL=ML(C@-'G"IPC`XY)ZY)KTSQ5--#X8OI8)'BD5`5=&P1R! MFMCR8O-,HC7S"-I;;R1Z9]*)[>*YB:*:-9(VZJXR#0]@3L[GC]EK&MVVJV;B M:XF5""8VG($_;G)Z\5V5OXEUR[)$.GZ((DNK)B%AU`KR.P63'0_[5*',UI;\2JL MG%K3FU<<#&,8XQBM75M#E9>WGS\G*3S&=+>^,[J)3'IEM;H03A9AO/_`'UTK#N/%&O:/>O; M7<1"=0.XSP:N/+)70]&;YNY%CWF MWPIQ@EU`YZ?87A_^)I#?^+#_P`P6RZ?\_A_ MPH40Y6;WGW'_`#ZL/^!K1]HN/^?1O^_BUP;:IX@\B55L%-A]HPSK=YQGJN_& M=N>I[=,UT"ZOXC4#_BFU9>V+Y>GY53A8.5FYYT__`#ZM_P!]K2>?\,2_\!O$-)_PD6KK][PM??\``98S_6ERL+,W/M%Q_P`^I_[^ M+1]HN/\`GU/_`'\6L3_A)[Y?O^&=5'T5#_[-2#Q7(!E_#^M#W%N#_6ERL+&W M]HN/^?4_]_%H^T7'_/J?^_BUB'QA`H^?2=83ZV;?TI/^$WTX'Y[74D_WK-Q1 MRL+&[Y]Q_P`^I_[^+1Y]Q_SZG_OXM8?_``F^B_QOM_M_ MWHG']*.5A8V?/N/^?0_]_%J2)Y'!+Q&/'0;@<_E6#)XUT#RV,>JVX<#C?N`S M[\<4:;XEBU@1QZ?LEF##[1SE81ZY[Y_A]?;LLW_H<5%$W_(>M M?^O6;_T.*B@`UC_CQ3_KYM__`$*+><+YCA=Q]LGF@"S15-9(I%VNK#@BL'Q5;&Y\.ZJ$^_ M&PE7ZJ%;^E;>G7*WFG6MROW9HEX]/> MF>`%GCTB:*YFAV(Z4C#(/Y4HZ4&L7 MKH;&/X?.RSFMO^>%Q)&!Z#.1_.MC%8^G_N]:U2$]"4E`^JX/\JV!44W>(!@' MM2XHHK0`Q1BBB@`Q1BBB@`Q2$`]12T4`1&"+RO*\M?+(P5(X(]*DQ@8[4M%` M"8I<444`)@48'I2T4`)M%&T4M%`";1Z4TQHW50?K3Z*+@59;2*1&4(BL1@-L M!*^_-48M!MK80-;$PSQ-N:5<;I,G+!O7/Z=JV*0J",&B[```!Q2T44`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110!GS?\AZU_Z]9O\`T.*BB;_D M/6O_`%ZS?^AQ44`&L?\`'BG_`%\V_P#Z.2M"L_6/^/%/^OFW_P#1R5H4`5-0 MO#96$]RMO/,3>#+Z..0%D3[;;F=E'7$6_)/M MGBNIU5]FF7C&W>XVP.?)C.'DX^ZON>@]Z\YT*PGU?4K76;NUN[BV@GC@B:.7 M+H$.Y"VY5,B*SD%A@@J00X&0`>F6MP;JSAG,4D0D0/Y2>(XU M?3;J+6#KT-TLK1,Q2R$(R#+C&T;<4.PC/8D9%.V#TI<4`9?DW$R7 M<3O"5=L'Y&[J,]ZRO!TETWAV*WWQ![1WMR&0DC:2!W]*Z"$#S;CM^\'_`*"* MP=`_T3Q%KE@>!YRW*#U#KS^HJ7N:1U@U\S>V7><[X/\`OV?_`(JN;E%QI/B^ M-]\0BU5"C?*=HE0?+W[CC\*ZT=*PO%5G))J%A!=Q_D'_`'P?\:S]2_=:QIDWJSQD_5?_ M`*U;`K*GHV@*^+S_`)Z0?]^S_P#%48O/^>D'_?L__%59HK496Q>?\](/^_9_ M^*HQ>?\`/2#_`+]G_P"*JS10!6Q>?\](/^_9_P#BJ,7G_/2#_OV?_BJLT4`5 ML7G_`#T@_P"_9_\`BJ,7G_/2#_OV?_BJLT4`5L7G_/2#_OV?_BJ,7G_/2#_O MV?\`XJK-%`%;%Y_ST@_[]G_XJC%Y_P`](/\`OV?_`(JK-%`%;%Y_ST@_[]G_ M`.*HQ>?\](/^_9_^*JS10!6Q>?\`/2#_`+]G_P"*HQ>?\](/^_9_^*JS10!6 MQ>?\](/^_9_^*HQ>?\](/^_9_P#BJLT4`5L7G_/2#_OV?_BJDB$P!\TH3VV` MBI:,4`)1FBL34-"EO;MIEU?4;8$?ZN"4!1QC@8H23$V:QF02"/>OF$9"YYQ3 MB^!G(''>N+E\%7K:Y%=#6;LPJF#*S_OE/H#C&/PK7M_#LT$Z3?VWJDNTYV23 M#:WL?EZ53C%+1D*4F]461XET5K&*^&JVGV66;[/'-YJ[7DSC:#ZY'2FR^*-" MMY;F.75[))+;'G*TRYCY`YY]2!]37G=K\+=6@LK>U-W9_9H1#<+`"P`N@Z>8 M_3O&G'N3TK8/A'6CX=F\/;K);?[9]HCO%D=9F!N!*2R[2`P&1NR02!4FAV4V MOZ5;Z;'J4M_`ME)]R_O63?Z M5K*Z5=0Z;J\KW$EMY$(N@FV-S@&7!P2K%2/S!'X5YQ!\/-?L+66WCU*SO8;A;:2YC<-!YTL< MFY@Q4'(<$Y;KP.*?IW@'6++^S8TN[2&U56:]ACE`-G&0HXH M`]+:18T+NP55&22<8%8Y\7^'TLQ=-K%GY&\Q&3S1C>!DCZUS?A/PGXAT6VO3 M=:A`DDLPF6WM\-"Y"`%6W(-JEAGY><'KG)++;PKKDOAO4K*[^QV^H:K=*U_= M07#-OA.`X0;!MP@"`<^I.:`.[@NHKJVCGAE22*50\*?]?-O_P"CDK0K/UC_ M`(\4_P"OFW_]')6A0!3U"S&H6,UHTT\*RH5\R"0QR+GNK#H:\\D&GIK/]AR_ M$_5/M/F"(68FA$NX]$+B/=G]:]"U".66PN(HKE[21XR%G10QC..H!!!Q[BO) M/#&MV$>L10:=XNUF\DNM48RV7]EQ*)G+Y>0L8QM3C)(((S0!Z]9VR6MG#;(T MCI$@16DJ:[INCO#'?7(CEG)\J)49W?'4A5!)QGK MB@#5HK#;Q/HR:V-(>_C6^+!1$<_>(W!=V,!L<[6KQ'_`'E.[^5=!"?WMS_UT_\`95K`\7@P1:;J2_\` M+G>(S'T5CM/\ZF6US2EO;OH=/36`8$$9!ZT(05%.JD^IDUT.:\+L;-K_`$A^ M#9SDQ@_\\WRRX_45T@Y'7-+6[VU0@8AB";1CZC/-)CBDWJ:GVVV#[#/'OSC& MX9S4Y/&2>!WKR>?P)KK:VTRC?&9]WVII5WXS]['K7;6WAZ_@N(Y7\07\P0[C M$X3:WL<+TJ5)LWJTJ<4G&1HC7-*^RI=C4[/[-))Y23F==C/G&T'.-V<\4V77 M]&MY;B*?4[*.2W`:>-IT#1<]6&>.2/S%>:6GPQUN"PMK,RVGV6W\BZ2!6(Q= MAT$C9QTV)D>Y-:[>$-9_X1VXT!;:T0?;/M$>I+,/,D!N!+DJ5/S`9Z\<59SG M<2:UI<-C'J$FI6:V,A`6Y:=1&V>F&Z'GWJ>"]M;JT%W;W4,MN02LR.&3`ZG( MX[5BZGIFN+I5Y%I^IBYN'MO)MTN8T4)(<`R%E7D@9.,8X'%9QUC3-3CWV-_;7*;MF89ED>#M4M[?PS]NM%:;2)-K-+?F0A?*V[T(4856&=I_/ MDUFW/A;Q%80VXF62X\V[MHIHXKZ4_;&#N7G=L9B#`@$#.._:@#U\?0_C58WE MJM]%9M*IN7C,JQ]RHP"WZC\Z\XL_!GB:&?3FN+P2R0K!MN1>R9M51F,D0'\8 M8$+N/ID]!3;;P7XICTV>!;M8G-G<00L;IVD)>2-EWO\`WB%<%@!][UH`](MK MRWNS+]GE60PR&&7!SL<8R#[\BK@Z5Y'+X#\1-#$EI,EC`;R:?[-#>,3#OV>6 MX/6<;67Q M'GDMHIH]6GU4K+9_V8#$UH3_`*[S]I()`W9W_>XVT`>Q#H*\]\;^'];O?$$> MI:0EV[_V=+:1-:WHMS!.6#([9(W)Z@9Z#@UZ$.E&T9SCGUH`\P@\+>(!J:V5 MQ`LD)UR+6'U)9%"86)59`GWMVY2.F,'J*],()0A6VL>A'.*>%`&`,4``=*`, M^"&?S+C_`$M\^9S\B_W1[52\1:=->Z!?6YN78M$2HVK]XH:83\UE=NH'^PQW+_`#-=/0MAS5I,P?$.E3ZAHMQ$MP[S M*OFQ#:H^=3E>WMC\:GTBY?4])MKU+IQYJ`D;%X;N.GKFM8]#Q7%V^KVWAKQ# M=Z94^G/\ZTBG*-D<\FHN[.K>VF=&4W3X(Q]Q?\*S-!28 MZ=Y/VEU,#O$1M4XP?I6VI#(",$&L>R_T;7;ZV(^68"=/Y-_2N>>DDS0TA!/C M_C[?_OA?\*7R)_\`G[?_`+X7_"K`Z45J,K^1/_S]O_WPO^%'D3_\_;_]\+_A M5BB@"OY$_P#S]O\`]\+_`(4>1/\`\_;_`/?"_P"%6**`*_D3_P#/V_\`WPO^ M%'D3_P#/V_\`WPO^%6**`*_D3_\`/V__`'PO^%'D3_\`/V__`'PO^%6**`*_ MD3_\_;_]\+_A1Y$__/V__?"_X58HH`K^1/\`\_;_`/?"_P"%'D3_`//V_P#W MPO\`A5BB@"OY$_\`S]O_`-\+_A1Y$_\`S]O_`-\+_A5BB@"OY$__`#]O_P!\ M+_A1Y$__`#]O_P!\+_A5BB@"OY$__/V__?"_X4^))$!#RM)Z$@#'Y5+10`E' M%%9MU;:E).6M]02&(@80P!L'ZYJ92ML!HTAZYYKE)(O$']J*RN[*OR"4(H&. MYVYK6CM-5613+J:.@/S+]G`R/KGBLH57)VLQ7+']I6+VR7"WEL8'?RUD\U2I M;TSG!.>,>M)+K&FQ-,DNHVD;P\RJ\Z@QC_:YXKRBS^&VO1:5:6++;"T@,%XE MOY@.V[WJ).?[H121_M,:V)?".KOX?N]$&FVOG->>. M>,KZ5N,]`DU2PCL5O);ZVCM6("SF51&V>F&/%,EU?38HK:5[Z#R[AMD,F\%9 M"`6."..BDY]C6/J6E:Q'HMU!8W%O>L;<16T,]O&@64\>:6'&!DG;M[5AW'A: M62*ZT6QMB+;2]$>RLFD78LMQ,A#,#T.`!GT,AH`[K^T+(QP.+RW*W',)\T8E M[_+Z_A4*:OI4UO):V_P_UN&[L4;[.UII":.:&095T8,C?0CK21W-O+-+#',CR18$B*P+(3R,CJ#BN M#T_P=KEM'IL::DUI]CU.>XF\I8R+D,),28VX4G>`4Z#DCM6V\ M]FEYJEO,+@1.8W1]^^,;\G<=NZ/<`,#'7'`!Z=!#_`!+``+4M917=Y*+N(WK2-%;.8VW!NK2#8RY]&ZFM/P]H MGBZ#6]4N;N[2T@G9?+&\W"MAW)P&;*@J5YSP>Q%`'8MK6F)'+*^I6BQQ,$D< MSH`C'H"<\'ZU:@N8;J%)[>:.:)QE7C8,K<]B*\^M-"UI5\27O]@VMOJM\JQV MH\R-H$520IP.=PW%R2.3P.!2CPKKFF>(M`ATHJFBV"1)(RSLI<`/O#)G!)9E M/0]3GI0!Z..E+2#I2T`9\W_(>M?^O6;_`-#BHHF_Y#UK_P!>LW_H<5%`!K'_ M`!XI_P!?-O\`^CDK0K/UC_CQ3_KYM_\`TI[4`;M%9'S_`.@G]*Z8'`ZYK@_B)J4^ MGW&E/`J;TE:96.<@KCCZ'-7?!7B6^U\W@NXX5\G9M\I2.N>N3[5FII.QTRH3 M=)5>AV%<'XI\$-?WKW]BZAW!:6)\G<ZM(; M*W>.&0HK,YRV![5HJWLG%CAE$;'S.P)P..U=>#FIIU(U%=#L[#A2TW-&:L!:6DS1FF`M)1FD) MQ0`4M53?6PE\LW$7F'D)O&:L`@C(HT&TUT'T4E'XT"%HI.:.:`%HI.:.:`%H MI.:.:`%S24A.*;N!/_UJ`LQ](>?K2]JP]2M?$,MXS:?J5G!!@!4EMBY![\YH M2!&WD8YZ4AX'0'T%*(]%LM*DLY?L=O)!J M04R@M]H,B*\9&?NJ-[^GS5KW'AS4)M"O]/DT.=MK$@8.>GO^E1/IP"<=>#7*:MI-_#X M;FLUTK2=0AAM@MK:16Y0>?G`.TDJJ#))[\5BW'AZ06DN@V4;SKH>B2QQ'!!E MNYXV`(SWVAO8>90!Z66&>O)_/_/-&X8R2`/KQ7C]KX3\2)'H[6QT66P'V"U@O(IPNV[N%FC9W,8;D!58 MEB06!Q0![*-H`P/3C-`(/OQS_P#7_P`]J\[TC0?%5C;Z7;6EQ#916VISO=QM M&2C(?,VM&`_^J.Y<1GE2NO&&FQ:I>O/J,"H[K(P,1B(,Z"#[. M.N=A;=N[YS4K0^._*A1&U,*'E-EN:+>I$OR?:3T*[,]/YXH`]0>2-7168!V) MVJ3RW'.!WI5="Q0$;EQD#J/3CM7FL=GXPEU;S6AGF:WN[I[>>Z\L`$P.$^7G M:@R#I2 MU2TH78TBS%^P:\$">>P&`9-HWM?^ MO6;_`-#BHH`-8_X\4_Z^;?\`]')6A6?K'_'BG_7S;_\`HY*T*`*&J6;ZCIEU M9I*(3-&4$AB60+D==K9!^A%>5Z1:V]GXIVMJ3L+*\BB:0^'K6..9VD*8215# M##J5+<8/YUZGJL]S:Z1>3VD7G74<#O#'C.]PI(';J17ET%QX7OM:\.:OIDUM M>Z]>74/VJTAEAZX.*?M'I2T`4(+2+S+@9EP)/\`GJW]T>]3_8XO M67_OZW^-%O\`ZVX_ZZ?^RK5B@#F]>$V6O&$W$URGE9QL?/7_>S65:^"[[19 M9)-%U,(LH&]+F/=G'3E2/4UV_;K1VJ'&+=S6->HH\E].QR8\+ZC=L6U37KJ1 M".8;?,2'ZG)/ZUFW/PRLYKB22*_GB1SD(%#;>/4\G\:[^DQ0X1>XXXBI!^Z[ M'+6G@+0H+..*6S6:51AI!^3Q M=>?\"3_Z]*OAGQ&O_,URD^\6?_9JV,ZO8?+A;^$>X64#^1J2/7[$OY)5/UM_P#Z]=3' M-'*,QRJX_P!D@U)GWJK)C]M+R^XY`Z%XI'_,QK_X#_\`UZ8=%\6@'_B?0-Z@ MP'I_WU7948!I\HE6>]D?/%Q%*MQ,'1V<,P8[2,G/6O4;33_%QM(3%?:?L\M= MH99`0,<=#79^4F>5!IX&*F-.S;N;UL7[1)*.QR(LO&2_\M]*;ZM**7[/XQ'5 M=*;Z33#^M==156,/:>2./*>,5_Y=--;Z7,H_K1GQ>.NEV+?2^D%=@?I13Y0] MIY(Y`S>*QUT.V;Z:@])]K\4KU\.H?]W43_C788%&!2Y0]HOY5^)QYU#Q(IY\ M,2$>VH__`%Z8=7\0+U\*71^E_79X%)BCE#VB_E7XG"WFO:RMG-N\-7$$;'S M!=E@G!YKA[#Q#K#:A:J^J7;*9D!!D.",@&O<)(DFC:.10R,,$'H163'X5T.* M42)IELK@@@A.A'2IE!MZ,Z*.(IPBU*.YLIR@I<4#@4M:'&)@4;1G-+10`@4# MM1M'/'7K2T4`)M&,8XHV@=!CZ4M%`"!0!@`8HP!2T4`)@>E)M!`!&<4ZB@!C M1HZX90P]#R*=M'I2T4`)M&LW_`*'%11-_ MR'K7_KUF_P#0XJ*`#6/^/%/^OFW_`/1R5H5GZQ_QXI_U\V__`*.2M"@!,"JT M=C:17,EQ':P)/)]^58P&;ZGJ:M44`%%%QH`ZBBN*E\0-._XEPU)=*:Z,V'$[(&_U>W[H)`SN MZ]J[,'C.:`(;?_6W/_73_P!E6K%5[<_O+@Y_Y:?^RK4^?I0`M%)GZ49^E`"X MHQ29^E&?I0`M&*3/THS]*`%Q28%&?I1GZ4`+BHI(8IEVR(KKZ,,BI,_2C\J3 M2>X&5+X>TUR2EN(F_O0L4/Z5&=%EC'^CZI>1XZ!G#C]16SQ[49'M4.G$#&^R MZS&?DU"&4>DL./U%'G:W&?FMK28>J2%<_F*VW6QMB?^ MN8_PIO\`9&F_\^%M_P!^Q_A1>IY`2_VC9_\`/U!_W\%']HV?_/U!_P!_!47] MD:;_`,^%M_W['^%']D:;_P`^%M_W['^%%ZGD!+_:-E_S]0?]_!2?VC8_\_4' M_?P5'_9&F_\`/A;?]^Q_A1_9&F_\^%M_W['^%%ZGD!+_`&A:'I=0'_MH*KVV MK6]W?S6D1RT2AMPZ-Z_S'YT2Z+8-&P2RM0Y!"DQ#BL:P\-7=C?1W,=W%E&Y4 M(0"#VK.4JB:L!U:]*6D'04M=(PHHHH`****`"BBB@`HHHH`****`"BBB@`HH MHH`****`,^;_`)#UK_UZS?\`H<5%$W_(>M?^O6;_`-#BHH`-8_X\4_Z^;?\` M]')6A6?K'_'BG_7S;_\`HY*T*`"BBB@`KE?$?A>YU[5-.O$U7[.EBQD2WDMQ M+&TO9R"1DKSCTZ]:ZJDP*`.-7P.@ULWCZE*;-K]=2>T\I0&N0@7=NZA>`VWU MKL"JNI#*"#U!YIVT9SCFEH`HP6=L9+C_`$>+_6?W1_=%3?8K7_GWC_[Y%%O_ M`*VX_P"NG_LJU8H`K_8K7_GWC_[Y%'V*U_Y]X_\`OD58HH`K_8K7_GWC_P"^ M11]BM?\`GWC_`.^15BB@"O\`8K7_`)]X_P#OD4?8K7_GWC_[Y%6**`*_V*U_ MY]X_^^11]BM?^?>/_OD58HH`K_8K7_GWC_[Y%'V*U_Y]X_\`OD58HH`K_8K7 M_GWC_P"^11]BM?\`GWC_`.^15BB@"O\`8K7_`)]X_P#OD4?8[7_GWB_[Y%6* M*`*_V.U_Y]XO^^11]CM?^?>+_OD58HH`K_8K7_GWC_[Y%'V*U_Y]X_\`OD58 MHH`K_8[7_GWB_P"^11]CM?\`GWB_[Y%6**`*_P!CM?\`GWB_[Y%'V.U_Y]XO M^^15BB@"O]CM?^?>+_OD4?8[7_GWB_[Y%6**`(/L5M_S[1?]\"GQPQ1#$:*@ M/]T8J2B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#/F_ MY#UK_P!>LW_H<5%$W_(>M?\`KUF_]#BHH`-8_P"/%/\`KYM__1R5H5GZQ_QX MI_U\V_\`Z.2M"@`HHHH`***0DYXH`7-%>@STY_&@"W15;[?:_\`/9?SH^WVO_/9/SH`LT56^WVO_/9/SH^WVO\` MSV3\Z`+-%5OM]K_SW3\Z0:A:$9$Z$?6@"U15;[?:_P#/9/SH^WVO_/9/SH`L MT56^WVO_`#V3\Z/M]K_SV7\Z`+-%5/M]KG'GID]L_P"?6G?;[7_GLOYT`6:* MK?;[7_GLGYT?;[7_`)[)^=`%FBJWV^U_Y[)^=!O[4R?G0!9HJM]OM?^>R?G1]OM?^>R?G0!9HJM]OMO^>RT^*>*8GRW M#8ZX]Z`)J***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`SYO^ M0]:_]>LW_H<5%$W_`"'K7_KUF_\`0XJ*`#6/^/%/^OFW_P#1R5H5GZQ_QXI_ MU\V__HY*T*`"BBB@`I,`TM%`'-'P;I?]N-JI:XR;D7AMO,_<9KHP./K3L50U>].FZ/>WRIO-M!),%_O%5)Q^-`%I$V.[`D[V!/MP!_2I: MX/PEK^KWFM16.I7<=VMWI$.J(\Q(Z5YAJ'C#7M*NO$BPW4&HVUA#"BW)M]BV]U)(%\OC[X56 M5CWZ#/-`'J`I:Y3PMJ>I7&IZ]I.HW*W3Z9M<+\1O%UWX?LQ;:3<6\6H"(W3M-@A8E8*1@]2 MQ8`?0FJEQXOU8:Y)=07,+:;#K5OI/V41!C*LBJ3)OZ[LN"`.,+TYS0!Z3135 M.5!XY]*=0`4E+69KVIG1M!U'4_+,GV2VDGV?WBJDX_2@"\4!F$@)RJD`=NL7]S;)^^LD1;>.4,V^,!B'7Y"H+'.>HKK_!FK M7FK:/.;]E>XM+ZXLWE5-@E\J0J'V]B0.1ZYH`Z6B@=**`"F2('1E.?F&.*=7 MFOBSQAK&D^,EL+29([1/LN6\@20IYDA5OM$F08N/NXSF@#TA!M15YX&.:?7G M&B^+=7O=[8KT93D9H`6DI:2 M@`XJ,(%F9QU8`'CT_P#UUR_B#4]5T_Q9X=@M[B!=/OKAH)HC%F1B(W?.[/`^ M4?F:XO5_B-KVE6`UM6@FM;NZO+2&T:'`A,6X(Y8')Y0[@?7C%`'L-%M?^O6;_P!#BHHF_P"0]:_]>LW_`*'% M10`:Q_QXI_U\V_\`Z.2M"L_6/^/%/^OFW_\`1R5H4`%%%%`!1110`5%+''-& MTNG MHQ0!EZ3HEAHD4L5C$R^=(999))&D>1SQEG8EF.`!R>@K4HK'\1:Y#X*&TNW1_$-O'8S3,1##:N]VT@"[F.% M0-\HSG`('K36\=^'5N881J:L9A$R.B.R;9?N$N%VJ">`2>O%`&EK'A[2/$%L M\&J:?!4SB"3:\FX)L1MN';<0-JDG-0R^/O#MO;QS27SXD21\ M+;R,RB-@K[E"Y7:3SD#'?%`'4C@45R"?$#1UO]6@G:>*WTR.*62\:%C$ZN,@ MA@,=Q]>HXJU%XUT2X>V6.XNJ%L;2ZCN))!>AXW58ADLO MR[64=SG';KQ6@OCOP\;U`#H_`WA^* MR>V6R22222>23S5>WUVPO-`?6K>7?9+&\A8*5("9W`A@""-I!!':LK3_&UB=" M@O=7D2RN3IZ:C/"JLPBA_0U5T?XA3:I%IMQ-I7V2&ZU-M.D#R[GC;R]\;=!] MX\8]Z`._K`O_``CHNIZDU_=VC//)Y?F@3.J3;#E-Z`A7VGIN!K>7.!GK2T`8 M5GX4T6PU1]2MK/9N`,UN`8'%+10`4444`8>J>%],U MC4;2_O!M?^O6;_P!#BHH`-8_X\4_Z^;?_`-')6A6?K'_'BG_7S;_^CDK0 MH`****`"BBB@`HHHH`****`"BBB@`HHHH`*R/$6B6_B+1+K3+B5XTF`(D3[T M;J0RL/H0#6O28&%=5O+FSOI?$.-4L_,6&=;)=H21=K`INY/`."?1Y='?5 M&;3TNOM=I"UN"87\PR$,<_.N688XZ]:EC^']O'&H%VD9^QW=JY@MPBL9]N7P M6)W#;W)SFNW`P,4N*`.%G^'PEMM0M5U618+ZRMK:8&$$[H]27? M@7[9XQB\02:I,WE7*7"0-%NV%4V;%;/"G).`."3S7:X&E`'.67AF*R\+WVBFY::.[-R3*RA?]GINZ MUQH\":[JR6]M?W*Z=`=`BTRZ>$+,SNCG[OH"`#GW([9KU7`SFC:,YH`X'4?A MI;ZJLYO-1D\V:\ANGDCCV<+"L+H,'A74'([9J:X\'W$>I645M)OLVUQM7N7; M"F+$>$C4=\MCGL!7<```>U&!0`#I2T44`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`9\W_(>M?^O6;_T.*BB;_D/6 MO_7K-_Z'%10`_4+9[NU,4M,\K5O\`G]L__`-O_CE% M%`"^3JW_`#^V?_@(W_QRCR=6_P"?VS_\!&_^.444`'DZM_S^V?\`X"-_\3J MW_/[9_\`@(W_`,3JW_/[9_^`C?_`!RCR=6_ MY_;/_P`!&_\`CE%%`!Y.K?\`/[9_^`C?_'*/)U;_`)_;/_P$;_XY110`>3JW M_/[9_P#@(W_QRCR=6_Y_;/\`\!&_^.444`'DZM_S^V?_`("-_P#'*/)U;_G] ML_\`P$;_`..444`'DZM_S^V?_@(W_P`3JW_ M`#^V?_@(W_QRCR=6_P"?VS_\!&_^.444`'DZM_S^V?\`X"-_\3JW_/[9_\` M@(W_`,3JW_/[9_^`C?_`!RCR=6_Y_;/_P`! M&_\`CE%%`!Y.K?\`/[9_^`C?_'*/)U;_`)_;/_P$;_XY110`>3JW_/[9_P#@ M(W_QRCR=6_Y_;/\`\!&_^.444`'DZM_S^V?_`("-_P#'*/)U;_G]L_\`P$;_ M`..444`'DZM_S^V?_@(W_P`3JW_`#^V?_@( MW_QRCR=6_P"?VS_\!&_^.444`'DZM_S^V?\`X"-_\ GRAPHIC 7 img003jpg.jpg begin 644 img003jpg.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W+4-073T1 MF0ON.,"J'_"21=[>3\Q1XE_U$/\`O5SE`'1_\))%_P`\'_.E_P"$CB_YX/\` MG7-T4`=)_P`)'%_SP?\`.C_A(XO^>#_G7-T4`=)_PD<7_/!_SH_X2.+_`)X/ M^=#_ M`)US=%`'2?\`"1Q?\\'_`#H_X2.+_G@_YUS=%`'2?\)'%_SP?\Z3_A)(O^># M_G7.4L8!D4>I`H`Z+_A)(L?\>\GYBE/B.+_GW?\`,5XMH?C#Q#J/B);8K'<6 MWVJ6*5%LV01(I(#^;T.,#BD\-^*]?U5WFN+B,QK!-)Y8TYT7*@X_>GY3R*`/ M:?\`A)8L_P#'O)^8H'B2+_GWD_,5XGX8\;ZQJ%WF[,5W;I9/=7*):F!H`HR# MD_>!/&16_IVH>)7M8]2OY=*:SN[1[B**(XDAPN5QD_/Z&@#TW_A)(O\`GVD_ M,4?\))#_`,^\GYBO$M'\7^(+O1[Z_GN8V\FP>X5#IKQJ'`&!O/#L_P#"21?\^\GYTG_"2P_\ M^\GYUYMX,O->U6"6\U:\M)8/-D@2."`HVY&QNR>,''2LBV\::DM[9O,=3;2([Q?*5GTRYNOFB/WD/H>E`'L/_"21 M?\^\GYBC_A)(O^?>3\Z\5L/&>M26FK&XDAE>WL?M,+/9M;MO#`%0K$[UP>OT MK52\\5R^*[73UU+31;3VJWN#:MN";@"F?7K0!ZK_`,))%_S[O^8H_P"$DBQ_ MQ[O^=>2:5XA\0>(%LK'3Y+"VO989+B:>XC)!42%%54'7IDG-1_\`";:E'<:8 M);6!HUDN(]2$/S`K$0#)&?8'.*`/7_\`A)(O^>#_`)T?\)+#_P`^\GYBO-M+ M\2R3^$-1UR81S_9I+CRA&-H=$/R?F.M58=9\1V,VG2ZM)IMQ;ZHC&%+5"&A; M877DGYEXY-`'J?\`PDD7_/O)^='_``D<7_/N_P"8KR3P)XCU?Q#-OO[J-XO( MWF-;%H@"3@;7/##Z5>.I^(K_`%"\N--?2X].L;K[,\%SD/+C[Q+]$Z\#O0!Z M;_PDD6,_9Y/S%'_"2Q?\^TGYBO'?^$HUN?QCU,#$9.,\^W-`'??\))%_SP?\Z/\`A)(O M^?>3\Q7%^';R?5/#>F7]SM\ZY@5WV+@;CUQSTKF=6\3ZO"=0O[:ZTVTTZPN1 M:M'<1L[S,`"22/N=>,T`>M?\))%C_CVD_,4?\)+#_P`^\GYBO%-?\;:O9Z[< M6]A<6ZP*D)MXVM&D$S2+D*9.`N3T)K=N-3\1W]_?1:6=.LETV-#<1W0+,[E- M[+_LJ.F?7-`'IW_"21?\^\GYT?\`"21?\^\GYUXU-XWU6>U9;&WB%_>P07&G M0LF?E(/F`^N"I_,5:D\2:UJNF:KJ6C75G!;6$2/^^A+^8PCW.HQT.>*`/6_^ M$DA'6WD_,4O_``D<7_/O)^8KR1?%&I:*=%DUV1;R*_B>5A8V;%U^52J[?Q/- M;GAK6CJWATZK=,$C\R4EMFTK&K'&0>AP.?>@#OO^$DASC[/)^='_``DD7_/O M)^=>1>&O%VH>*%U*SM+RP@OB%N+-RI98XBV"CCJ6&.WK6KX,OM:U33&U#5[N MTFBD9TB2"$H4*.RDL3U!QQ0!Z1_PDD7_`#[N/QH_X22+_G@_YUY5-XHU:T7Q M$UY:V\3V(@%M$&W`>8<`NW?KDX^E:^DZE>2PZO;WK1R7>FS&(RQQE1)\@<'; MVX(H`[[_`(22+_GW?\Z/^$DB_P"?>3\Q7B=MXZUB;3M*C;[-_:+W*_;,1G`@ M8KM('8GZ)N)XR46**3:%"CJQ^M`'K/_``DD M6,_9Y/SH_P"$EA_Y]Y#^(KQ[7_$^NZ3;Z4DMS907$RRFYEMX&ND^0C!"CD=> M?2K%EXA\0ZK;:+8VZ6=MJ6H12SFYFC)0Q(0`RH.[`@XSQ0!ZQ_PDL/\`S[R? MG2_\))#_`,^\GYUXW?>,=;L4MH'2T-U;7SV]^\2EDDC158NOH<,>.Q!I4\<: MC+>:LL"6KP>;!%II?A0)'*;W/ID9H`]C_P"$DB_Y]Y/S%'_"2P_\\)/SKR34 M?$/B'01>V.HR6-Q>QP1W,$\$9`VF0(RLI/N<'VKH/%>L?$[X?GO=T<<'&?I6EHFM^)=7T*UO(;>TFW73*\[(8P\`_C"YXYX MQUXH`]5_X22'_GA)^='_``D<7_/!_P`ZYL]>WX44`=)_PD<7_/!_SH_X2.+_ M`)X/^=#_`)US=%`'2?\`"1Q?\\'_`#H_X2.+_G@_YUS=%`'2?$'%_SP?\Z/^$CB M_P">#_G7-T4`=)_PD<7_`#P?\Z/^$CB_YX/^=(_\`40_[ MQKG*Z/Q)_P`>\/\`O&N!' MKFJ5EX-T+3KN2YMK-U=T9`K2LRQJPP0BDX6MZB@#FK7P'H-G%+%$EX8I86@: M.2Z=D"'J`"<5J1:)I\&K0:I%!MO8;<6R2!O^68Q@$=^@K1R:,GUH`JZ=IUKI M=LUO9H4C:5I2"<_,QRQY]S52V\-Z59R[X[S:VD5+;=Y3QS,DBACEAN!R M02>E7+?P]I-G)9-;VBQ_8HGBA56^4*_W\CN3WK3R2,9HH`H:9HNGZ5IC:;9V MX6S8NS1N=P.[[PY[>U4=/\&Z#I5RUQ:VCB1D9%,DK,(@PP0@).WCTK=]L4PM0R6\">7&A;.U?3-95]X1T+4-4_M&YL]TY8.X61E21AT+J M#@G\*W![#^E';C/UZ4`<_+X,T:;57U(B\2X>43L([MU1F&.=HX["DB\%:)#J M#W\272S.[.RBZ<1DL"#\O3OZ5T(]J*`,/1_"6D:%=&YT];E'VE`LERSJH/8* M>!1J'@_0]5U#[?=V;-,<>8$E9$EQTWJ#@_C6Y1@GI0!F2>']+FCOXVM@8[]4 M6=-V!A!A2H[8'I534/!NAZG+#+=V\K21QK&76=D,J+T#X/S_`(UO9]23ZFC4[+4!;*L]E$8;_M1GIS^M`&;9Z!I>GFT^RVWEBTCDCB&XD;7^_N]2:J3^#]$N-.CL)+>3R M8I&EAVS,KPECDA&!R![=*W>]';':@#%3PKHD=K;6R6>(;8R%%WY+&1=K%B>I M(]:2+PGH<5I):_8]UO)!';M&TA/RI]W'H02>>M;=&:`.?B\%:#!IMW8K:RF* M[`6=WF+2,!R!O))Q19^#-#LWB9([B<12>:J7-PTJ[L8SAL@\5T%+D]R30!E1 M>'=+M]3&H0VYBG$HF"QMM0.%*Y"]!P2*L:?IEKI@N!9H4CGE,S)NRBN>I4=L M]<#C-7.GM^%'U'/TH`****`"BBB@`HHHH`***/P_QH`****`"BBB@`HHH_"@ M`HH_"B@`HHHH`****`.NT/\`Y!,/_`O_`$(T4:'_`,@F'_@7_H1HH`J>)/\` MCWA_WC7-R,4B=E7>P4E5'\1`)Q^-=)XD_P"/>'_>-6TTUM5N=6COI3;&:32XX@'A8-C&1R`.^[ZBJ\_C*_N]/M[RW068>" M1FC(#ABLB#=TLGMX9$:7[7-;A(IT!Y.[N/KC/TJP=2\/Q MV\)-WIL<$@Q"=R!2,\A>G&<9%`#+G5DL_%T=A=7L$%J]D9`LLBKN??C@_3M6 M$WC.\MD?;91W21K+/+(\P0B-9=GRX'/˗,^BW-S)%=/ITUQ;IYC+*58Q+ MZ\]![T)>Z+*8%CGL'^T@^2%*GS5ZD#U&0":`,K0O%_\`;FO7FFKI\D4<`.V4 MGDX..1[]O:NFK"_MVS@UV>Q;2+N"95WRW9@14V`X#ELY*UHSZQIEL#Y^H6L6 M,?>E`'(R.<^G/TH`N4576_LGNOLR7<#W!3>(ED^8KC.<>F*L=*`"BBB@`HJM MJ-]#I>F7.H7`G%0MK&C/;-*`.(O?$FK&VTLVNK*LUQ'2MNDFA5V.W;DXZXJD^H^'KK4OL,HLI M)75)D:55(GW]"I_B/'7UJY_;6DHLC?VE9JD+"-_WH`C8]`?3T_"@"_15-]7T MV.%97U"U6-LE7,@`(!P3GTS0NKZ:\2RI?VS(REPRR@Y4'!Q]#Q0!]`!7*>);[6H]-&RX8`;RW1>>W-:$_BFRM]7DL)+> MZ`CG2W:X\L&)9'`*KG.=9*/,D.TO""?7DCKTSWH?6="L4N'^ MVV,.U//F",H8J0/F(')R#Z4`:GX8HJK!J5A<3+;PWEN\Q02")7&_:1D';[_2 MK5`!1110`J\L,]/05YC;>,=_V5=7W]OP-=FUFD.G>4,V[*<`#N,=]W7/%/F?Q%#X>MWGU2ZMM1N+A(K=7 M6%PY<#&<#``Y/KP:Z7[9HH>[?SK`.B!KI@5R%[;SW'/ZT[^UM(8VP-_9DR@/ M!EQ\P'&Y?\:`+R*R(JN_F.H`9_[Q'4TM5=.U&SU:S6[L9UG@8E0Z],@X(/X@ MU:H`*YWQGJ5_IFD6TNFRB.=[M(R2N#G&,D]ZLW.IZW#UH`R9;S5+;5-6\K5Y9H+<1VZ1R1)_P`?$A&`I'91SSZUS\GC#7(K MQK#[2&E_M`,)3&,?9@XC9?3.X]>M=7IGBS1=16=_*:S146X9[I456!("L6!Z M_7!K36\T=Y65)[%I%3SF'RDA,YW8],\T`ZYK0\':MJ=]'D5+ MB*XTQ!>,8Q(C(/./=<]^>W-)%KVDS7(%J?M#H6@+PQ%A%LY*D]AZ#UH`U\8X M]**@L[I+VU6XC21%8\+*NUNN.14]`"K@GV&,UYM<^+=6MKC6(I+]'D6WN)+0 M0*DD2[,8)Q\RD=]PP<\5Z1WSW'(]JYO4/$6BZ;K%Q83:>S3,(Q<2QPI@[_N[ MN7*TF``<9X]>#3$U'3+A5E6Z MM)58,-P=6R%Y8?0=Z`,'0O$CW"72WM]`UPMK;RPPLRH[LT6Y@!G)RWIGVQ7/ MVOB_5;FP99M0%K*[AY)FC0I`"C,$STR2`OS[:H(.X],9Z=\ MUNUD7VO65GJ(MVM;JYDAV^;)!#Y@MPY&-W<9QT%`&!8W>M:A/X>D;6YH1J$, MCRPB%"%*#.,^A[_I5.;Q'JH@OY8-,Y.5B5NH`P,MU.:Z^X MU72;..XQ+;L]C&7>&':7C4]?ESD>]-670$:XCQIR.L8DN(L*"J\'+C]>?6@" M70;RXU#P_8WEVFRXEC!=<8YZ9_'&:T*@M;NTO8?,LKB">-#LW0N"H([<5/0` M4444`%8WB?4Y=,TC_1/,-["]T\1`@SR1NH!)Z;C[^]`$/A;49-5\*Z=?SR^;++#F20+MW M-D@G''I6O4-I-;3VZ26;Q/;]$,6-O'IBIJ`"BBB@#KM#_P"03#_P+_T(T4:' M_P`@F'_@7_H1HH`J>(_]1#_O&N:95D1HW&492K#U!H>)/^/>'_>-U"5RHQYG8PH_#M[%8R6*:_` M4_@36O-XOTB!KE9990(%8LQA;:Q7[Z*>[#N*KE.E827=%*;P-!-;7MJ^H2+: MW)+JGDJ'60XR2_WB..F:MZ'X3MM#F@F68S20P-$"Z=V;<6&<[?P-.;QAI20E MPUR7W,AA%NWF@`9+%5[6$S%C&0C#`/!^G-'*/ZG+N MB_+I4;ZI/?L3)YMH;0P8PK+DGK_D5R]MX,OTL],C-Q&ERDLSW4Q02E59=B*` M1SA>/PK3G\9Z?%>PP`$Q$N+BX92(X]L>XX;H<#J/>M/1]=L=>LS=6$QDC5MA M#+@@CVHY06#DW9-&/IG@2QTO7H=4@NI6$2`+&Y_B"[=V[.!QVQ754W<>.>G3 MVHW'UHY2_P"SJG<=138!G'(.?T_6L M*7P;'YMXUKJ,ULEUY>Z,(&50H((Y[$Y/L:Z;)HW'U-'*P_LZIW.6M_`\,#VH M&H2+!%!Y$BQQ!6G&TCYFSSP?2H)/!=Q$EH;>_66>.>+,KVZ!4BC!`^3HQYZG MK78;B#G.#[54U*^.GZ7T:DJR.7R/3.2,#I1:^"TAO1=7.HMU5;J6X\GR%?@+N`,G/(`SWKKBQR3G\1_2CE9,<%.6S.4/@\7EYK$E MPP@@NI$^RQ@AMBA@[\=/F(J>;P;%+.KI?/&L5X]Y#&D2@+(Q!`.>PQC'OFND MW'%&31RLO^SZG<=G/).2>I]32CL?>F9-&XT!X6DO`E^\4%S!Y(A6(8&,?,QS\Q&T M>E%SX*:\N9;BZU620O$\2C[.H*!@`><\X*@@'WJ)O&-Y/I=U?V&G02+!=?9] MDT^UI,XV$8ZEB?R%=6C2%%,B[)"`67T/I1RLB."G+8YW3/!L&G>)#K0NWEE* M\QE=JAL8)&#C;QTQ73#&!BFY-&X^M'*R_P"SJG<=13]8%IX(CAFBFGNUD>.XAFVQ6BQ1L(\[04!().3E MJZ?Q>'47C^RR,Y=(`KR`L6VAL\#KQ@U6@\:ZA#FGTXV]_J;W M6VU%M"?LX18XMP;&,\DXQR>E:.G>'K728-0M;1BEI>$D18!\LD8.&)R1W&>G M:M4$#L/RI2Y_#T_S^E'*P_L^IW./A^'T:6S02WZ%O+2(>39I$"%8-EP#\Y)' M4U8D\#VQUR^U6VO98)+D-Y:J@;R7..1S@@`=,=Z=_P`)+J?FWUO_`&,@EMP& M3=<`(BEL9F.,+P-W%;.DZB^IZ5;7SPM`TR;O+8Y(_'N*.1DK!5'HF8*^!@D$ M:1ZFR3+<-.UPMN-_S8W*IS\HR,^G-;FBZ0NCK>I%,98KFY:XP4`*%A@@GOSS M5[/'_P!:E+$G)Y/O1R,K^SZO<=_2BF[CZT9-'*P_LZIW'=ZYG5?!ZZIK-Q?F M]2-9Q&LBFU5W4)TVR'E,^U=)F@'..>_>GR"_L^KO@QGO3BKQS_LY_&K^@:(N@VXT9.*.5E_V=4[COJ6RW5O;/K40(_E.70Y`(P<`YQ@'\J M7*R%@YWL7--TF+2Y;QH2#]ID5]NT`)A0O&/I6A3`<``'@<4N31RLO^SJG<=1 M3\-I<6LXGCD$/FGVITEXY+V MSCAC59%5%?8^XL>H).<<\<5JW_B<67B@1@RJ99'(I]=:[2XLTM'A*LL3$[BASAR#ZXXQ1RF:P=2]KEKPMIMQI'AZWM+OR_M&]Y M)!']T%F)P/SK7[#Z4TL23[FC<:?*:?V?4[CJ*:"-)/^/> M'_>-9>D*K7PWJI78<;AU-1.IR1YD5!N+NCDHO">GQ64EGY]\]LRA1"]TQ5`# MN!`)XY]*BOO!NGW=M=QPL\4LZ,JLSETC9OO.%S@,<M:FF_$/3KB767GAM MWAM?GM1`F7D3?Y>&!P-Q8@X'9A4MIXWMP+O^U-):V=)Y(;>(*K,[+LQ%P<;R M6Z#L*Y?K\E]DZ?;S9E_\(CI30!#]H,NXEK@3L)&!7:5+9R5(XQZ5(_A72I;C MS624?N3"J+*0B(1M.!G@XKH8_&&D?VI?6-[;?9/LL?F>?(JM&Z[MI((S@[N, M'TK/DUK5VO=7A2'2HK>UA,ZW&TR+;@'Y1)C[S,H+8'3C/6A8]O[(_K$S+D\( MZ--.TDD4CJVXM$9CY>2NTMMS@$BKVDZ/9Z+9FVL@RQ[MQWMEB?U1=D/F-B/>I.>>_I6Y&NM_N?-L--Y+^;M8\#^'''TS2 M>86WB"Q%1.Z9D8]Q1C_:%=/812M91M?VMO',?_`'P* MS_M5=B_K=7NYQ^/<5!>6<%_9RVE MRH>&5=K#./RKM_L\/_/&/_OD5F:],^G:)>WEG917$\*%DB*CD_YYQ[4UFE]. M43Q=6UKG"2^#-!FMA!/9",;RXTJR MG&F6LC/JBZ?<3[/+0`L!N"MSDYZ5WPMX?^>,?_?`JIYBX?9)CB:BV:^XY#'N M*,?[0KL#;P?\\8_^^11Y$/\`SQC_`.^!4?VJNQ?UNMW./Q_M"C'^T*[#R(?^ M>,?_`'P*/(A_YXQ_]\"C^U5V#ZW5[G'X]Q3)H(KB%X9D26&12KHW1AZ5V?V> M'_GC'_WR*J:E+!I^FW5X;9'%O$TFT*`6P,XZ4+-;ZH%8T?C+59O#UQ>QVNEB\MSYSVTD+K(8"H<80 M\]#][D8YKT.V6WN;6&=(H2LB!QM`(P1G@XK2>8N/V28XJJMF'_GC'_WP*8\ M<"(S&*+"C/*BA9K?2P/%U;;GG,/A32H(9$6.1@\D;DR2LQ^0Y51DYV@]NE;) M&>I'YUAVGB_6KK3M2+6>FPZG$%N+>U>$DO;G<05P3O8A>G&.M=]I$]OJFCV5 M\(8/](A63]V`RC(S@&M:F8..O*3'%55LSG=ON/SHQ[BNP^SP_P#/&/\`[X%' MD0?\\8_^^!6/]JKL5];K=SC\?[0HQ_M"NP\B'_GC'_WP*/(A_P">,?\`WP*? M]JKL'UNKW./P/448P>H_.NP^SP_\\8_^^!2&"'H(8\_[HH_M1;6!XNKW/,&\ M&:6UM=6YFO\`R;J3S)5^TM@MG.:VK6U6SM8[=99'5!@-*Y9B/ MHVWEZ1.%NXK&VG6!E59I#GY_4*N,X[FNI\.WJZSH-K?/;0QR2`A@BC:2&*DC MV.,BM)9CRQORD+$U%JC%Q[BC'N*[#[/#_P`\8_\`O@4>1!_SQC_[X%9_VLNQ M?UNMW./Q_M"C'^T*[#R(?^>,?_?`H\B'_GC'_P!\"C^U5V#ZW5[G'[?E=A]GA_YXQ_\`?`H^SPGCR8_P04?VKTL'UNKW/,IO".DR_:MRS#[2K*X$ M[?*&.6"C/`)Y.*U+&QCTZS2UBEED1!A3+(7;'ID]JIMXVO'N-96&PM%\E94L M(GC*M+)&X0_,<*PR>0.G'K73>%+]]9T-9[V&W6]CE>&X1(MHCD4\KSGIZUJ\ MP<5=Q(6(J)W1G8]Q1C_:%=AY$&.(8_\`OD4>1#_SQC_[X%9?VJNQ?UNMW./Q M_M"C'^T*[#R(?^>,?_?`H\B'_GC'_P!\"C^U5V#ZW5[G'X_VA1C_`&A78>1# M_P`\8_\`OD4GD0_\\8_^^10LU78/K=7N<%+I%G.]\9%+&^14F^8\A>F/3\*? MI^F6VEP-#;[_`)W+NTKEW=O4D\GCBI-5U;7;#6=2BM;33KVUM+4W'E)"PD0D MXC4GHQ.&)''"UJ^#M7'B#1Y;BXMH5F@N'@=HX2BN5`.X*W('/>M7F#4>:Q*Q M52^Y1Q_M"C'^T*[#R(?^>,?_`'R*/(A_YXQ_]\"L?[578KZW5[G'X_VA1C_: M%=AY$/\`SQC_`.^!1Y$/_/&/_O@4_P"UEV#ZW5[G'X_VA1CW%=AY$/\`SQC_ M`.^11Y$/_/&//^Z*%FR[!];K=SA'TRU>[GNF#&:>#R'.X_1#A93&7&2.`>!\O< M1#_SQC_[X%9?VJNQ7UNMW./Q_M"C'^T*[#R(?^>,? M_?`H\B'_`)XQ_P#?`H_M5=@^MU>YQ^/]H48XZBNP\B'_`)XQ_P#?(H\B#_GC M'_WP*7]JKL'UNMW//;W0-/O[Z.\N(BTB;0P#D(^#E=R]"0>E.TS1;/2?,-IY MFZ3`+2R%B%&<*,DX`R<"MC6KS4[/Q+IMK9KIAM;C+2QRPMO6-!F1]PX'50,] MSWJOX)\0W/B/[:-0L;6$QA)(5CCP2C@D'G.5XX;C/I6W]H>[S58C)YD?F1R1F-USC<#U'ZUN^(_P#40_[QKG,5,DI* MS`EGBT>YMH;>;1K=XH8S%&AX"H1@C]!^51V]IHEK!!##HD"QP7`NH@6SME`P M'&>^*0@^F/KQFCGW_P#KUC]6I]AW)+*'1M.O9;RTT>&*XEW;W5N3N.3^O-01 M:=H,,M[)'HL8:^5EN?WK$2ANN1G'/K3_`,Z6CZK#M^(7'7D&C:A>Q7EUHT,M MQ$JHDA;!`!R!QZ&M4Z]S_P`>X_[[K'/0FE/!QDBD\)2>Z#F9K_V\?^?/\`S[C_`+ZK(Y'/./>DY`Y/ M(H^I4>WXASLV/[?/_/N/^^ZBN=4AO+:6VN;))895V.C/P1Z5F?,#ZGTSBC!^ MOTIK!TM^4.9D\?\`94-C!91Z5$MO!*LT:;B=K@Y#9ZDY[FM'^WS_`,^X_P"^ MJQP#TYI>?7'MFF\'2>Z#F9K_`-O'_GW'_?5']O'_`)]Q_P!]5D8/3DT8;WJ? MJ5'M^(<[-?\`MX_\^X_[ZH_MX_\`/N/^^JR,'W]J#D`GD=.M'U*CV_$.=FO_ M`&\?^?'39BT M_L"W\D2^<%WG._IG/7IQCI6XNN!%"):JJ@8`#8`%9%'XFF\)2>Z#F9L?V\?^ M?/_/N M/^^JQ^?4_AUI<-[_`(`T?4J/;\0YV:_]O'_GW'_?=!UW((:V!!X(W<&LCD8Z MFCGKDXQ36"H]@YF0?V3X<^Q2V8\/VWD2R>:ZAB,MV.>H^@K:AU>.V@C@@LTC MBC4*B*#SUX_G2_G3>$IO=!S,U_[?/_/N/^^J/[>/_/N/^^JQ^?4T M<^IJ?J5#^7\0YV;']O'_`)]Q_P!]4?V\?^?K>QX'2K=MJD%E:Q6UM9I%!$H5$1L!0*SOS'XTG.>]-X.D]U^( MN9FQ_;Q_Y]Q_WU1_;Q_Y]Q_WW6.C/O1]2H]OQ#G9L?V\?\`GW'_`'W1 M_;W_`$[C_OJL?/O1D^]'U&C_`"ASLN27%A-]L\S38G^V*%N-S?ZP`8`/X4ZP MO;32[1+2RL$A@3HBOG]3R?QJCS[TO.,X/YT_J=+L',S7_MX_\^X_[ZH_MX_\ M^X_[ZK'_`#HR?>E]2H]OQ#G9L?V\?^?/_/N/^^Z/[?/_`#[C_OJL?/O1D^IH^I4>WXAS MLT&O[5[\7S:>C70B,(D+<["XS5>;4]9B6"U(E$K1B*7]SG:3&6WY]<@5 MV@L[L'(MIAW_`-6?\*/L=V/^7:;_`+X-`'*V6JWLFJ6-L/->!ODF+P;2/D!W M@_6HYM9U/S;S[-B9H9I$:(0D>4BD8;=_$>O%==]CNR,?9IL8Q]PTU-/N(PP2 MTE7@#CCJM^^LS3PR2!%1X[9/()6;YUP#Z$@GGVIIU#5+0.$!14" MGYXV9FY8E5)R">!7:FTO"U2XFACDE$L MTNV&2/'EX`()/XGBH;[4M4DTR17EV!E/ER0QDF8AU^7_`&>"3GVKM?L=W_S[ M3#Z(:!:7@Z6\_P#WPU`'/:EL6T%K^[CE"*\IC+[W85',;W4-'TUG MBQ,\P$J,75<#.0#@=ZZ7['=CI;3#_`+9FC[%=<_Z-,,]<1GF@#EGMS9/Y M.I3S/;>6QA,1?`D)SM!ZG`QC/%.:W5-:BN3#=$+I[2%9)&SYF>,@'&[`Z=*Z M<6=V"<6TPSU_=FC['=_\^TW_`'[-`')VMA=G4KYI@72-(R&=Y`V?+S\@'R]3 M5*R\ZSM;>34EN8X7LM[&V,CM*_=6SG:WTQ7[9J1/-,4[>7/*RV[>J&=3,`"&]=S]CN_\`GVF'&.(S1]CN_P#G MWF_[]F@#AR;@J##-*MB54S-)O/[W8>!SGEOP'TJU`UTVIHLB2,H+-2!FQB2 M/[PP<"7.(C&=K- MY:$#VYS7;BTO!TMY_P#OAJ/L=V?^7:;_`+X-`'''4-4DOXF21_,?$MS(82/*`D"JW/!.W)Q76FSNSUMIC_P!LS4]=;'IT\2!([*2-`,!5C('\J?]CN\8^SSX_P!QJ`.- M_MC4Q(91$Z1[T.UH2)'!1>/3KGTJ-]4U6UM&2-IY;D3N=LEOU7S,!<^R\UVW MV.[SG[//US]P]:/L=V!C[//Q_L&@#D+JZUAXH6:9T1Y$D;9!@QKYFTCW&W&> M]3W]Y>6VO71M9'?='#Y`8^SSX_W&H`YNWO+T6.JW`$KSKMDB@DCQL!4 M8''7O^55+W6;ZWAB:UE>Z8$$DVQ429<`K^`)KKOL5WD'[--D?],S0+2\&,6\ MXQ_L-18#D1J>L)%&\F0LR[G?[,3Y`\PKG'?C%$VKZJD\@A\MXTCS&7B*F;Y2 M=P';GC%==]BN_P#GVF_[]FC[)>?\^\__`'PU`&?8^<;"W:X2,] M/TJQ4_V*Z_Y]IO\`OV:/L5U_S[3?]^S0!!14_P!BNO\`GVF_[]FC[%=?\^TW M_?LT`045/]BNO^?:;_OV:/L5U_S[3?\`?LT`045/]BNO^?:;_OV:/L5U_P`^ MTW_?LT`05#=0&YM9H5D:(R+M\Q#\R^XJ[]BNO^?:;_OV:/L5U_S[3?\`?LT` M8;Z-(ZN!JEVNZ)8\ANFT\M]352X\Q7NDD:HV&@#DEU?59FCM]C).`1.1;G]VWF8[_P"S5C6+ MJ_L[I6M^ M3S[4?;M;W[V(4&-Y/+\C[I5@`F<]P?TKJ_L=W_S[3?\`?#4"SNQTMIO^_9H` MX^VUG49XU=90T+%O/E%N?]&`?`('\7'-/&M:HB%9(2'9XQ"?)/[Q-S!F]N`. M#ZUU::?<11A$M)54=`(SQ3OL=WDG[/-S_L&@#EQ?:I$B">;:DBAY)Q!GR;_O@T?8KO.?LTW_?LT`5Z*G^ MQ77_`#[3?]^S1]BNO^?:;_OV:`(**G^Q77_/M-_W[-'V*Z_Y]IO^_9H`@HJ? M[%=?\^TW_?LT?8KK_GVF_P"_9H`@HJ?[%=?\^TW_`'[-'V*Z_P"?:;_OV:`( M**G^Q77_`#[3?]^S1]BNO^?:;_OV:`.GT/\`Y!,/_`O_`$(T4NCH\>FQ*ZE6 M& GRAPHIC 8 img004.jpg begin 644 img004.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#VG5]7.E&+ M]SYOF9_BQC&/;WK,'B\X_P"/+\I?_K4GB\?-9G_?_P#9:YFMH0BXW..K5G&= MD=/_`,)?_P!.7_D7_P"M1_PE_P#TY?\`D7_ZUIW.G_P"$O_ZM/V<;7L.-6K)V1U'_"7_\`3E_Y%_\`K4?\)?\`]./_ M`)%_^M7+1SVLC!6O+>,DX^=L5:>RE$1EC*31C^.)@P'^?I4+V;=D=$J6+C'F M<6EYHW_^$O\`^G+_`,B__6H_X2__`*&[RY17D9(5([\G\J ML/X3F"$I=(S=@R$"HM3-%*LT3?\`"7_].7_D7_ZU'_"7G_GR_P#(O_UJP;RQ MN;%]MQ"4ST8'(/T-5JI0BS-UJB=FSI_^$O\`^G'_`,B__6H_X2__`*?;>YT_B_K9_\#_I7,5T_ MB_K9_P#`_P"EK7Y@0 MD1K@N_;Z?6N1UO6#(YAC.$7C(H\,^(/[$U#S)MS6[_?`ZK[BO,GCE[3DCL?8 M8?AJI]4=:>LGLNW_``3VJ'2[&%-J6L>/5ER3^=9NK>'X)H&EM$$4R?,`/NM[ M8[5>TW6++5(%DMKF-\@'`/(^HJ>[O([2!Y'8`*,CD<^U;JI?5,\66'=^1QLS MS2[NEL[=I64DCMC^?I7)W>KS3N3OX_*O0K?R[RWE,T8*SY9@1ZY.*\J=0LSJ M"<*Q`_.N3'3G=.^A]=P[E]"FI=(_)8_G5RQU&YL9Q/;3/$Z\!E MJI:!9)E5N`3BNBNO#YE6)=/1YIG&=B=*X(1E>ZW/H<54H0]RJM']QIV MFIC41O*JL@'S8_B/K5OC%8H\/ZSH:+=7%L?)5=SLC!MOL1Z_I6Q'*D@1@00X MW#WKU(XQ4J+E6TY?Q/SC.\'2C5]IAG>,OP9/#;RSG$:$C^\:OQZ'.ZY,L:GT M-3V7(';%:R?=&*^.Q?%M?GM1C9>9QT,)">[.;N-)O+==S1AU]8^M>KE/$JKU%2Q"LWLR<1@N6/-!F!1117UQYUW MU"MO0K5/.65QENV>U8E;MA,(KD#H,"LZFQTX=7EJ=BH&T4V22.)"TCJBCN3B MJLVHQ6MH)7R2>$0=7/H*H+IDVHOY]_*P!/RP(>%'I_\`7KG.T2\U*WO(G@$! MEC;@LPP/PKC]9M[C3+![I$\R-.7/=!V..]=Z-(ME'RAP?=LU7N]/#021L/,B M92K9ZX[T2;Y6D52Y(U(RFKI,\4N-9GF8DL>3V-;VAZ!J&H1+8J^C?Y%>E?V=FMCX_$4%B*;G&-I+73JNN@44=S16][]3P9*2" MBBBF3<****`N%%%%`7"BBB@+A1110%PH]/K11Z?6DP6YT_B_K9_\#_I7,5T_ MB_K9_P#`_P"EE2ZT@AUN[`(VL^\8&!@\_P!:2PM+B^NX[>VA M>65S@*HS_P#J^M?-.+YG$_8U5C&@JDG96-?0+R.QO1*V1D_PG!/Y5NS6%_JE MT+Q4D6U3YL2R$9QZ`ULZ%X!FLE6:XCB-P.09#D#V`KH_L4]M@RQ_+SD]017H M4,.U&\V?%8_.*;K1 M7N7A#1_[+T2'S[:/KL;6\:2$8(!4YZ\5> M"2;;9YG%,IQA"*V=[G021+(A1E!4C!'J/2O+;^,Z=KLUEC;';A8XQ_LA1C], M5Z8^HVRKGS.3T`ZFO*-;N)&\17DTF>*]!>I\5*3Y>4ZJPE^ M5>];4+CC-<=I]Z,`9KH+>Y!`YK\\K0E"?,*A5Y'9FY(R%!CK5<8;CL>#4(F! M%(\X4$YZ>E4\3.I6C)*VVQV\\.5ZG+SQB.YE1>0KD#CWJ/\`SSQ7*Z]XPE_M M6[AB01>7*R$]R0<5J_#>\AUC79Q?R;Y(HP\$;L?F/(;CH>,5^Z4LOK1P:Q%3 M:R9XGLW*1JG(7)!`/0E2!5TRX19^0`"6_`*%MH5M;USM4X20]AZ&NN^)UNDWAX29/ MF0N)%P,\9`/\Z\?5L+C@^]>=5FZ-7FB?AZ_)XBT^*$2/=P M[?4-G]*Y2*>3Q1XL!MU(MXP/,;)X09[CN2>*R/#_`(:OM=E0QKY%OG#3L,#' MHOJ:]=TOPY:Z)8^1:(0.KNW+.?4FNA5*M=)/1(\[&3PV`3A3?--Z>2]3@/$& MDWNB!;B&626T'#%FY0^_M6;::Z^0LGS`<<]:].O+:*ZM9K:508Y$*,,=C_\` M7KR;5=&ETJ,%%%%`!1110`44 M44`%'I]:*/3ZTF"W^XZ?Q?UL_P#@?]*YBNG\7];/_@?]*YBHA\)KB/C849P/ M8T4#DX`)/H!FK=K:DPDXR4EN6XU&)H$SY@6-?3.>]>G>#O#]GHUDOE M1J9V'[R4CYF/?GTK$A4)-\X`8*64'!_2NMT:<&)4_"N'V$(S/-'@U+P^QD7B"02#!(VCH3^M>.W/AF\0[K M7;.AYX8!@/H<5]"W<*W-K/;N,K(A7'U%>-R7ZZ<)5F)#1,5('4D&L*U&G-:A0UOT.431]5#$#3[DX](S72:+:^(D"6YEBM8?6Z*DJ/89S1IM] M=>(-1%M+(8;8`LT<9QD=N>O4UZ#9:=:1(JI!&".F1DC\36.'PL9/FBV?09CC M:WL_9UXKF]+V%TZQ\B+#RO,YQO=L8S[`=*Y[7M,$FKR88*6"E3U!XQS773V< MBQL;9C#.1E21D'ZCN*Y:[U:*^N%#JL%_`6BN(5Y!QT=3W7VZUTXBC3G'V=38 M^2J8>J<\UI6UW,#@Q29'4;#5R&=8UWGCZ>M:M MG=SLI$;;5/7U-?(YM@,'AES2FT^VYQAGI>2JH)CD`_P!PU9@$US-&98V2 M#/))QG\ZUD!(RS$Y]32N@=<-G'<@U\_@<1@H5U.JFTGY?D;K"RY;W/GS7SCQ M/JP!'%Y+C'^^:JP3RVTR3P2M%,ARKHQ!7WR*Z#XA:1)O'6H^)IXXWA2WMH6S'%&2QW8QN+8'/6LL>)9 M_P"S/L><)Z5C*PW`GI65#*J$9NI*"OT_X8I"_TR/)Q-'\IXQGWK MK].U,Q$*QYKE/`.AB7PR;R3.U<9=R;Q3J0U2&X@C<*I0QIGOGJ:YG1O#-I"ZR3@WF&!&GME.T M2%L;``5Y]A7<&ZRO##M7FVNEK_Q#.MNC M22,P4*`23@`5R8Q^XDCW^'$OK+DWHEU*EJ^+E<5W,1S"A_V16)I_@?Q!*R2F MT5`3TEE`(_#%=7-HM_90@RP911RR'HCXH****`"BBB@`HHHH`*/3ZT4>GUI,%O\`<=/XOZV?_`_Z5S%=/XOZV?\` MP/\`I7,5$/A-<1\;#OV%8.K>)#;M]GL&P1P\V.2?05?UBZ-MI[E20S?+GTKD M-/TN]U>8_9XMPSR['"C\:X<96GS>SIGV'#66T73>+Q&RT5S4T'4G.K+Y[[O- M!3^M!YN M/,0#YAQNK'#U''W:FYTYW@H5VL1AW=;.W0].M+Y)8QD\U_DBP0V M1[&M&/7G`QAB<=`,FNVQ\M?N=#?3I:6&*477=27160_3;V73[I)XL;EX(/1AW%>CZ-XNL+@JKOY,HZK(./P->6( MWOQ4\;F-@R]17)0Q,Z.D=CZC'9=3Q*O+1GM&K>);*TM1<2$,`/E5!DL:\JN] M3EN-5EOR2'9RV/1>F/R%03ZC/<0JCN2!ZU5W_)UJJ^*E4M;H<>#RFGAX23UO MI\CM+:[^TS)_=`!P/?FNKL/NBO/M)FVQPL3U4GW(*CFOA\WE.M445LFSI8QOP*GDBV+D50@G[BK1F+CDUYE&=*%*2FO>>QV0ESV:9C>)-& M@UW0[FR=5\PH3$^.4<#Y2/Y?0FOGMPREHW!5D8J0>Q!Z5],L0HSFOGK6((AK M6H&U.8/M#["<]-Q]>:_5O#+,Y)5<-4^%6:[+O]YQXU*ZL90BYZUL>&_#\NO: MO%;ABENIW3RX)"+W_/IC\:T-`\+/J#":]WQP=H_XG'K["O3M.L8+6%888D1% MZ!1^OU]Z_0,RSRG"+IT=9;7Z(YHT[ZLZBV&F6]K'!!-$J1H%51Z`8K-U6!'0 MW4>"R?>P<[A4D,*MP!T`&*IWMX(IS;VZ@L!\['M[5\6VV[LV((;C&`&&?RS5 M*YU$W%UY47\!Y?KS5ZWM4(!(R>O-6!H\##**(V)SN%("WH$@'!Z^M=0!D5P] MI(]E=F.0%3FNNL[I98QR,TAIENFL,@@C.>,4[-)04>7^(;G^SM5GLX@=[R`0 MKZENGX?X5TGA+0;;2[4N$#W,GS23'[S$]>?2LG6+>VG\5S7I&9HE$:-NX`P/ MRKI]&G7R@H]*GE;^(V=;E@H4[Z[^?_`-E5`%.VBFKC'%.JC"R.6\0:*B*U[; M*%V\R1@<'WKF:]*FC62)D895A@CVKS>*)Y7$42,[=`%&2:WIRNM3AQ$$I:#: M*VH/#-]*`9#'"".C')_2HKGP[J-N"PC651WC//Y57/$R]E+>QE44I&UBI!!' M!'<4E40%%%%,`H]/K11Z?6DP6_W'3^+^MG_P/^E`H'YU#J5M]KL7C'WL96L[3;XX`/$L?R MNO?BN.:Y*W,^I]EE5;VN!C27V6[_`#U3/0K2=,`2#D6R M_=P2H)%0'IUS^HKK+74U*EE>'G]8:M[K6O8U=.ORT2G)Z<\UU6DZ=>ZD,QXBB'65QG\A7">&(#>WPC M;/E1X=SZ^U>UZ6BI:*%``P*NC/F@I'S.8X5X?%2I]%^ID7?A=&T^6-)Y&E*\ M9Q@D5Y)XIAD$,+2*5DB8QL".F>>:^@/PKEO%?A"V\0VD@!\JY*_+(!D$CID= MZ5>#G!HZLHQZPM5HWD!EO9X[,G&U<;V_'H!^M=;X,T;2]'LU==CWC+B6XNN,<65*DN6"NH!(B%7[P[=A6];*,@8!`'2ON^'\'4RZA);2EO^A6LMR@FCO;+NB/F*O4$?-5N MV8#%;-O&6'R@Y]A5:_LF0^>BX(&74?SKV+MNXR6*5(+.XN9,E84+X'?':NYK4B:) M@?WR?+U&:P+6$<9Y^M:D,",.0/RH`DO[-;J'Y6'F+RK#G\*S[74)+9MLG';( MK5CMF+!800W7`Z54N='U`3.\<*LA&2`W?VH!(T(=;C(`9P*=)JS2X2$'G^+T MKGSNBD\N6,H_]UEY^HK1LU$DBJ,C-!1BZC"(M7DQ_P`M`&)/0^M7K"X,+*R] M/2G^)[0VSVEP#P
@[C^M4+:3@8H).SL[Y9UP58$5;,BK]Y@/J:Y_3+Q86 M.[H:NW=W%+@+CZTAW+EW=1VUL\K$?*I(&>I]*R/#MK''`'P!(WWC5+5)0;0H M,G<0#[5;T.X'E@57035WBI>J;B+"3H.N/O#TK*M? M#$T\0DEN5C!Z!4W&NO;A6/M5>R;,3+C[K&JYVM#)T8-W.?F\)D9\F[/L'3^9 M%85W8W-A*([B/:3]UNH->C?2JU[9Q7ML\,HR".#Z&JC4=]3.>'BU='G5'I]: MEN8&M;F2W?[T;8/TJ+T^M;[G%:SLSI_%_6S_`.!_TKF*Z?Q?UL_^!_TKF*B' MPFF(^-A61J6BBZ;S;=BDW7K@5KT45:<:BL]S?!XVMA*G/3?_``3S_48]8M24 MG><+ZG./TK.MXKBXE$<,,LKY^Y&I->K).X78V'3^Z_(%<]J=]J%_<-8Z6C!, M8?R1M+?\"KR,1@^1ZNY]WE6?SQ*Y(P2:W>R1)X3LWLH[@3E4N-ZAX]X)48SR M!_C7IND78>)03U%>3Z-'WL^ M79GAYW"?UF563O>UGT.\'/-&T>E9EGJ:2(`S5?%Q&1PPK8\HI:LD9TRX#(K* M$Z$9'I^E?/E];3:!K3JC%&C;?#)ZKV(_E7MWBC68;6Q-LCCS9N#D\*/4UR$7 MAL>+BOFI-'%$"4G4`9SV!/45SXBBZD;QW1[.49BL)4:JZPEN4O#FM7>HIF9% M1%X,BG!8^PKK8;C(!:1B1ZGI6:?",/A[33^_ED*N!'OQ@YZY(';K4&X[<`_+ M]:Z*$)\MY/4RQN-P<:DIT8_@6+V?S[@G^%1@'UJMSG'SBG=(]&+5C`LY45`S'C^=:UO/+(/E`4>O>N.H]_:G6W+CG``Y M-<_YYN[R69LX9B`/0=A0!8ELUU!2LJ[4W;@JGH:>-%\H!K8'`'W6JU;@8'`K M6MXF=`5&10!B6S8(!R"/6M[3H!/D$].U4[^RPIE48=?O#U]ZCLKUK=LCJ>M` M)G306ZP[B.IJ;`]*C@??$#GG%2TBRI>V45]"8Y!@_P`+CJIKFQYEC=F)_OH? MS'K77UR_B8K%>6[]"Z$'W`(IH3(M=N_MVCR(5`>,AP<>G7^=<`&M6WDZ>OK0!KM;/ M=:?,$&6`W<>U9EA=&!AZ(^-A1116 MIEU(+R1H[21ESD@`8/J:NZ-"D$(50,]R>YK,U08L]_9&!-3Z?>*K[<\'E3VQ M7))_O=3ZW*(?[)[O5NYTUWID&L6$UI,O!0E6QRK8X(]QQ7#Z'K#RQB"Z8;D' MWFZG'K747>L16&GS7$C<*AZ=SCH/?FO*DE:/D,1[YYKCQ=;DE&2/9P.7+$TJ MD:BTTMZZGI4&I)P8YNO8U=74IV7B4*, MF?O&NF$E./,CY7%4)8>LZ19(EQC@=!VJ>GE>C]ZXKQ0/^)OC'6(?CUK6EO8Y\3%.-S%Z<44$Y-%;G"689%:/RW.,? M=-<[KGB.V>UDT^)3,P8'?G"J1_.EU[4/LMOY2-AG'S8]*X]-TLH$:,S,<`+U M)]!7DXO$N,^2!]UD.2QK4?;XE:=#3M]8N(6PGEG!Z$'D5U6D:[;W4BQ-^ZFQ M]UNA^A]:AT3X;WU]"LU[.+1&&0BKE_Q[5T%M\,;*+!EO9Y#SG"A1[=/\:SH^ MWO=FV8O*FG&+M)=E_2)+J?R]-N&#%6\IE!],\5A0W45M$'FE6-.F6-=1<>&V M2T^S2LSPG:N]6R1S[UY-K,-Q;ZQ<6MPQ+0N0-W0+U!_*NBO6=.-['D97ERQM M9PD[)([+_A,-.@("B:4'C*)CG\36_I'CS1?+$4[RVK%N#-'P?Q&0*P?"6AP+ M:)>2HLDLHW989VCMBNR:PM[B`QRPJ\?0JR@U5*%2<>9RMY'7BL/@J,G3BF[= M;_\``+"2OS@XSR/\`)H$>?6=QTRP)K=MK MCC'6D&EVEX%)4QOV:.I(]!N]P$$\<@)Q\W!H`T(;GH?3O6=J6G)?:A#<%L1E M=L@'4D=*G?2]7M1F6RD*XR63Y@!3(W=A\Z.H]60B@+'6:)IVG10*8[*`-M`S ML!/ZUMBUM_\`GA%_WP*YK1[W80K'%=1'()%!!I%(J2Z9939+VR9/=1@_I63J M&@M'&TMI(QVC/EL>?P-=%44Y"02$\*%)/Y4+<'MX0 MQJV$/7GDUG<&EKHC32U//G6;T"CT^M%'I]:MF2W^XZ?Q?UL_^!_TKF*Z?Q?U ML_\`@?\`2N8J(?":8CXV%%%%:F3&2QB:%XVZ.,5QMW<7VCSE``\8Z!AP/H>M M=K56]L(+^/;*HW`<-CI7'B:$I^]!V9[^1YI3PE3V=57@]_)G!7>L76H$"XE. MT=$'`%5PXQUK=N?!M^[DVPC=<]2X%36GPZ\0W4BKMM8U(.'><$?3`YKQITJW M-[RN?HM+-,!&FFII(QK>9E<%>O2O0M%)73(9(QS@D_G4=A\/(='MC?:O>"8J M/EAB^568]!GK_*K,+FW`5``N,;:]'!T:D8NY\;Q#F6#K5%['62W?D=-INJ!, M*Q_"MZ.\C<=:X1986.0VPU86^\D?Z[/TKJY&?/JHK7N=K+=PPQM([@*HR37! M:E=&]U"6<\`G:HSV'`HNK^6Y7820G<>M5*TA&VIRUZO-H@HHH[BM.ASKI/S%U"9`78XAS_".YKFO%-JRWADQP>?KQ7>^'G%O:V@ M`VJ84X_`&O&I4[UY.1^AX_&.&54HTOM)?D>B1@>6,4[`JO:3"6,<]JLUW'R9 M&P4@@CBO(/B9I@L]9M[U%Q'.GED]MR^OX?UKV`CK7(?$*P6_\.3!?]="/-3U MXZ_IFL:\.:FSTLHQ'L,7&3V>GWG.>$]46?3XX.`\8VD=R.Q_*NTMKWRXRHQ@ M]S7A5M+-52/8)E/^V4Y']*RH8V,8\L^A]/C\5H8X_!0PN6N$GK>_S/0M M"\.Z38J'6-KB8CF2;G\ATKBM8\W3O$%Y:LS!!(6C`)QM;D?EFNDMKR>V(!!P M.,UD^+4_M!8+U/\`61C8XQU&G0UKV M<^<$GF@9TUN^",UTEFL4]@T3'.]2K<]C7'03<=:T8;DIQDX]C0!B0LT4CQ,> M48K^1Q6G!/@@YK(U1A!JC.<;9?GX_7]:DAN<`<\T`=3'J(3J4AM+I-&)[>0.G]X?R-=#8ZQLP&.*Y/PUID*W4)>7]W*"&3= MW[5U-SH,4;+Y5T<'^\N?Y55)NI&X8W">PJ\D'=&TNKP[*R]>U-GL!%$ M,+.2I<\<#&<5#!I\,)\Q]T^TY*-P/RJOXCO([F:WBB`VQID^Q../T%:P7O'F MUVX1:9B4445TGFA1Z?6BCT^M)@M_N.G\7];/_@?]*YBNG\7];/\`X'_2N8J( M?":XCXV%%%%:F3"BBBD`^.5HSQR#U%6X]0:$?(K#Z'BJ-'2DXIFD*DH*R+%S M>S71S(Y(["J]%%-*Q#;>K"BBB@04444`%%%%`%+4]/6_M2G&\#Y34NBLRV"0 M,"LMO\I!.21GC\,8JQ0I*,63`A'O7/.BG/F1Z=+,&J"H5-8IW7D='IFI M[3M8G-=)#>1RJ.<&O-AJ<"OME;R7']_@'\:M1Z]%$/ENHF'LP/Z"H*3T/0S* MF,EABN;U&^CNKI@`3&%V<]_6N?E\0/,I0/M!ZY/7]*B6^&0`V23VYYI6NK,< M9---'F^IVYT[4[JT/2*0JOT[?IBJR.%[@UV/B'P_=7]W#>QP.JNNPEAC)''\ ML51MO"D@(,K!0.N37D3PU5S:BM#]$PV>X-8:,JLTG;57U,RPMI+F8*%SS753 MIV6K.7U#P+I5XK&'S;>4_P`2/D?B#7.2^$;[391&]S%(K?=95(S]:],JAJR@ MVB_[XJ32QP@T^]MTW&,.!U*FA+H#@G:?1J[FRLD9`[C.>U6&T^SU@)]3& M,T[A8\PUM_,M4E09:,_F#65'?[5.Y@`.YKT?5/"-K=*S6K-;N?X1RK?GTKRW MQ7H=Y8W4,-NDIBDRI0=5<=B?<!PJQ-=4Y2M14E4F^:2/ MTK!T,/0I^SH6-.TU6X@GAE5CF)@P!/7';\J]0T_7;>_LA<1.",<@]5/H:\>6 M3G!J:#S9KB.W@R9)&"J/<]./SK?#8J5)V74Y,PRZG6CSOW;?D>RV=]%>6N^` M%@9&08'WB#CCVHU?094B^U0Y=P,R(!^HK1\-Z1_9>F6\;@>8B!1WQZ_GUK^IX\ERMH*/3 MZT4>GUH8H[_<=/XOZV?_``/^E4QY'W:NVM[):OM/05SRC8]*G)21U<6D:;"X>* MQMT8=UC`JR+>$'(B0$X?OPH]!56NJ":1YU67-+0*EML>>F?6HJ56* M.K#DJ7-L).,UU44@DC#"N##D8EC/OBMK3]5``#'!KE:/ M2B[ZG35D:M<@3PPYY!W-4\NKVT%NTTK@*!^9]*Y1[UKB5YF/S,V?P[4BFSM; M5@81CI4]8^EWBN@!;M6N.>]`(;COBN:\4V$4L"S%!@G8_'?L?PKIZQ/$TBQZ M60W.77`IK5V#GY+2['GZ/)8RX.=F>#T!%.O8K#5;P^[1*DY:-'IT\YA%*75'G\NGW*WSVT"&3:Q4,.C> ME>I>!?!L.F^7J-Z1+>D912.(L_UK-T_2XHY3('!=1E5QC'O7066HO`0KGI7- M#"QIN[-\;G];&4N2.D=GYG:*.*6LFWU=&`W$&G7.M0V\+2$C@<#U/I72DVSQ M')):G/>)V!UC`(XB4'\R:Q:EN9WNKAYY.7384>GUHH] M/K3)6_W'3^+^MG_P/^E/QJ*2:27[S9'8#I4=%'*ANI*6X44451`4444`/CF:-B0,CN*9>WQLUWM;RX MZY7[OXGM16K!($F`8!D*@$,,@UC4.O#-MNYR_P#;,MZX#M\@/RH#TJ]!=@\$ M]:Z>?PEHNJ+YPC>VF(^]`VT?7!XK/F\!W439L]0C89Z3+M./J,_RK*YTV&V= MZ82"#E:Z.TUA649(KFU\,:[;2%$6VG3U\S'\Q3[FWGTP1"Z0"60$[$;..W6F ME?8)-15V=A_:4."GUHH]/K28+?[CI_%_6S_X'_2N8KI_%_6S_P"!_P!* MYBHA\)KB/C84445J9,****0!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`5;B;S8L`_.@_2JE*I*G<#@CI4RC8?ZL#:F?2H9[R6==A)"=<>M5_PJX0MJ7NQ\N[.<>_M69_PB)_ MY_/_`"%_]E75=J2N93:T/3E2C)W9R_\`PB!_Y_?_`"%_]>C_`(1`_P#/[_Y" M_P#KUU%%/VDB?80['+_\(@?^?W_R%_\`7H_X1`_\_O\`Y"_^O7449H]I(/84 M^QR__"('_G]_\A?_`%Z/^$0/_/[_`.0O_KUU&:,T>TD'L*?8Y?\`X1`_\_O_ M`)"_^O1_PB!_Y_?_`"%_]>NHS1FCVD@]A3['+_\`"('_`)_?_(7_`->C_A$# M_P`_O_D+_P"O749HS1[20>PI]CE_^$0/_/[_`.0O_KT?\(@?^?W_`,A?_7KJ M,T9H]I(/84^QR_\`PB!_Y_?_`"%_]>C_`(1`_P#/[_Y"_P#KUU&:,T>TD'L* M?8Y?_A$#_P`_O_D+_P"O1_PB!_Y_?_(7_P!>NHS1FCVD@]A3['+_`/"('_G] M_P#(7_UZ/^$0/_/[_P"0O_KUU&:,T>TD'L*?8Y?_`(1`_P#/[_Y"_P#KT?\` M"('_`)_?_(7_`->NHS1FCVD@]A3['+_\(@?^?W_R%_\`7H_X1`_\_O\`Y"_^ MO749HS1[20>PI]CE_P#A$#_S^_\`D+_Z]'_"('_G]_\`(7_UZZC-&:/:2#V% M/LC_A$3_P`_W_D+_P"O74T4N>0>PI]CEO\`A$#_`,_O_D+_`.O2 M?\(@?^?[_P`A?_7KJ:,T_:2#V%/LC_A$#_S^_P#D+_Z]=1FC-'M)!["G MV.7_`.$0/_/[_P"0O_KT?\(@?^?W_P`A?_7KJ,T9H]I(/84^QR__``B!_P"? MW_R%_P#7H_X1`_\`/[_Y"_\`KUU&:,T>TD'L*?8Y?_A$#_S^_P#D+_Z]'_"( M'_G]_P#(7_UZZC-&:/:2#V%/L EX-101.INS 9 sbfm-20140630.xml 0001402328 2014-01-01 2014-06-30 0001402328 2014-06-30 0001402328 2013-12-31 0001402328 2013-01-01 2013-06-30 0001402328 2012-12-31 0001402328 2013-06-30 0001402328 2014-04-01 2014-06-30 0001402328 2013-04-01 2013-06-30 0001402328 2014-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Sunshine Biopharma, Inc 0001402328 10-Q 2014-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2014 0.10 0.10 5000000 5000000 0 0 0 0 0.001 0.001 200000000 200000000 44051 31240 5640 0 38411 31240 44051 31240 282500 12500 93874 23809 5898 2641 382272 38950 0 0 65966 60299 6409606 5426140 0 0 -6813793 -5494149 -338221 -7710 44051 31240 65965728 60299061 65965728 60299061 Mountain West Business Solutions, Inc. (MWBS) was incorporated August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009 MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. The financial statements represent the activity of Sunshine Etopo, Inc. from August 17, 2009 (inception) through October 15, 2009, and the consolidated activity of Sunshine Etopo, Inc. and Sunshine Biopharma Inc. from October 15, 2009 forward. Sunshine Etopo, Inc. and Sunshine Biopharma Inc. are hereinafter referred to collectively as the "Company". The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.   During the last six month period the Company has continued to raise money through stock sales and borrowings.   The Companys activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Companys current technology before another company develops a similar technology and drug.   The unaudited financial information included for the six month interim period ended June 30, 2014 was taken from the books and records without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations for the six month interim period ended June 30, 2014 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2014.   The Company had outstanding loans of $12,500 accruing interest at a rate of 12% and $100,000 accruing interest at 10%. At June 30, 2014 and December 31, 2013 accrued interest was $5,898 and $2,641, respectively. During the six months ended June 30, 2014 the Company issued 5,666,667 shares of $0.001 par value Common Stock as follows:   In January 2014 the Company issued 200,000 shares of $0.001 par value Common Stock for cash of $40,000 or $0.20 per share and was paid directly to an affiliated company for licensing rights.   In January 2014 the Company issued 600,000 shares of $0.001 par value Common Stock for R&D services valued at $96,000 or $0.16 per share.   In February 2014 the Company issued 66,667 shares of $0.001 par value Common Stock for cash of $13,333 or $0.20 per share and $3,333 was paid directly to an affiliated company for licensing rights.   In March 2014 the Company issued 10,000 shares of $0.001 par value Common Stock for services valued at $1,400 or $0.14 per share.   In March 2014 the Company issued 1,000,000 shares of $0.001 par value Common Stock for services valued at $170,000 or $0.17 per share.   On March 27, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for origination fee valued at $75,000 or $0.15 per share as part of a convertible note payable for $100,000.   On April 14, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for services valued at $100,000 or $0.20 per share.   On April 17, 2014 the Company issued 1,700,000 shares of $0.001 par value Common Stock for services valued at $323,000 or $0.19 per share.   On April 25, 2014 the Company issued 400,000 shares of $0.001 par value Common Stock for services valued at $60,000 or $0.15 per share.   On May 15, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for services valued at $80,000 or $0.16 per share.   On June 12, 2014 the Company issued 190,000 shares of $0.001 par value Common Stock for services valued at $30,400 or $0.16 per share.   March 27, 2014 the Company issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $100,000 plus 500,000 Common shares (paid) and $20,000 (unpaid) for origination fee.  This Convertible Note accrues interest at the rate of 10% per annum and is convertible at the option of the Holder into shares of the Companys Common Stock at $0.20 per share on or before September 27, 2014.  Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon Conversion, the stock may be valued at either the book value or the market value of the bonds.   May 7, 2014 the Company issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $500,000.  The note proceeds are payable on an as needed basis. During the quarter ended June 30, 2014 $100,000 was disbursed. This Convertible Note accrues interest at the rate of 10% per annum beginning in three months from the date issued and is convertible at the option of the Holder into shares of the Companys Common Stock at $0.20 per share on or before September 27, 2014.   Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon Conversion, the stock may be valued at either the book value or the market value of the bonds.   For a complete set of footnotes, reference is made to the Companys Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission and the audited financial statements included therein. 5666667 68270961 5898 2641 0 0 0 0 12889 8279 7983 5665 153333 325000 70000 5655 214777 24689 169405 75000 326000 684610 60000 64500 37200 5400 32020 1620 1171387 1072984 765513 152593 100000 0 100000 0 323000 23400 323000 0 4188 1606 3105 153 148257 5705 52875 375 -148257 -554656 -52875 -375 -1319644 -1627640 -818388 -152968 -0.02 -0.03 -0.01 0.00 63309853 54248411 65468255 56564063 0 0 0 0 0 0 0 0 -1171387 -1072984 -765513 -152593 0 -548951 0 0 280000 463000 10000 0 60000 0 160000 463000 0 0 -272829 -439006 3257 619 70065 -302 5640 2030 -43333 0 -75000 -5086 860800 636310 7171 23994 38411 31240 132638 156632 593400 576310 0 513000 0 0 170000 0 43333 0 40000 0 0 0 50000 0 EX-101.SCH 10 sbfm-20140630.xsd 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Unaudited Statement Of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Unaudited Statement Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. Nature of Operations/Activities link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. Unaudited Financial Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. Issuance of Common Stock link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. Convertible Notes link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 3. Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 4. Issuance of Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 sbfm-20140630_cal.xml EX-101.DEF 12 sbfm-20140630_def.xml EX-101.LAB 13 sbfm-20140630_lab.xml Minimum [Member] Range [Axis] Maximum [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Prepaid expenses Total Current Assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Current portion of note payable Accounts payable Interest payable TOTAL LIABILITIES SHAREHOLDERS' EQUITY Preferred stock, $0.10 par value per share; Authorized 5,000,000 Shares; Issued and outstanding -0- shares Common Stock, $0.001 per share; Authorized 200,000,000 Shares; Issued and outstanding 65,965,728 and 60,299,061 at June 30, 2014 and December 31, 2013 respectively Capital paid in excess of par value Accumulated other comprehensive (Loss) (Deficit) accumulated during the development stage TOTAL SHAREHOLDERS' EQUITY TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Preferred stock, par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock, par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Revenue: General & Administrative Expenses Accounting Financial Consulting Legal Licenses & fees Office Merger costs Public Relations Research and Development Stock Transfer Fee Writedown of intangible assets Total G & A (Loss) from operations Other (expense): Interest expense Beneficial conversion feature Total Other (Expense) Net (Loss) Basic (Loss) per common share Weighted Average Common Shares Oustanding Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net (Loss) Adjustments to reconcile net loss to net cash used in operating activities: Stock issued for licenses, services, and other assets Stock issued for payment interest on notes payable Stock issued for payment of expenses Beneficial conversion feature on note conversion (Increase) Decrease in prepaid expenses Increase (decrease) in accounts payable Increase in interest payable Net Cash Flows (used) in operations Cash Flows From Investing Activities: Net Cash Flows (used) in Investing activities Cash Flows From Financing Activities: Proceed from note payable Note payable used to pay expenses Note payable used to pay origionation fees Sale of common stock Net Cash Flows provided by financing activities Net Increase (Decrease) In Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplementary Disclosure Of Cash Flow Information: Stock issued for services, licenses and other assets Stock issued for note conversions Stock issued for net deficit of MWBS Stock issued for interest Stock issued for payment of expenses Loan proceeds used to pay expenses Cash paid for interest Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. Nature of Operations/Activities 2. Unaudited Financial Information Notes to Financial Statements 3. Notes Payable Text Block [Abstract] 4. Issuance of Common Stock Debt Disclosure [Abstract] 5. Convertible Notes 6. Financial Statements Interest accrued Issuance of Common Stock Shares issued Par value of common stock Custom Element. Custom Element. Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity General and Administrative Expense Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Repayments of Notes Payable StockIssuedForPaymentOfExpenses Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash EX-101.PRE 14 sbfm-20140630_pre.xml EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0"I$?$9D@$``/0*```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EEU/PC`4AN]-_`]+;PWK MAHIH&%SX<:DDX@^HZQEKV-JF+0C_WK/R$4,FA$AB;]9L[7G?9V=+^PY&R[J* M%F"L4#(C:9R0"&2NN)#3C'Q,7CI]$EG')&>5DI"1%5@R&EY>#"8K#3;":FDS M4CJG'RBU>0DUL['2('&F4*9F#F_-E&J6S]@4:#=)>C17TH%T'==HD.'@"0HV MKUSTO,3':Q(#E271XWIAXY41IG4E]=J>*V?5@^@8B)G:13'&HX<85?= MWFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B] MSCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`HI?_(5$!``!A M"0``&@`(`7AL+U]R96QS+W=O81$U"$SM8WD?__40HZ0J==@F^&"235P]O+,O;W7?;1)_@L+8F M%6H2BPA,;HO:E*EX/[P\K42$7IM"-]9`*LZ`8I<]/FQ?H=&>/L*J[C`B%8.I MJ+SO-E)B7D&K<6([,+1SM*[5GD)7RD[G)UV"3.)X(=UO#9'=:$;[(A5N7U#] MP[FCRO]KV^.QSN'9YA\M&'^GA/RR[H05@"=1[4KPJ1A2*/N=U82(A;P/HZ:! M:=24PPE-P$L`UNSY)Q126`:E7`XH6E8&+48TQNLM(/BS3NZ,9"$+VUUD^:L M46/"#,U\!1E2E_Y6',RHS@R5_X99<#`JN#6L-_/`/VK.>C,J#?IS0W/M>GC[ MF*U/DSZ4_3JTCKQY&&4_```` M__\#`%!+`P04``8`"````"$`6>O_$D`"``!-!0``#P```'AL+W=O`?KI-%S%E]$+`"=FDSJ[9P]/RU_7;'`>:$S MH8R&.3N"8]>+GS]F>V-W;\;L`B30;LX*[ZMI&+JT@%*X"U.!QIWT8Z-;>.1&.E>+WVDM_Y"M]2E\:+&&3 M^@J=Q2RP4XD?=I7%C7#*_`R^D6AOQE^: M\_L<&DK*0QLT;CLT;.N)OQQVWFFA"2H(41`+^?; M[QB3P$P(H7UH&^;GL?\>XYG,P[?/XJ"]9U6=E\>USI:FKF7'M-SDQ]U:_^?O MYX6G:W63'#?)H3QF:_UG5NO?'G_]Y>&CK%[K?98U&G@XUFM]WS2GE6'4Z3XK MDGI9GK(C6+9E520-?*QV1GVJLF33#BH.!C=-811)?M25AU4UQT>YW>9I%I7I M6Y$=&^6DR@Y)`^NO]_FI/GLKTCGNBJ1Z?3LMTK(X@8N7_)`W/UNGNE:DJ^^[ M8UDE+P?0_<^E2U]*WNBF+_Q3$ M.E?*">^-#57YH<%A@JOJ4R*/'5N#P+$A-?Y%X M2R%(DTZ>I)>U[NH:++Z&L+P_.MZ#\0X[F79(,(+X&`G/B-PWZ38Z/^C=,CPD M/A,R:*#H(@LV9"AK/#[GU4M8KOX\;Z`>@.^+'([G#:$86(DND:(D_B:&#A! MZ[!WE^`(LK&! M0KSV()*PA!.V:,(6C]N0#'A_YLN0,(F2A6,0*`0FOBBE4;I+1'>)>(I`\L17 MY$F81,DF\A0BVBA9W.0T4D,[$]0<#F)$HN+/FQTS"1!2) M2*`0)4J8\(-7%2*[[5![-+1;7'K`#N(A(#Q;L!Y`PF3),;C8IV]`"1-A`L\; M*$0)8\*W3:(\'`(N".O7I2[SH9TSVW5=/$.,`%MX?7I`PORO"),P$4:F#12B MA+DC$1O:'>$0V='0S!P+?HBL(6!QM#%(%X-J9'[$6IHHNTJYTN-:[Z3Y'EE9 MV/E0=D<(*@W9&?<&$6E#&B/`X^Z-B#&9I6>?Q98FRGK'[<1!Q]BC-_R4,9HR MQC>,.$PR:\\7HW+\,%NYY,4(9/5V"1.3)Y`084>,RHWN#H]O#,>R9+*>+TNE M=B2+UAA,,>IT6=P:D74N$&3!2#1'=X?'B.#6S2N>R=0]7YI*]$@:K2]:C^<7 MRV)75V%G5_&"2P'?"!$:;C./O+)F1&Z(".9PQR=$A`GF,LLC MZ2/&B.ERW^M7@B7*U#U?HDKT2"*YH`,V+`86XQH1,BX2(^,J,3,I4^;Q^3)5 MUH>;X%+DNOUY[VY[Q4P5PNPN$MU'XDD$QU)F]?DB50V`8DG.4<"&=<+"X9Y+ MHAUVA'H[%Q:U1]@#LSWND$EBC$#CH9\#R>-?JD5:&F=LE]QI0<>,7RU3QFC* M&'=&E606CNWY3I^'L*0O%2%<-190Q&@1TC'GN4%W:\&RY1%P^PWCZL28QA'KS\@ZGKI&+\M)A?FTB1`V`&C_83H:C0I%N(K MH$\R6!@I4V0KSH+WW9K-]/)5BU5U4;LLBJ719FAT.MI>6;;)U: M$(?+TTM;]XG+]AQY'K`5-`VOGT?0!FZ?&YEF5S_B";CI<._N/_```` M__\#`%!+`P04``8`"````"$`XMC8UEP"``#8!0``&0```'AL+W=OF.,C*5U3BM5\Q3ON<'/V>=/TU;IM2DYMP@8:I/BTMHF(<2PDDMJ`M7P M&FX*I26U<-0K8AK-:=X%R8KTPW!$)!4U]@R)?H1#%85@?*[81O+:>A+-*VI! MORE%8XYLDCU")ZE>;YH>4[(!BJ6HA-UWI!A)EKRM:J7ILH*\=]&0LB-W=[BA MEX)I951A`Z`C7NAMSA,R(<"437,!&3C;D>9%BE^B9#;$))MV_OP1O#5G>V1* MU7[5(G\7-0>SH4RN`$NEU@[ZEKM7$$QNHA==`7YHE/.";BK[4[7?N%B5%JH= M0T(NKR3?S[EA8"C0!/W8,3%5@0#X15*XS@!#Z*Y;6Y';,L6#41`_A8,(X&C) MC5T(1XD1VQBKY%\/B@Y4GJ1_(('U0!+!]L'@P2$8UE-PT!_'43SZOP3BT^G< MF5-+LZE6+8*.`\&FH:Y_HP28G2T#,/>^+>"'BWEQ05THH`V4;S']2\3L%C$(3Q`"^DXBP:1SD1^+KK1YS*BS-1ZYYPHQ\XC[ZB^T`>1Q;0Y\K6U\IJV)7Q!.?1@&`"X4,H>#V[X3]_D[!\```#__P,`4$L#!!0`!@`(```` M(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_ M#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM M,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(D MY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P M/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC M?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO7 M6U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C M/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=% M^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=7 M0/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1 MZ!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+F MF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;3 M0IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU M4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO= M3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+ M-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX798 M8*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35 M`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`( MH6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\ M/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L: MPV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<< MS=*MOP```/__`P!02P,$%``&``@````A`*.FGJM["0``6$@```T```!X;"]S M='EL97,N>&ULQ%QK;^/&%?U>H/^!X+9%`]0KB:(LR;$N.]1I%M"9"UB*E.??<>^[<>9#BY7?/46A\\=,L M2.*)V7O?-0T_]I)Y$#],S+_?.6_1IP(2N>G3:GGF)='2S8/[(`SR%X%E&I%W\?$A3E+W/@35 MYY[M>A6V.%B#CP(O3;)DD;\'7"=9+`+/7V1$^69X26K.)^8 M5GW**#[Y.)^8YZ91N#Q+YB#QAY]72?[M[XH_[_[T[EWW/]]\^Z\?_/F_?_SC M^F<_?F-V*C,,$QKLQGS?W0F+CPOD3NG!U>4BB9DC4%T$Z.(I3K[&#GV&9(![ M]+6KR^P7XXL;XDR/Z'E)F*1&#I7AGS@3NY%??&/FAL%]&M#7%FX4A"_%:8M. MB,0HOQ<%D(E.=@H+I[5S3VPJGT9$0_*I3V>X3Q%<(RM6BMF)WVXGYB.@QK2ZW8IK%RP-S(VGG5A[V3& MS@4QKL@\C/CUO]J_)!$;DQQY6.:^/;& M(7DO\J\=^86U##2",*QG5OT^S3UPYNH2D[S<3V,'!T;Y_NYEB9E'C/DH\>\4 MW]OS[8?4?>E98OQ5:Y`E83`G%@\S,=\IQYO9^8TSNQ%V&3-5%EM`'6K*E976,_=)^D%VNIXMS59>@O816[P=$^+=3_W--C@Y9X6JC[*>5.I*X'72WPJSQN8O(JW]/5=-,I2 MCY'#\\/P,]7R?R[JX0,[%U>7SPMV3127+.FB(5URI;?8'BS?%D-%<0".VQI9 M6QL9[G(9OMRNHGL_=<35:V%"G*5MR.9H*L:XYOA#&#S$D2_V7LP"YOLTR7TO M%U?7Q9;O-C[]+7QZ)9`*GV/LVUOL(T[*\3C&/M;V&T5$7+3:1W(IVV\S'^@^ M@C*I(0%/ZEU\VF2`%5S%`"+H8$#W/90Q0'KJ8("9<<4`"=HP`)T=67%,/\!$ MN3:)'&A,POY;F42-J;R43+ZAE]O*+^SO\-*1RN]186;U%HG>A!D'.P@<97); MB=558ICLZ&E-"'"P(P0.1MUVAKS>MIJO+2"LZ()#$Q&4@5T1:2\K6#IB&84Y#&X!/V":Z$-$)J MX@`^6GI%,T_H22/&"@JT8V4O1UE4A&05>%9$KTW[A$=OBV:;&) MRO9/>_:OVC\UGA=[-U)[VQ9-T+UJ7JR>BI4CM!!K*;:4IE^:N-7>J?&8I,$O M6&32+TX\;*;ZJ4F_4,H#CY_YFKK+._\92]'BDL7S8OM>+YA4^QNODU%FN)53 M8Q];WJ9QB/'6XW,$E^,#L==SL:C?NS'_*C/DS>V]&;*7!&WNZ.9`L2XYM)X" M+741ZKFZPX1!4CL'+A7Q*?><<5J:0\BUPD'DJ/CLJ69[#JR,(+<2XB9&277>4KSK6XZI!/Z/`KSZ[OS?.C`\> M#4U0OTB*'LVS5D&(&\1HP*0YCP>7DVA:G"Q'J5U8F!\46!:M9!@6%A6'8@&A MQ*)Y,,."QH=BP7R!U8>W#`N79`_&PMJDQ*)52L/+1B4ZE!>:E%AR[`>*L;QT5&._4`Q]J\KJISQEF+&%RB-=GC'8H3?E2G% MJ$!I5).SO*^8Y05*HY>DS'#O4(UD-P?:!A5 M`;IY7H9N[.9)^F+0@K*&DT4?*,+].4GJ&,D(%@Y5"/T%S\C`XS<,Q*6(D)S# MM)@X!*;N"W)XZ.K2(3!H7;"1\X^N`QP"@]8%C%Q4:?ZD`O,Q7JYJA>1:2D.W M"L2G('[RYW+FR!&V0%(%Z=9?Y:E;YY_,M[BA MK`HB+;99,:`+MBK$_[;*61C%9=YFGF(IUJ6[(,<]I%4GEGF`E@J/NP2;/#7$ MJXJBB/$/-XVIMTA=]U6.;O&HV3+#['_^W-QM*.*>TU-DQ'V(]7H`X9W["W<5 MYG?UAQ.S>?]7<7?^);GM'+\;-B2@WGS+<2HV_QBH- M)N9_;Z;#\?6-8YV-NM/1F=WW!V?CP?3Z;&#/IM?7SKAK=6?_0\CHD3L7>&;+ M$8^T$8_>P:99S[[(0CSX)BV=+&PO3!LL[9;]YZ[ MG>JG7[Y/8O%.I38R^ME&O]O;$$H')HST[-G&=[<7NT\VA,VD#F5LM'JV<:_L MQI?/__J7I]9F`FNU?;8QS[+%YWM[-IBK1-JN62B-D:E)$YGAO^ELSRY2)4,[ M5RI+XKU!KW>XE\A(;XC`Y#I[MC'8/]X0N8Y^S-6I^Z6/7YX_M='SI]GS,Q/D MB=*9@!CB7&=1=B\NM=L?8C_=RYX_W:.I;OJA>&ET-K>8&JJP.OIUKKMBV.N( M0:^_7QT+MH;#`=/JD/%A6[O%W4Y M^KW=;UM7O%9I9,@8H3B366WQ".8*V607L9Q5=]F:RMC6UISF:8K+B(O(!KC0 M]TJFK?MO[>[V![O#?G7G2S(ZXT.*-RJ.=]]J56^&O5S_Q>V>JA7G8^ M19Q"KS.3U@TZ3F0,,4I'G9ID(75MIM\.HXF!$C(3O.V(,2"EK+C.,W9K2%J5 MHH"%MX2W]06\L";QUK>#CRUG0S8O;G+!$QE+'2C(B6`AMK_3,@^C3(4[^/?X M3&SNU,Y3`1RZSSX[K`XN036R5F7V\]JPM'..*@']0_V81^]DK'16N^?K5"UD M%`KU'L'-UBUW:S)@]N%IU<-NKV]'5V(T'I_?CJMCRY57D9Q$<91%JD%8[R`, M,!C43(4VF1(+>2\G<-.W*O+T7MY7E-YO&+ MT"WJ8*?ATBB3#\-GO=?@]'I@*:SB$\@&P) MDE^(49[-31K]A,D''40M^N/A^H7SW)!M95;0%;N]7;>\9K&'J,>Q"(,MIR$? M/?:\PX/.,?X<#9ZP*(>]SN#XN-,[[`N9":065:06'C]3@4HFN.(2GP(:7Z@@ MB]ZIN.:OIW(1$8P8:9$&V`)E+=FYT%=5OS!RGN0Q0D4H3#;'20%B0:KF0"G. M$-M7QMJ:RVR?J6D41-F.D*7U89Y2W,(N(E20SRPX@B-,S&K@`U0(*TKK((Z:$U&M0`UZJZRDP/(R$+%%9UW;(@HIQ2*S-:)I>P M6]W>`];[2:O8Y6D?E[EI=K/`33/72%O$99H2BS;>%Z^.CJ M;%C5$*H@DR`S(+&Z`_\QFE`E%63_K$Z]`8!UKFH!_RNE(6`L_B:3!2).F$2: MBS%R2''>$MQ])&U(E1>11K***/3CRGE,B;\JRI6:R;CV8Q1P'O&"3%4]I5Q/ MX:,UQWNITAE[N6U(4ODDC@+4!8@'9(+JH3?*HJ@*7,8[6[EX=1Y7"N(6):I% M\!87JB;%FY12,I56"$X1:B,]BY""A.0T6]W/)<>OEDJO#KL8)::I201Z!X^? MZJQKCF[;/@'OU"Q;I#,_H[K^!):GH`=;!4;[CD=,%8JTM'8_)[$_TL.B%D5? M47W2&%]/I(4=_+THPP&W5()QHJL*]D9%LSG%[Q&$0J@%E%R]MBS4VNJT%A<\ MI5+F(C9WK2Y8FG%!2O=.B]@_HLS47'V,PA]RFY&?6Y$9D2IH,4`Y+#34$"/+ MT*_T;RZEV)K>&G;U@YO+BP)M'4"*&;OZ`BKTG?XC^VXS,\8:`99 M;1.411R5`$]7Y\``&O52:T'4N@,P[D%54$WLK+ZY*S7WDJ*:1-!Z0_WJ26Y!CR'AC,'+<*'#!%E7;/_Z\[])H;_^_)\=<2'GZ1\1<](Z[XGPZ=9VAN`XR0UUC_\"-,4SX1C(`1T'M M-)R^44R<*`6QBY:B)HX)8N3+:!IA#30BD;BI]D&I1CM9Y'H#/I2T1C`.',6` M2P9SU'18$R&;:-"4E-V+`RL7%[?0HP]!**]0K[CZW.(P9#*R/*O:Q_%[TG:Q M5UG'')$K>A';L*):D)P[V"4U^6Q>4Y`K#\BAT!C4A1:> MRUH9P3(//; M?/(#;D$'T47AE0$]`Z21?>NVSDFM%.F(`.Q0_(K!?L*64PE6$'_32@4OA?^& MH$6IIHC%--<\"8-%<4:FA=-6Y/'^+3(5S#7BW>P>61M6Q79Z11^1V3P#!+$@ M:A+%(.Q*BT@-A)>:`@9=L6I+5E%^S6L-J2Q?DKRE*!*M'GB\'F"A)>(+H_[R M@9-8E/SRP54<0!_51`^I.,H%F7RKM'-JTLK$&*]SZF32T(J["/1CCDG`UE%B`C$+&Q*I$:+L3M"^%&@T:TE@H?F-@?3XD?5\8I=!WX.MB' MPCF\4CSDX6TN"BO$+=)W:78!F)7K%\K%K1&H/J);EL]DA8P1)(J`QP#)'IP* M+E.6C_JH@/Q[:^VYI]<>F(XTA-+T`6FZ7T/9$`4*=W*OFZEO-PA=K1"X MJC.J`8,4LHH'"#8E>CE&A<5*W<2CX`'H:'18:4Y"LFJH&D$X0U)%S**K]@>? M<8C8['OZNG%^O_=9]Y/.@\.784].:@<[B/UP_8M""6 M:PK;[S*!S@\K$!/7+5Z$:NI0[U%BQ13RV@NR4I`MT&(;78^,O]2N[_`/.H>' MA_ASM*0O(=&2GR_>!7DNV;Q'J)SL.URLU"_5%F?/)`J'6A$NCB"G3Y M*5$3N/K'?XRJ\"U3*;2LD^J@BU2\JV]!OAX/)"UXR@] MHK?B,DKQ9QVH:X@DAJ&WX=7<':+F3*A%))J,/MI!=X.D2X7$F*IH?IZ@EPHN MN(Z'0VX=05%0X<\,-4V5LUF*AS>493(A]H@F+X.!6,1H9I>H\)6&#Z;;E,[Q M+HX&9W/@#+2=:_\'J+P9`@ M208A+FJE3?1%H)=P'B`"Z$1XB,S$'0@6"*=!99603CN@,5U`"&B,I$UD^A8TKON`Q6M_`MZE7L]19%H3Q_]T#N)] MPJ,:C2?GTR7#3*V>?RTB`I/J7)"#>$J!!29X\K1=46H,?D2A"%=N[`H*3Z1R M+HSL)`DU3,$&"@0AHKY'/H>E.E%,B"8:8\Y0(>`]:=QO&HX_K\3 M.I?[/4YXV'T4#W`![Z9J,L$[$^"![P4IYDZ-R<@+P,:!>$%TH:`(O"0R9$Z< MX%2.O#<TT/FH3C,E+(=@?3\?<"< M/!V7(&!22*7?20+_C62)/BN1\(Y%Q,Z82?1SK82JTBD"KX,@(6.+9Z"4/L=X MA^?IEJ\O+Y>OZYZGJ`)X#?/P2<<@\SR&O1B[E.@Z_ZHLKXM^'X:%H?F3C(4+BOL(MZTF.GHE`-\N/'Q8[QA]$0XCTP*$7 M.6JD'.9!(,J&=%CX;"`]S-2,=UC"D&\",7""*QW4M4$&A-.6BR!7S1T$"]N73G&KL/\83MMO(GVWTA=--(V.X$,E*)S:OG.R)*J"C8^'&BG$K6`@!\>QU5 M1P,J@I_T=41H`M%K(N0]55;(*[="LNZOF8SV%B8XW@?#=1\
W(X,D^ M&*Z'8#^^3J(D!=+_N`0F#5V5.RSQ*27B0!(!U8(/:C&=38M@,Y+VR10=; MC5\8R?2-)+$5JW,*"PW6&8^FQ#D"[P-:\IJQ03.23-\%)7:@G">K M,!)SFJ#EG3Q/YS467G8)GA([>*E3,R,Q>&F2IN"XFFU@S>SUR[VFK-\MN8TH&F+I@$,>$.^8[ZAO?!:4L.[*?1G\/1PTQ3- M0+)!O_#73$)3T[<-_'DAT`U"'\0U8_)EH-KNX>_0\A\```#__P,`4$L#!!0` M!@`(````(0!^ZH9A"P0``/,.```8````>&PO=V]R:W-H965T&ULE)==;Z,Z$(;O5SK_`7'?@,%\14E6"U7/KK0K'1V=CVL"3H(*&&':M/]^ MQPQ-L$D:OQC%E]?:M*XY6UHN#UVB0+VS18G?&\J/=K\]]_GAY" MTQ!=6N=IR6NV-M^9,+]N_OBR.O+V61P8ZPR(4(NU>>BZ9FE9(CNP*A4+WK`: M1G:\K=(.'MN])9J6I7D_J2HMQ[9]JTJ+VL0(RW9.#+[;%1E[Y-E+Q>H.@[2L M3#O@%X>B$1_1JFQ.N"IMGU^:AXQ7#838%F71O?=!3:/*EC_V-6_3;0GK?B,T MS3YB]P^3\%61M5SP7;>`R3$AD6IM5 M;]!_!3N*T7=#'/CQS[;(?Q8U`[=AG^0.;#E_EM(?N?P73+8FLY_Z'?BK-7*V M2U_*[F]^_,Z*_:&#[?9@17)AR_S]D8D,'(4P"\>3D3)>`@#\-:I"I@8XDK[U MG\9J\<$*/>/YM!`N7T[OSF';I9M7RHP$I!\"B264"DR5$OFP'^""UWZ2X MGP(K%;"'KQLG6EFO8'LV2.(+$E613!6N?9)8@'5B`V_FLTDQ;(IIG-A<<@K; MX\S M.4)6]L^_!TN*-2PM<6*47,<:CW^"%=R#)<5:QON:6RB!;3IEG@:>?*90').- M<':AD&+-L4!#0PDZYH2.9Y\3")-K+(`B.QI7N*)[N*18XPHU+I0@5^2&@9:` MR7C<<4/[7``5+`(=:KY?O5H#.P?&ZC5HD,P+(PT\4<8=GYY/A@IV7\7':CVN M7:,C-8"A!L'R=V@$8+7I@0\UG)V`(ZN[T6^5F,256`[T3EQ5419FD>(-US#0JXDGG848WE_`_P!C=J1;T_@QA*/ M.CX9I:^*I[4$Z:`+A_@&YK0W4*W$Q@0U5S;W\J"*IK6%F6A8VA4'-7MB@AIT M\,$/B1M$6@(DJL:C$27TVA;?U23(M$M0O4L,F@'0E=7E7->&XS%N%`]!0*X5 M%ZU3S'1QVC*H5GEC>&^1>8BWMTN7$D5PJ?WC:PM>S)MTSWZE[;ZHA5&R':2A MO9!'N<67%GSH>--?Q+>\@Y>-_NL!7BX9W-+M!8AWG'&PO=V]R:W-H965T M&ULE)=;CYL\$(;O*_4_(-\W8'*.0JJ%U;:56JGJ=^BU`TZ" M%C"UG)7@&?(W MZR9!_^?T)(S?GCBPTR>>9U_SBD*V89XDV?Y#"YI*FL',(4_-R):Q9_7J%[@5 M0!#1"%00\>LH(TDE=-EV?R$*'Q;#2=!V,,%LB'TCXH<83F,'$1$C`W+YM@[;]`]M-6$6L% M?'8*;"N2LT)-(#!T()";X2!*K$#4?"FR6-\PXX9.W+YBW"DL$,C"%]R0TV**3A65-B MA\U9XK&63)O"G.!%Z+`G^KG)?@-,G9B#-P4E=L`NE:5K0$O,P-@IDZ0ON<&V MO(=-B1VVBZUFTQ*+S2F4I"^YF%AE@.%,,Q.G#ILQW/O+KJK>LLVM!#OU&+>:/_-I'U-SBT]MUL/Y]-9N\KE+/\9: M8\8.W;J]HKG%I[;LX7QZ@[?XW-+%_4,@=*HHN:*YQ0?C-/D&KD/UEKT.0Z=, M8ZPU9AXO#$U!):UDUFQ#LT4X#Y:S2ZKM>KGKW%!MF\OG!(];CJX?SB$O3KN:UP^W?KJ1JZD?$\36A3"2]E1M;(84M_=[7KS MMFGN'D"76Y,]_4;X/J^$5]`=O!J,YI!EKOMD?2%9W;2)6R:AOVU^'N!/$(6V M*QB!>,>8/%^HIJ[[6[7Y#0``__\#`%!+`P04``8`"````"$`6!>"ND@"```\ M!0``&0```'AL+W=O2BA8'AI%^ MA$-5E6!\KMA&\M8&$LT;:D&_J45G3FR2/4(GJ5YONB>F9`<42]$(>_"D&$DV M>ENU2M-E`WGODQYE)VZ_N*.7@FEE5&4CH"-!Z'W.0S(DP#09EP(R<+8CS:L" MOR:C68;)9.S]^2WXSES-D:G5[HL6Y3?10N>N$+ M\%VCDE=TT]@?:O>5BU5MH=HY).3R&I6'.3<,#`6:*,T=$U,-"(`ODL)U!AA" M]W[#L M&`SC.3A*!WF2]_\O@81TO#MS:NEDK-4.0<>!8--1U[_)")B=+1F8^V];P`\7 M\^J"?"B@#91R.TEZV9ALP7]VQ$SO,>DM8G:/R.(SA("^LT@PZ5KDQ^(<&)+` MZ"(NO?#Z!*8!T[O"Y.>3/6+V$>)&&QSTN#8'+C!P7[3U>KB=:@AE=P9AP]0[?JT/YA857G2[E4 M%MK63VMXI3C4.8X`7"EE3PMWP<[OWN0O````__\#`%!+`P04``8`"````"$` MEKR68<$"``"^!P``&0```'AL+W=O':,`:N`D>TT[;_?M4TH+%%+7P!? MCL^YYUYSV=P\U15ZY$H+V:0X"D*,>,-D)IHBQ;]_W5]=8Z0-;3):R8:G^)EK M?+/]^&%SE.I!EYP;!`R-3G%I3)L0HEG):ZH#V?(&WN12U=3`4A5$MXK3S&VJ M*Q*'X9+45#38,R1J"H?,<\'XG62'FC?&DRA>40/YZU*T^L16LRET-54/A_:* MR;H%BKVHA'EVI!C5+/E:-%+1?06^GZ(Y92=NMSBCKP534LO]>!'PIE/*>'ROR4QR]<%*6!=B_`D3669,]W7#.H*-`$ M\<(R,5E!`G!%M;!'`RI"G]S]*#)3ICB>!_-XL;J.`(_V7)M[83DQ8@=M9/W7 MHZ*.R[/$'0O<.Y;9,EBLPMD$$N(S<@;OJ*';C9)'!*<&)'5+[1F,$B"^[`BL M6.S.@E.\P@ARU="&QVTT6V[((Y2.=9A;CX'K"Z9'$!#ME4%MNK(%6V5;6YO* MK0\,9>++,K/WR%APBN'ZDOQLU?-Z98^9#S"+'C$R")#I!BT8>C`T=%Y;#YH@ M#8=J*.W.Z_K-]MI=+H>^RET$/IA!0:XOVUV.-5\_218\ENHB_D, M9HM@!;F]KF$WCC6ZR-C.^K(=.[LG?Q@6/);J(N=VUF->VYK5.GC3C-TV5N@B M(S/S\+(9&([O<./08[%3:.;FI&N/GY9^F-1<%?P3KRJ-F#S821C#>.BC_93> MQ7;___%YLO/3F_1O8'JVM.#?J2I$HU'%<^`,7=.5G[]^860+B<((E0;&IGLL MX3_)842$MJBYE.:T`&72_WFW_P```/__`P!02P,$%``&``@````A`(?LM4P[814*3GHN92?R[ M^%PNUQ^\_/:1'XUW7M596:Q,-K--@Q=IN6B:T\*RZO3`\Z2>E2=>P,BNK/*D@8_5 MWJI/%4^V[:3\:#FV'5AYDA4F1EA44V*4NUV6\JWTX/:9F?(,1+=LR:GVU0T\C3Q?=]45;)RQ'6_<&\)+W$;C\, MPN=96I5UN6MF$,Y"T.&:(RNR(-)ZN6[Y.W8 M_%6>?^?9_M#`=ONP(K&PQ?;G$Z]3R"B$F3F^B)261P"`OXT\$Z4!&4D^VG_/ MV;8YK$PWF/ESVV4@-UYXW3QG(J1II&]U4^;_H8C)4!C$D4%%V`"@ZQ!A<2KB]5Q?2(18D(C<"[08OX#8'9I# MGCM4!'8GT4@@0=-)A!CV5WEPZ'5AD0TEGB+Q=<5F3*&A09#I:$*\,F'=74[" M?L6(AI*PW*S(6S-[Z38A+)'\E.C!+@ MZ-9!%)LQA888?`513")Y#/0-C%$2X)D([-#N4]0F>J,*`C=P62_0`.%PW9]# M,8D`S@D@2A!P[ML#/G7#RW4H,(#[YZ)!%1%SBVVT?0$44[5K9T(B(V<;6U1'T.)")J9,G!#QAZ:!D* M,,4/KMTW;)U0-&Z%<+SH&+9YC:P/+,E0@V2NXY.SLI$Q$"Q@?67H7*)I3^?" M%J]QD6J/&6KDICIS)W3Z9\MMU22>&T%>N\+5\43?GHZ'71ZB=STV(D80,]2, M]>%1B8[W);,0/\+(P8U(6<52<_WDWAC4T8A)?%)PV-FUS/5;(@L.-:.9&Y/H M>,0B/L$;>D-$ZCUF:O-G`9A#WRQDV:D*+W!5A0YWET.PH45$U"*D!@_%5;8) M)L&^Y!+M+-*(R8&,I0;QA*\.4G?=2+2L.<0GQK>T5>M8C#XVEB+D@F$JV$@! M/28ZUY?,P1F:`[.I.T@1\CGP>VD(J/K'6,TYHITKG6Z:A;6S:!:I4T@14L[9 MG*QBHXT[;J3T3#V1HFW?CXC-7O4,9E/3<%"$B/""J?PXQ[.K"9CK!&Y_Q'1( MT=_OAT17T"&I=3@HDI"AQP:)5`7,#P*WWPH=\DN^(5Z[P3?4)LUL:AQ2!"2= M!Q+)9E2BKH8;5\Q7$8*$=ZCT%\`-P8Q5W@'B7=U.:_V M?,./Q]I(RS=QO^C`FV_W;7?W^=A>?9+O8[@3;2\0K6X`KB1/R9[_2*I]5M3& MD>\@I#V;0S.L\%(3/S3EJ;TA?"D;N(QL_WN`RV<.]VKV#,2[LFPN'\2M77>= MO?X?``#__P,`4$L#!!0`!@`(````(0"?^@W_JP(``"('```8````>&PO=V]R M:W-H965T&ULC%7;;J,P$'U?:?_!\GLA$)(V**1*M^INI5UI MM=K+LV,,6,48V4[3_OW.X(1`TTM>$!Z.SYDS8P_+ZR=5DT=AK-1-1J-@0HEH MN,YE4V;TS^^[BRM*K&--SFK=B(P^"TNO5Y\_+7?:/-A*"$>`H;$9K9QKTS"T MO!**V4"WHH$OA3:*.5B:,K2M$2SO-JDZC">3>:B8;*AG2,TY'+HH)!>WFF^5 M:)PG,:)F#O*WE6SM@4WQ<^@4,P_;]H)KU0+%1M;2/7>DE"B>WI>--FQ3@^^G M*&'\P-TM3NB5Y$9;7;@`Z$*?Z*GG1;@(@6FUS"4XP+(3(XJ,KJ/T9D'#U;*K MSU\I=G;P3FRE=U^-S+_+1D"QH4W8@(W6#PB]SS$$F\.3W7==`WX:DHN";6OW M2^^^"5E6#KH]`T/H*\V?;X7E4%"@">(9,G%=0P+P)$KBR8""L*>,QB`L3:01PLA'6W4FDI(1OK=/JGP=%75*>JTOMECFV6AJ](]!N0-N6X>&) M4B!^/1=(`K%K!&?TDA*0L5"_QU44Q;&8^!YQ/2($$1[95`[7QG! MJ(Q5P51N?&`H+?C"*FZ"\0Q/1M+?A,_"89("9]8A1!@`Y MWRB"H1=#8Z34S&+, MB[V905[O%PLWC?GWD;&5^8N^^)GD+[X2IA1?1%U;PO46YTT,5[F/]J-P'>-M M>QE/TG4W(L/^`XRHEI7B!S.E;"RI10&4D^`2VF+\D/,+IUO('`:5=C"UAH[0X+$`[[O]OJ/P```/__`P!02P,$%``&``@````A`![>FT%S M`@``$@8``!D```!X;"]W;W)K&ULE%1;;]L@%'Z? MM/^`>*^QG4M7*TZ5+.I6:9.F:9=G@H]M%&,L($WR[W]D6I8&L=3IKAL M:6#(S#4[0 MDU*B1/98M=KP=8-Q[Y,Q%R?N?G-!KZ0PVNK214C'@J.7,=^Q.X9,\UDA,0*? M=F*@S.DBR993RN:S/C^_).SLV3^QM=Y],K+X(EO`9&.9?`'66F\\]+'P1VC, M+JP?^@)\,Z2`DF\;]UWO/H.L:H?5GF!`/JZL.*S`"DPHTD3IQ#,)W:`#N!(E M?6=@0OB^_^YDX>J04G;<=]Y28;$;P>"$7CLPH-S>DL)^FHQ^4_S M9)S,V!-F3!PQRX#!]1DS(!B*#LJH=KVR!WMEGU+ORC(*.7],<3+.%SFL>ORQ=F,/2J`E/!1V@:2X3>^OE* ML?N&TV'T%ZEW^?7Y.%OT3P(;+G`D.U[!5VXJV5K20(F4<72+<9LPU&'C=(>> MXVQIAT/9_];X]@(V8!PAN-3:G38HS(;7?/X'``#__P,`4$L#!!0`!@`(```` M(0`0)RF*&PO=V]R:W-H965T&ULE%1; M;]L@%'Z?M/^`>*^QG4L7*TZ5KLI6:9.F:9=G@H]M%&,L($G[[W]D6I8 M&L=3IKAL:6#(S#4)FL^UNA%8= M4JQE(]US3TJ)$MECU6K#UPW&_92,N3AR]YL+>B6%T5:7+D(Z%AR]C'G&9@R9 M%O-"8@0^[<1`F=-EDMU/*5O,^_S\DK"W)__$UGK_R]07X9D@!)=\V[KO>?P99U0ZK/<&`?%Q9\?P`5F!"D29*)YY) MZ`8=P)4HZ3L#$\*?^N]>%J[.:8J=L0;K5M)342*VUFGU.UPF!XI@G!Z,\7LP M'DVCR6T\2E#K'R0L.-+']<`=7\R-WA/L%92T'?>=EV1(_'8@&(''+CTXI[>4 MH*\6D[];),ELSG:8,7'`W`<,KB^8`<%0=%!&M>N5/=@K^Y1Z5^[#P:E,^K;, MZ']D/#BGN+XXG\8#;U`.F/$)9C(@S@)$R/4!>C#6X#2@R]P&T!72V`_72WMP M+STD-YR,^U$X+=GTG-9W_P2[X>]-XXW.Z0\G6,*3-">ODAAF,/2J`E/!1V@: M2X3>^OE*L?N&TV'TEZEW^?7Y.%OV3P(;+G`D.U[!5VXJV5K20(F4<72+<9LP MU&'C=(>>XVQIAT/9_];X]@(V8!PAN-3:'3&PO=V]R:W-H965T&ULG%?;;J,P$'U?:?\!\=X0()D)3G-')?J72O-Y\_K8],YLHD$30E"NJ7 M>U;(*EL6CTF7$?%T*"YBGA60XI&E3+WJI*Z3Q:N'74R!]XL_(W&56S]T MTF'!$T0['6B[W4'?@HGH5MR2-4O?OQ& MV6ZOH-US8(3$5LGK'94QK"BDF01SS!3S%`J`3R=C.!JP(N1%?Q]9HO:1&RQ= MYY%*=<\PE>O$!ZEX]L_\Z9'H#6R(`V'AF=$1F7%$NY-88FS*D0"R8\!P:=(Q<^3\4'85V^038^LX;/ MO/:PD,%E/$%TAAXT"777UCB-@(9Y:$+CF(:SR>"@5OW%,%U$OIAU^JA=%3K1^5J8=02S'&=L@WP@#,ZMU3F6Q*EP.4SM(+OQ:, M$UIIZJ&$V[@QS*,I=04!WW;=+ET-4#I+$ORN)E2F'DH?506_*PN5R6I3.!W@ M=)8P^%UEJ$P]G#ZH#7Y7'"J33NI6I2RGH48K*@TX%N':7!HX-0%5PS^`*+BCZYQXN MHA0.XU,\66XY5]4#5EY?;3?_`0``__\#`%!+`P04``8`"````"$`$?J>\GH" M```Y!@``&````'AL+W=OW;L[ MEG>OJB8O8*S434;C:$()-$+GLBDS^O/'X]4-)=;Q)N>U;B"C;V#IW>KCA^5> MFZVM`!Q!AL9FM'*N31FSH@+%;:1;:/!+H8WB#H^F9+8UP//NDJI9,IE<,\5E M0P-#:L9PZ**0`AZTV"EH7"`Q4'.'^=M*MO;(IL08.L7-=M=>":U:I-C(6KJW MCI02)=*GLM&&;VJL^S6><7'D[@YG]$H*HZTN7(1T+"1Z7O,MNV7(M%KF$BOP MMA,#14;7<7J_H&RU[/SY)6%O!^_$5GK_V]_P*RK!QV>XX%^;K2_.T!K$!#D29*YIY)Z!H3P"=1 MTD\&&L)?,YJ@L,Q=E='I=31?3*8QPLD&K'N4GI(2L;-.J]\!%'=)!:XNM0?N M^&II])Y@NQ%M6^Z')TZ1^'(NF(3'KCTXHPM*4,:B?R^K.%XLV0L6+0Z8^X#! MYSNF1S`4[951;;RR!WME[XI/Y3X$AC+)99GIJ8PW??9/TX^%^DMH[["(>-KS MAPP"9C;`S'O$2:$(&5^H!V,OAH6=>QQ`(Z2QT/'2'MQ)]R8?(F&LA[V[/N7M M)CF91?_UU=\[E3A$<)G>YR6^N6PD#M[X:CSX5.H0&5035C7L@P)3PB>H:TN$ MWODU3'#"^VC_AU@G?@C_CL_2=3>7B^CW*QTVWR M"QMG&G7/V5(< MPZF]\VHJ]GV?];-!(_H3O%D]/`VCILH<=B4`L<-^6N[#*JYRJT#>[MGNS;6) M]TV)?V>E%(,=%0YX`)G$]^C1[I2\S.[NUTO$BIQ(\KXD/*R:D$G505$K M;04)Z%Y:KG,A%L:.[",J^_2[$!%"ETK;WMEWY[]_]V"SN[>]#DIP7EDS"?N] M.`S`2)LJLYV$F_7\YFL8>!0F%=H:F(1'\.%=\OD36SI;@$,%/B`)XR=ACEB, MH\C+'/;"]\AMR)-9MQ=(6[>-;)8I"3,K#WLP&`WB^#:"-P230GI3-()AK3@N M\7]%4RLK/O^R/A8$G+#[HM!*"J0LDQ]*.NMMAL'#FP3-HK:3$=T*Y,$I/"8Q MB]I;MI)"PY2$DTQH#RRZ&-@CB*IH2Z&<3UB)XQ(D6A=X]8O*-@B#5^&APIF$ MI7!*&"2L*JS>G-:Z\.B2G];M?`Z`GD444!M/RW9L>ZU&27]XBJ#5=62E4).0 MXYIQK5"#7V1+X;`#N3]L,Y\H:N(:Z-Q%3K/!'PQ2O?B3J;NM;)N\R>&;T,)( MX*LJ.;XQXI`JA/0O8@F1!B8'I!Y2PQK%JH`U3J/&5R@0JOGBBXPO:$:IZ_]R M9"I\SN?=M_3YL\"#`VX;:6O\O415J@]N&5P2Y7-EJ`!*Z*92G6!#_FP1/%^* MHWC5-&9-EI=\1_S)^\.IG,0RM?N]-92ZE;O.\"\48NB9HR+!6KXS[K;%V!3R M:@X;EG>4?`8HE/94(4C9?S&P1WJ$3E7!E&UL4$L!`BT`%``&``@````A`+55 M,"/U````3`(```L`````````````````RP,``%]R96QS+RYR96QS4$L!`BT` M%``&``@````A`**7_R%1`0``80D``!H`````````````````\08``'AL+U]R M96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*.FGJM["0``6$@` M``T`````````````````2AL``'AL+W-T>6QE&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`'[JAF$+!```\PX``!@`````````````````+#<``'AL+W=O&UL M4$L!`BT`%``&``@````A`(&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`!'ZGO)Z`@``.08``!@`````````````````PE8``'AL+W=O&UL4$L%!@`````6`!8`S`4``$U?```````` ` end XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 17 0001354488-14-004103-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-14-004103-xbrl.zip M4$L#!!0````(`%2+#$6)(1UU$A8``"NF```1`!P`.MM$Z=QNMW]2(F0A"U%J`3IQ_[U]QR`E$B)E/B`[,;I M-+$)`N>'@_/"P8-O_O:X",@]C03CX=LC\\0X(C2<<)^%L[='O][U+NXN;VZ. MR-]^^-__(?#GS?_U>N2:T<`_(U=\TKL)I_RG9-_>D$" M3W[YUTT8P[-)S.XI/%5DSHAS8HY)KU>CS3N>1!.Z:O#NW?4'8KBV81FF0TSC M#^OD<0KTKKP82O'AM]:5,82_3.N+99Z9QIEIUJ04>W$B5I2,QZ$!5."/JO[F M<1P%[`S_)L"R4)P]"O;V:!['R[/3TX>'AY,'^X1'LU.H8Y[^Z\//=Y,Y77@] M%HK8"R?T**L5L/#WLGKF:#0ZE:79JUMO(O&,AGV*Q6-/K%M&@#O>WT("I7Z\ MJI!_N7^J"@NOLM)77?4JRU[UZ<9[@DY.9OS^%`I.<8!ZAMFSS>SUB$XK(;NG M4)J]R`1W+'.PJW_JC:Q"(GHSSUNN*DP],98OIP4E8*`DX@$5I75D24FED(=A MLBC'YHA&;K.KMKU2L`!CP<3DZ65*"#A5F54$DH9BSD(X9 M7\Z]:.&=3/A"5D*5.LJ4!`7K3$CQ_4RG1,KDV5R.E!A/%[VLPLFC$_28J0/ MQ6RQ#$#`3K.FE-),.%B!QY@P_^W1=<07&4S#C+GZV>VMZ:^JT3!F\=/JZ>HY M\[%DRFA$)$I:X&,F;YEX]U_EP^=FT9G==E&9OS^3DL(Z`:@FWYRGA;C&6P M`_J4/@F9XM"O=U=;;%E03R01_2&=%YW!.UEC65&1!+96T?X=3!>HJ"212HI\ MJ34-P/>I@H[/[F$\MGF+=3_B+`FS#KGBYCS8Q%C6:H[H%0WY@H7[R.[GRR;= MLH:S\@(7RA@*4^RS]U(X/],9$W$$TH7)#9(*SV>4C]&R$2,,%UR7[D>0&H M:&V;[#]YD(3@JIZN64`CT9+<1BLEXJWX$DN>12S<*:RAK6I_1OMP+[6MJE* M-)?`[AF/ZJO4W<(+H!Y9-4\N^6+IA4]Y"(6FRQ1!#;D2X&MX5K^SOUA%)=AJ MJ9H<2E@S8OAS&;E52QFQ-/UW]BFB4PKL]^]B/OG]DQ?=1LA^ZLL$,*"4OJA` M?R.G0M#VRH*DS<.NJJ`-;3Z M>6-3TG1+ZG5Z:S8F?C&9<)@3:NK]R!X.G!RW2QMO#Z$."RQ[:(R:0I#[>*B( M]7"A/QP-UPC*VVZ/H!837,=LBN!GYHU9P&)&6^NS/;2L@;4FG&NR(;5:JCT< M]8U:Q(K19B>K7AG#EIK'FH2;^[9]A',Q3J?NNOV1ZY:&3JW)UNFL:UBC47VR M%[X/X\Y#+_@$/O\FO/26+/:"UIUVC)%KY+I=T7X'&'68T'>(,K6QX6-&'H? M&1VP6L3=36%MS=$U9`S1E_4'UG!')J`\4]<`3.V\A/1PAEN>RFD$1E?.L`9[ MZF7H]"8-:S!J!ZR/7IQ$]'9ZN\3U;O"=]9=<_AK$YTLBXJ>`OCU:>-&,A6?$ M6,9'?YW%YUAXNI0__<6TT[_R%:9`Y8P,E_%IR"/H#OG"%A#J?J0/Y#-?>.&Q M>G!,[FC$IN=D14`V_P'G+&!8R6\0MI-WB0`;*P2YXT$B.R'7K4_(=W_U%LOS MOYC.X/S#;^_NLM^&Y]]+0`^>(`R<6;3D$5ID3YX- MH(1/R24/X$V?GY#54OG[F"]Y1FX*7:%1\$0J5M)/OB>;-"60*CJ$AQDF.(,Z+!8DQ/T&,:]D M`/D"_9RRT`LG#`9=8(]QM4X`,8@P!/PHH2`[Y+D1-+'`D=).3$$Z-_E#O@/N MTB5B_1Z8&O%D-M]BU#$!;9`LAXX('C!?#G^.H`112A1K;OU)$)@4APB,`L^F,$TEV=P&N3SA0:!D`88!A@Q[I(3<=L[3U=[5[XKW MZ5,I)5)Q'BB:"M*>"@E*H);>-"=0'!"PYDW MHU):X3''4%2B&&<:'\^]F#!!P'PM6!PKB0^\AV-DAT\%FX5>^A2AO.,P$$CU M"K0#QBF2$.(UZ9,#&Z[4!+G&H2WD51+AX&'70*MC(M@C`:\0SXG:7Y;O-)E[ MRNRS,$DM$@A7Y#'0?:A#GU:*)-"I$.$%``1'?\RCB#]@8/MJ&)>3P\Q?N.%U8[1[`>)]/=3#V(] M'!VH3<&0@JU;35W)-%%!`13RS"NC=M'\D.6AI9:8Q'0R#\%SS)Z4CE#0,6@Y ME&J#BBK'.E5@M.^"+5C@1;F*$C9J;_EPEO.[VO?G,JU;<<9F)/)+XD4Q.L_K MS#O@\3P8/WS["P0D[P*4O5;1R5DGH@8R@R5I[2;9F1"I$.:N]4NPU3(;Y M3+98/U`J+^'2$"O_(P%G8QO'\LRD]`6Q]SL-E0/#5L>\L_3PQ]+9,H%.14+A82!] M>\JJ"#5!&JU"I8IC@)O@&I0?`C$/Z03\@1<]H=ZD$,@R0@T* ME.T'/Y8$\!N@8 M*/S$0S>N^#(MX*6/2^A+;L2G0*OC"208U?0V@*##A6ZFLY+F..UMM?3 MY4T+<$7'\17T+>"X0[:CRF.-'IC-&4!&:6+3IW,B'P*W*78=S%76JU[$9G-\ MM'H0T*GZ?<6FW?S)]%?R>>U6(=;(3?,"#O$V2M,WIG7<-PQP*I,HP1*6KD`0 MB&8@[DZG`:;UK53!;TS#.#:JWC>-;T_6PW&AG-"&T$$CFR)BJ]8P;L\:0SOP M3?]X.!HJLM:QZ\#+4+;,HLR3LN&N&+C]R25+H)R3^\ M,$$S7,$KG!))6=[DDC+$Y9Q"RS?QQ%R^[:CZ\`@J6@;&LZHQ*;0HP[BQ@?@R MP@^D/_!@_C"=0LPEYP)9)(2M!FR"26V#UA;(V1<%N.Q.=T2CD\OX+P M-;H'%@KUKH_VZ)N1FQL@TUT/T&MB[C4=1[NY6VX,:HNY:1_;METEYM^HTK;2 MGDY47IO$?\`\1>6(F.7BCN998JD8D3(1-X^=M80[KU/"]S`3>=G*?)3RP`[*Y8I0Y;\PL415$IO!6R*&D?K. M2Q?K8N@AKMCY=(H;HT@2`J?4\C; M172&:3)O@5L!U(Q)*:V2J"`1*RU.A2H5O>]PPO1]FN%2+WR7A.IA22R5RZVM M?_HRAQYLL4`EU$0^.[=:S%[E](QOI;QZ>&VW$8!25?8-T>::@\#FT(Y>:`8[0*P,,]H M;$$ML?^Z!'92C8ZSC5T@:YN0[GAY/KO0SR8OI8JL3)::\D1\0JFO5GBS^0\/94)%D!"* M<">!)Y@X(;E\\1]JM:,T6;P*_%%;?";&2234\E+1@$@054:$5!N0,87!"=62 M`*[24YJEKE=+>;BW934^>^Q-?OVIN\TA#>S-*]&/;C8RVWI1M)/DQ6QDNN,' M["3Y<]G(@P5OI3'8]EY.7$($/5XM;]ZM]K%]AV,HG"#R"X\GV;^O,08J!M'4.>AZ07POO?3:O$Z6[6F)2N2"@68 M+A9`,6XXV+3_*,SO']6&0VES0/Z9M-!J0]/VWHG<#L/5UHE8[:2LZ M34=S,!K:+?O3:+C`?O9+Z:S/V4SD?0=-;M-Z7==/!L M/,QNZ*'=>$`-;:2;CW&_7Y,R3`6#:TJUC+1E.H-!SC.O&F]$M>D86XX[''4E MVG1P37?D&'T-76TTKH,-:=XD*K5Z%95!G(;;(S<#G9:#:UNN)%Y%HPV&ID/M M#AW7U(RAZ<:3%VYL#TQ[FG,`> MFAH@-A4("8R4KR&0:;KK3 M*8@;5[;MIM@=7X=)Y*&A-0YNGI]U;6>&VUCV33S<[T7X&U#UVQW!9OE=W7Z8V=H]7-QX0:)%@@:3Q@& M^5'L3K^I%/6MX4`K@*:"83<@_Y&'Z8'.<*9NL](H"[U-8:BDU@E64P'I]?N. MVW<\X,7+7 MAY82;(UJKVSL0F4?"M5>B=F%RCP@KW8+TJ[KZ1N"^HWB+@_J7\`$T)O1CPGN MF;B=;JW!MQ2WJAT`MFV,AOE@JQ$.[9W8+9U5VRD,OZRG=@MS)7WSCDN M!!3]/TLG=LM^Y<86O/O>U25.V8UOEWPQ3O=J7ZPO*?M,Y06;VA9Y MR!T2<"\%N<..CQ?DJDNXG__F%X9A1M. M'E@0:!;G1K2U`^\@U"\+O(-HOSC'VPIX)^"WQ>F3ONG1YH)<":&66)I/E397 MWO1A:3QMVEQBT\J6QE.HPEI:#2BX^?HF%'$D/^27.R7QCH;RTFRY(2#=B7Z= M;H[7:QC;0#A4-YIG>ISA*'_G]9^I,QU,YY^I&QT,J8YN?*0Q?H?H4\3QF\#^ MNZ=?!?5OPG2_3#B[6-]6J6/KV["X9%J?NE[<317!<6U-N#^E)\,0"&[&QSMK M;Z>Y'?':%O4+BQN[:6H!V2$&JPU0[N7"\U#I!W:0[5\X_)*F4;4(:7[KVBY: MG4"UX%9M0&5LS7^@2HN(N=4REJ?5!5-7+:V+J4*;;^3)4NTV<+\9*2&L%W(' M5=4.>17%Z>5RSQI80VNT%W@)>;W`&\=2-[8\5Z/U5=2!OOC#9'NH%N?/9.!S\',/[]73@W:&H!V5A.[?P"D@:, MQ>^(ZN!C\2.I^RCJ0-AXJYEAMT`H`P$9%ZGCG-<\`BZKA(K.0`A,D3R25(=> M5VQMXZ&:L-:[TI;J%7$[U1T2]3;.G531ZH*I^0S>&+K-(65KB)AH7B`GU24V M&I@T=(UAGDGEE-KC:>P1;-M&WGPS M[6CDZ(/>]@AXR2>BZS;?\@//=9NWZGQLV+9<>]@6?IVMD*YK6[O;SQE:=6.- M&C3YE=##F8O^J+@9NSF*P_2C^:;*#3-ST'ZLLWZ815FE!7/77^B=QW;"+;>Y99YGW.$\F1UPNUR7T1#N"6A8#:7TY+L&N12@N5D6B+1$_;6 M`+$5&9M:3E/4GR"8G<$=:(I0!/8S]$L;WB0[+*3$Z6=Q+K!:LNL6I#6$]8L M7$\S08KWW13LEUV@Y20K`L``00E#@``!#D!``#M M7.MOVS80_SY@_P/G8L#VP0\Y:=>XS0KG-1A(DRQNAWXK:(FVB4JD*U*)\]_O M*#^F-RG'CEA@^9#$\MWQ[G['X_$AOO^P#'ST0$)!.3MM.9U>"Q'F]CDCIRW&6Q_^_/DG!#_O?VFWT14EOC=`%]QMC]B4OT,W M."`#]!=A),22A^_0/]B/X,G?7T9,PC-7T@<"3U>M#M!QQYF@=MM`YIA'H4NV M`L=G5Q]1[\U1K]]SCI'3^][O+*?0W@66\*UZ^&O_HO<6?CG]3WUGX/0&CF/8 MDL0R$MN6>LNW/6@%?E;L[WW*O@W4KPD6!($3F1@L!3UMS:5<#+K=Q\?'SN-1 MAX>S+K`YW2\?K\?NG`2X39ERIDM:&RXEI8C/.3DYZ<;?;DASE,M)Z&_:..IN MU-E*AF]I!7U"$T$'(E;OFKM8QK&@;0:54JA/[0U96SUJ._WVD=-9"J^U<7[L MP9#[Y)Y,D?K[^7ZT;55$3,PI(Q/*%W,>J>X9]Y>/Q MG!"I4Z^(]H#JW.$0?#$GDKK8KZ-;(>.>%?W,<.1123S5$XD"[79ZNU`9!;`2 M.FW-N%]`Y7,LYE<^?]Q)XQSSGA6^@1P7DJ1GXMQ,)25:?4UX#^7?*\H@%BGV M:W1](^9]^Y=+(N[P$YXH<1I_%M#N69V1$)'JPQ!8/`@X&TON?M/I5P.G6YE]'M6:QLQVZZIU:R"Y8`Q=D$DIKZXP:'JD@^U8JZ,]R5B ML*[>M814&0##EQOY<0JXAL\I#K*4A'G$V\A1ZN^K/H''2EAO]0,E*=IP)?^% MDANM1*"4C,/;4%B(I'3N@Z+;V(;_UQPH9D&_;;/M[YMZ;Z.NS]V4BKXJ.'F8 MAGRM85Q53K&8Q*5E)-HSC!==%0I=XDNQ>1('1[OGK"O,5^O'7X="$"G.HU!5 M*YL&?#PA?MSLUS5=AJS;G,)JO(>P47\NOT?T`?LJ<0SE.<3T$\S(XLE(N2&& M[%D#$P$T#%W$0X^$,!7L]38MX=!-!4Z^X%]30$@%JR!M`_;!AG\:\J#*XVOO M\EV,22(#6K30(Z&SN03]&T7R+B0+3+W+Y8(P0;0A6$)NAE2_8:0J;;4.F95% MNFQ@3R\I<7HQ,+8Y^YKB"?53FO":07=L`W3FKK`.Q41],&1>G<%5 MS]G\:&5J70;/HJ+)"+A&2^\Z%E805AKZOENT*ONB*[;%V[.IY=NCZN7;E(3? M7V+%V7##-F7$<<:(K8S$T]LI2HAI+HNL3L/X$(%#+Z","KG:I5BOFI4G$2UC MH^4ZGQ(AXB'YBE2M\>0IFT]]AI#DJO9BF_!V"J5B4:Y4 MWVZ^;+XJWB'.TY;9%]IDILOP"1(S!%[;@T#>!$MQ.(L$E$]"G/-@`IDQ]J@+ MQ:F(Y\7W))Y0:1)0'1EF2+ZQ#LGZ?K(.ZH\X_$;4>!>;'A]S`IMFVGI1QV<& MZ1_606KF#^M@'`4+3,/5?&;$)&8S=5IMM7M[N73]2)VT_XMS[Y'Z%G".H("V=2O?0P)N$##/)"VX5-^>R(( MJ*-.)UV0!^+SA0I8+:H:-N/YL&UH&KG#.A#7BT)L-F(N#\@U%Q4E4R%QDSN\ MV"?B'IS-(J*RH;@A%5L)Q=3-K[]40)!=BZVPU]9E9W/K3+M=WM!VLWWHAC.> MME*;!"M8+#AGI%4_1]A\+]*"4'+.R/KHNB`3.6+0&>+#\(E7/".V#<%A[LW- MPDYF+./_E+%+WZH)4;;C%79.VS+Z&#H>.<-"K;X&*B^D7HLKF+N4T%N1#)\' M6+4KK$,.@BLDH.T%6?T=L?1[/U5%LXZS^5W09Z-IZA[[ZNR\YIGS[G60S;$V MOQM[`&A+'/0#]-G,6R:5ZT9FW,UO]AX`X'(W68?Q/629I_B"@=MIT1T210O1 M91S-;_<^&TN=.^S+OS_..L%SYV#HJ2HTOQ<6)U;P7QKGAXMXK1 MV^FZ.BB:J2@V+5?S&[V[`V=DH*V]ML3L]7G%9TVI"V4TNYWM$N*)*X#>;(0I MY[!VHET!7'[WNM(=UE4(284K;W.J!K*$U=J9^&Z(&EQW=<@3KBJ@UO&DK/C$ MX8-FC*AFL79J;0"/WKHF8;D-Z4P=89%Q/5$+GCRKM=/D9\!4YB`K=P",KC-, M;0"\45=U4>'Z7``G?'`Z:"4%\>1+1]VB8?P%MC(J[SE,6?)'UI)^)[&=L97S MTI>0%0ZN*<7?9A4_`@@4%\H5'(=3LWK$2.E[DM7WN(,V["IH5@)09F0]G.JE M]R`L``00E#@``!#D!``#%F%USFS@4AN]WIO]!96=GV@L^G:0)C;>3 M)IL=SZ1)-MYT>BN#7#05DHM$[/S['F'#@(,-M(;Z(K'%>5\]1SK"')]_6,4, M/9%$4L''AFLY!B(\$"'E7\?&X]2\F%Y.)@:2"O,0,\')V.#"^/#WJS\0O,Y? MFR:ZIH2%/KH2@3GA<_$>W>*8^.A?PDF"E4C>H\^8I3#RWY<)5S`6*/I$8'0] MJX^.+'>&3+.%YU2D24`*P^G'ZT_(.1DYGN,>(=?Y[EFK.5?. M*?QQO?\]UW<=WW5;SJ2P2F4QD[,Z=6`6>*WEYXSR;[[^,\.2(%A$+OV5I&,C M4FKAV_9RN;26(TLD7VV0N?:73S?3("(Q-BG7BQD0(U=IESJ=>W9V9F=7\]`7 MD:M9PO(Y1G:.4SC#U5`5@G+PL;V^6`ZE>ZQ+T)+Z,LOD1@1896732(1V1NA/ M9AYFZB'3],%@9>Q?Q?V(F5[C:42(:L*KB^T1YQXGL!81433`K`M;K?#`H($7X@/#'P+M\.$E%-;$'QIE(F>HS#(4E MXECPJ1+!MR:NO:(#`UX*#D\MBL(29,O1Q+8K_L!81<441[.1;(^DQQJ[(@I3 M)F]QHH_D4Z>:VZ4=H@:[-E=GO93%1>I,*%@#B;"8S)O&, M)!UQJ]+^63%CW0@S0?]<7*B+KFBY9M":)'.<,O7319G+J\PP3#G53P`W\+'" M35:*$"$.;DV/%1[`L/:S%F_H'E%N:K\%IISM+9`%8_>4ZAM0RK('G`6WVSP M?J-`F02]*9ZUW@Y,6]^85-!'^]$K#D/@M^Q4*CD<;>50>)1&[^:H;/-;\GC9 MOU32.&Z7AG9!&YO>TVC5UE2R.-%GELJ`"0E*^.!::.V"1'D/[(N2T7#;L;?= MJ23R;CL1SRIM2>$S\,VHMB^J<)]N*?=W217B=?&K,Q0H73$-]5W?JN2DJC#E6_.[OS[,?GXB=Z&/D!4$L#!!0````(`%2+ M#$5/\.LWW18``/XM`0`5`!P`&UL550)``.0 MANI3D(;J4W5X"P`!!"4.```$.0$``-U=^W/C-I+^_:KN?\!Y[RXS598M>9*Y MC"?9E,:/K&X]EF-Y-KN5NIJB2$CFA2(4DO+8^]S2:H\'`HLP9V20^+@NOJ8AC\>W&?9^O3X^,N7 M+T=?WAR19'E,U4;'?_]X-?/O\Z-V[=\?\:2':DGR< M)U'QCC?'!9RR9/HTU,A7D*3A:R,%$27+,](]CO*0= M'K`7O6,O&KUE+_I3_O.5-\?1`6*2GVXGRGJ]JY65*QV[!GN#DY`$%_%NJ)O: M/<&GWTZ2/:,"57WG5;@CF1?M!+ZJZ1SV-=ZMQ;=Z[EN:CO]XMY:N:-9A1^S' M*_JW&G#\F.$XP$$!G96E&>#XJ_BXFY==ED[\6KD1&RQ)(FT17N3"2^>\W$TZ M6'K>^IC-2<#3[.#/^=""5>5`^1!,_S<1-?N>/T>_,0D@_?[1>S2/`W49I^.`#%YM M'*@*@.&!#%5K'!`R>QL'TOEBQ7N9+5AX'[/ERV>Z\-BL<)R-8VJX96'VQ%8A MR8H;X>-YFK'E4J,6'?1<<*%S-1@_K)5ZYTQ7I$T>%:J(ZB*AC"K:^QQF4NP? M+B>,`5B3 M'SDEMK+<`]$?+AY"2#E9,%D^NSETI7$?*F:NC3D M7/>[%&:3`#4A4$R0(5-20@A3$R+@#NX^V#&F0`(&YC+REI)Z-9Z[8H,45L&" MVD,0O2]#U.SU4@8QH3[Z^FR3)`QCF/I>]`_L)>K!0"WJB@$FL`495'(@>&$` MUZ1(+HZ$/&(*O0X.PECY%4?17V/R)9YA+R4Q#B9INFFY+BSDW9J3!MAULU(A M#()$-@B;3)JDQ<+40TQS\#M3184N$LH_]4>JOY%H$V=>\G091CAI^D`UD(:46^Y((=8I4Q,!Q!09 M+H7G@XNB0K8_0MQLYE'H7T;$:SKC%3)NR2"!5Z="10`0$=JH%#00@HA+]CC' MD-6*Q+.,^+_/[CW:'---Q@/CZ-BE'A:U2H[G&XL*-&8=C08@(EG`5+E6N2;B MJH=(**.*=I\^.+&P$VZ?2_J;S)S1R+KVQ2GA-OUQ+4$03#*A4_KE\O5W[I[C M*OVSAGD#[#A3D>R',2VHR=*;M'F3##&S.`T\5E&'NQ M'](O@*2A)@BAFZK+F)0NE:F&JMCH]N>&`JX;7XT M!('11(Y.M2DA=$YAT.;,2^_'<<#^N/AC$SYX$868CK,S+TF>J)'/#_DH*F^I MZY)6G:I3I9F5(AC:=4';HB%50G0%AWSV%[Q5AT'(FP2OO3"X>%SC.,7Y-Z-H M!H6L2\)IX58))A4$0R@=NB:!5%5CF<96XV M!2GX"2]4G^(@$4-;M3ZHH.8`Q,Y7]?KT;GR%()G!5Z$W#R.Z6L,IG2"Y[_*> M1`%.4C919D\&R]A>W25CNE:JRBE;73!344?`34I>3<8?)E>3N\G%#(VOS]'L M+^/;B[],K\XO;F??H(M?/DWN_@&.JG;+-IU"3W2T6,"II2%2KMM2KJ((9#UW M33*C(9V<$O3`U-`:)RAEL6?OT7B3W9,D_"<5_NYP.!RR?_.XM/?B($;` M-S;(-D8-#88#H0[$&UD)Q]-NK;7$G.ZB*4#6-LP:,F"XIP#66I#5HALIZX;# MD8)L)X)J-G1[^]WA._KO?YU\SQ^]'1Z>O'MW.'P[0EZ&_GL38_1F>,C3+_+G MY]CG&530FQ'_]0VBA:\QSP(9[36F^QF+PB#@P2]>=..%P20^\]8A-3U4"QF5 MM--EH1YR;5TH%P7#9CV^]MXN?XKX_EP8(_SHXS1ESH9R0`5"*M_?K#81RU@W MS>YQ0K_&=8+O<9Q2YD]BGZSP%4G3:YQ-%W?>HWK5W*T4Q[Z)7:K8<%IT*0(. M:7?"+7%S%*4@PHI!?K4<](J5\1H&GV]QYH4Q#BZ\)*;S0%K!?HX7H1^JUBXV MBDZSUEE7I);.SJ@%AIO64)MT?)4_?HV\"C<+F?4I/%&`Z:9,U#Q^E!L$2 MR%#;7L19K_;Z7C[;+9MAN5V4^.3>%[@K9M,^[([;M[!VSG?9,8?%-TNT1M\? M\,WRND?AQDNF"0_6#_@:[P8G?&%FY8Y0*_?GY3%52.WX46F"F7`[P36ZAX"M M8^J5$\Z!K>?`JD7:2OW14%4!-?V:&D!IIX!IH%ON.41>J0>7=<(AU:$Q"H6^ MV58';F*:D`;-LAI$2X:%7` MMDW3`.66N[)%3'*E4Y9JD*AG;=\#:9F&NC__16Z_>H7@*Z M`)6#X"8A"YRF/%SK$BN/,K3%W/K&Y"#KSK"Z#!@J*8`I3DCMP6Y27$U7Y@8[ M(W&ZB;*VI:T6<^<1*;WSC8`:W;V-D_;5A3&>'"%E]J!H/+<:5!$ M$U8M^J%XV#L-5(A:)_[9+1>@W-R!J3YR-[74HY7`N?NZ]]]I8FITF'L+X:C]L MTC"F5L49664/-]&L>LY9M!Q>VC!`G[]O()&`0S! M;%"V_79")S]>6&K!X%EU^<[REY*8>WYF.'F@UD"J)YRMB0+%):%(`]0 M8E.#6WTW9SRH39`=-C]@',!@VW3-6;8X^7V_*ZBTE))EZS2 M0*TR22(&BSUJ@*VSJ?PH-&+-@(C0`K.VN"8QJ5?$;M?60L]MMDK+:M1S5QJ4 MP$R:MDA;?CQ^,/]5G@O^-9!X@2+)G7XJ;$GUD7U0,]4U1-QPY9W@2HR7S%>F M&Y[D\)3Y!G.*P"#(.9YGDY@RF]\]1E;EX'R M0LH+R8N;R&&=C:E<.\NNV+N,R!?3S:QZE9XN!E:"5UP(W)('0T(+D-H+@/E- MB5P+W-D9:@HP=#<)>0@#''QX^I3B8!*7'L,Q2R$KDD(9O&P[%.38IMNQH@W# MKV,I8$B\,W3IO9^"S9?,3UR6@+9%:-UW<"SW$TB](\$%W7`?!_]+)T\VS*5W MY!:S#@HC7*O+'=G/^/(RKW*;3/KE&JN>B7K_[P'SG;Q@Y5IG?[:O0AE!2?$R M%-.O,*(O8K^RO_/[CS?T+2Q3=NFB09[=:.C0L,Q7>2QR=<7<07QW3V7S*(2= M&I-:P#4S4BH)AK5:>/(@)Y$7`BU(@J+\7,(A2O,HJ4-Q7P!W[4&*)+G%:^^) M?S'31?5*.T6SJ,7=!GWJ0=?C/>6RT+;4##B-E,NU6<22V'2CRV5VS>#>KHI3 M'(SA0$0.E4N2W`@4TT5Q.K=16SL59T=I+,&79VP,\E`XU0&K-:_HHMCFUO?_ MKWN9CM8=]N/%LVK1:5NS&$DJCV#,7=2`3#"=HL^Q^',2WR28W7]BBOTPJ3E. M4F-5B4:V&JT.-*Y:XFV%MA5ZKU&AR>SUM="U&H[Z)&/C8E?KMFGI]4M'137T M?&PH@3'K;9%*,BH)_KT*<,%)2D4/Z'6\S4HVKHE59UNR4^V7D.K*Z#G9U@-, M2R58)3,I'4.0%_S:N[&?[0>'ND'QO(T)<.$JW7#+7.*5'8E7S`_WNN*(@Q.^ M+J_IA%K!Z3YVVK0%`2"R144M"*TI!V$PK MZV,'BXA@F=Y:^[*X+@Y0C8I_# M':'_H]MRT^>)+<+65%OAAHA`R`C[_[UY,SL09IJ$2Y;5 M(^,[!/;$:>OU2B!5-;1$:BK!)90"J36Q2$5_+QD2]S_%L5U*.A7CZ:)R>X+% MP*S0ZVO2TU9#-?M)E7IG8U>DK6UDC[*0+,I#)TP4!N_LS=%X3F3VA1+A"@K7X98):*B_[!KGI^H%\;V\+"24B"YEZ"HN&Z M%>'T6J`=*E>[)JB#/IB!=@?0,B9O]RG/RWW*22P(S@(0>>`KWKX`#ITU[>*> M?BI:.:7+FG?^+/.23#<"5G!)/1ZR;D=>AN9X&<;L."F;I\6[>@KLTK:XVP,? MHATN8FTX2PU7IS;'+`;8IK4=AIAOUNN(GWOSHN*HW"1>D&0E9CZ$4E9Q-^T<@(25;Q(Z MA(EYDM\^V^W(Q`X%N3V;NVM%ZR=VNY8"A]^[0C?&-6\/9A2'-8">T-`UP3;" MERW*RQ#@&?:II&8-^\PRH7P"UM6W_1J,!7X5'X9M+8S?2"/J^ROX("I7/NS" M_;HZ%)K+*F7+Z*KN5T%>"6`S3^G*-^`'&/@YE8^_?I@Y.>U4!&G*7/DJR9[. M-C6A*HXT%6*]4\6,S&"AF MY;I('PF1J^!DV9#9\]ZIH@$E]07RLVK[G(_VE-0_67IQ^$^^9F:7IY(H#(3/ M*`YN*$SF%,KX$J*\9+7,D&6*J=Q3V4XO#MAG<]2N&MA'P6!(O\_:M/+)5\H^ M1+72N6NF6CZ;E[>7_VY?`2];&S]"/5U,R[,MJHULB:#3\`$ET%J80$L*##65 MT)H\&QVAZ_Q@^P)MI8_'P#;Y?]EX"9TQHJ>2Z!5/_!U^S#Y$ZC`I6V67%.M6 MH2KM[#3!4+$3W"8]3X[0I]C;!.P6JLH85RGA!4-$TSMB/]U;:SD-#[6K0BTX M5*_2.ZVZX90%AO+$9[+Y$L9(QW*9;'ZQH'*("X*SQ[FC[YY$ M`4Y2%FB7/3$VVP\^'?2=;Q]UJ59K_\A&&0P1NR)N$O3;(U1$L_-LWWEV>3A1 MZO4QV3"HJ83[FP]UPYM<$@RUM/":/&+"U;@I<*/=/4FR.YRL&%#CT*80=IL_ M5@>XGC]6)@F&1EIX31I]=X0J<1K"OH)!(`HK8+L8@63=8>*3I:[3V.XNU:F% M(MLH@B%?%[1-+KX]>I&%HL+G4&RBC'T_V>#FSI1_1I0 MRJLY/2$&9;0ISQ76KPVZ\1(1'!0'_':\[91KVHIZ7I%NQZ;G5[X^9.U>7N]4 MWF,E6M0';?B+VHD`%J5I415QGMV_`:Z5TS]_#H9"$E"MZ!]QK9@(_^GK$-26 MZ93;TX1/O2(DLKCNS_"5J]0<'Z&B9NRO,P4A[KJ3P&U*`R5*T0TJU,3TW;=J?;;1,`:F@- M.&FL=R[Z#1+":)QE23C?9#Q]4D80-3/Z&S$JC*#K&[O>,>D`ZBMKJ)HOA4<$ M"O&>.NEG'./$BV@-QL$JC$.VZ,S"!ZRYM\.@`JB+;)$V>RC7X[U3UT2Y:D^] M5:8GUU\V*A$#U"LZ=*UHVO)60R%L<0OI"S9_X6_47FI3$P'4["ID2J=JOU2_ M)C&I$T73ZDIA0.UOQMB.>=MJE/S/E?KZ!/9R:2&<3C%";/;)5H%Y;JQCR%[* MD;#OJ__Z[YE.,*5&L5JOMVGC!2Y'Z[^G.D-57T=U7KV.*M?N>_YQ=2T.G([< M`;0R#^5-)0/EJT_BCNK7:&O.V1U3<=^_^T\T"KY_=:`[]J_L,@*(Z?C>@.F3 M&AS9R5M)\U5_NJ)_HS\7/]'_S.DX2G_Y/U!+`P04````"`!4BPQ%/V]G8"8/ M``#!U@``%0`<`'-B9FTM,C`Q-#`V,S!?<')E+GAM;%54"0`#D(;J4Y"&ZE-U M>`L``00E#@``!#D!``#M7=]SVS82?K^9^Q]X[MQ,^R#)LM,T<9/KR';4T=2U M5-MI>T\9B(0D7"E`!2C_Z%]_`"G*I`@0($4:4)H\)(Z,A7:_#PLLE@OPW0^/ MR]"[AY0A@M\?];O'1Q[$/@D0GK\_^GC;&=Q>C$9''HL`#D!(,'Q_A,G1#__Y MYS\\_N?=OSH=;XA@&)QYE\3OC/",?.]=@R4\\WZ$&%(0$?J]]RL(U_R37WX? MX8A_YD?H'O)/DV\]\UYU^U.OTS'H\Y:LJ0^W'=Z>#W_VCE^?'I\<]U]Y_>,_ M3[J/,_Y]ER#BOQ4?_OOD\O@-_ZM_TS MFC!TQF+UKH@/HG@L:+_&4[80_^NDS3KBHT[_I'/:[SZRX"@%/T:0DA#>P)DG M_OUX,]I^*UMCMD`83A%9+0!=@JY/ECW1JL>96B\AC@8X^(`C%#T)VG@+H36W M).YV0>'L_1&;SI8=,0K$$!'?_96);/2TXH.4JY,CT]E7W'(0"X]L%A)%. M/5G;%M69`,JQ6,`(^2"LHIM4L&%%/V*P#E`$`^&)4)`VGHU78D;A7#&=MF;2 M+Z#R!6"+84@>:FE<$&Y8X6L^QU&812:>FU&$H%9?$]FV\!TBS,]* MG909L**0<6[B.>"*?Y`3@8\1Q`$,THZ$_DT%*/QCT=EQ\H?'I%XJE?V1Q]Q> MTH67[6-C0FI$2/RMI1"*8PC+O_)&3-1'MU ME-U@'`>5#/K=.;GO!1#UA/[BA]B0SG%_$U)^Q3_ZE.AP`^=(?#6.1!@OT9PW ME;?<530[-`;4]P@-(.6,I7T"ZN<&1#$*WK3HK>)HJ>,O4+@=2S-*EE6AW,!& M-(9DT>4JO#@%%]P0*E;7`#[^!)_*."@T-22A[QX+"JMMT)#:<<>[E:.?;V$( M^HE+H,MLM(GU!%)$N`6!2#V4@[[3U!#]4Q?1EUIM@X8!UR80&@U#,)?#O]/$ M$/97+L$NM=(&W!=K*DP<(L;W__^%@)8.?'5K0Q*^=8D$G>WV%M[?8!C^A,D# MOH6`$0P#$29#6K8`*T4,F7GM$C-&*-BCYU<2KCF"]&F(0DA9&2V%IH9T?.<> M'0JK+8:GB?_>P!6A$<+S)-%?&J4J)`Q)>>,>*>48V.,F'B,7?#*=$UJZ<=AI M:,C$6_>8D%ILCX#)>AHB?Q@2(-OU;[7.-3/>L[F'OL18+F'C7:]@W17_H/W,N/3Y=BX3?N)UO.TC$_[S1L*+1;RO MMP_QOJF5!,^.K!E@TYBE->O,`5@EPPN&$4L_V1UGFX\_91[0;A_S3`A#FISY M1MQ,>F_'J6_>@#$8,;TAN^UL)=`KX9KW'H4ES4]C^[*Q"=A-22DTMY97;XH< M!0!N<"3*-/BD+?[Y\.<:W8.0J\H&T06@](D'*W$-F9HS0W%K:7HC(D@=DUPB M<4+A"J#@P^,*8@8W9JI)4S2WELVO05*IQ6Z0DC/'<-:SF%:N08+4P@SX7/<9 MY+\,KA*KE1K&ZD4D`F'@*@2D*XV(]/D_'>^P%"3G: M3,S7T9,^TC#OP5IV;O_@HRI,;LR:&:V-`\#)=(&?@^6?/`U90757M3:IJO-JA+3;GE;K`3'R:"+#)E1]7>E)W6 MXL7*[)1;[@8[&:.,5AUS'EH+!ROS(+'QT`/#.J%@`\%?W\7H[U#BO4DZT&*% M-=DF:6/CW%)[+&FA+B0O5#:[04KFZ:4N_U=H:4I':[F^RG2HK'6#BT$0Q/[. M/1^@8(0OP`I%SR<7)8&<2L"4F=8BN5FX0?2,.:6$8?``4 M(SQG&6,NX0SYJ"3,,)$UI;/YHKRZ=)HCX@:#10.K!(85GI`XPY#:XD,/]G7I MS?K97W.>W8EA3-%HE'4G:G'D]SGD"G-.RPMSK*,%H>BOYRE81V)1SG9M MSY[DJ8!PE[3X4%A%PE(9VS4^C9"5!\!=HLH/09086.<4A#M9&T,HW.`MD_RK MOKX9"5L[CMI`/O0P5K;"81N39:U4R'9QUSZ&-D+BGR:B0[R&/Q(2B*<<)8D/:6O+*0\-#[M9CA*#W9CLDFN> MPP$.!L$2X?@J,G']WN98@7Z<&7=@>Y-NX%PW M^#--;)\UVF_4%VQUA`+DQT?2""L[191O93M%L"<1$HM;FGK&LQGR90D9\=OT ME[8W[WM,,'G[W!C0YVO&=QV,\4W1E,]_,8H^WT4E3[IN8%SNH1GN5?JPO:_? MSQFJH^4&RS\#^@<4"UIL=WPS.3=DOC%:S:Q.SO;>?S\VS5!Q@\$;#BS709Q= MO^2;KI"L1*2O)5`C9N^&K$8(-`+%#?ZR4;RX?X#@V+!;2._YFL"T1)K*6S\1 MV=QF1P^3&]2.EBN`:)*7&W&H\5R\]B$YE?WAT0_7(K$H4B0/*"RI[*[8C;T; MNAHANA9H;O"M,;QV/LF!TYC[<6H(S*'7IFZ2YGC^7-*NYES:V)1G1[>$)0`< M.K?7!).\=<;98@-14]X=W?T8@^/&/)V>1=;.RX6&UH^&FB,M/WZ]]XS[-O%* M#.=B1VO?+R_A-!IA;GM\H63F[5KG?$2+LRAQUG;SMM`AC-\`IR:\7F_6CZ+6 M'17[@.>&*RLMKS$=.W"(M2Z16A@.?OF%D4E0M=/,^M'7/9=5F=&'SF1Z:#"M M*3P'#/EJ1A7-K9^!W8_94A#):]5;3LD;U*PG9MY0M2 MJX/-9D934;T6'RA)#OT,"9TDZH]GFQV%;!478EHIVV6<+T&Z$1#VB?_;I;); M2ZN\X$S24/+[0`<;QY-"OD)>PN3?$O2OJR_LCDO-\#,#&WY?Q].G'@!3"-,B@L:H3##]B!YU*WZ]4J MC+?:($RWVB,\(W0)#%^@8=J!`Z^'J9Q4J(B.&Y-JIN+CVPZG5QWO M$C$_)(Q+\O_TNU[2BT>R+SWH93*4%N^3HG.`T5^Q2N+J:1*B(.$-!Y,,H)DW M$6ZWB`8/UAOJWF:&OC``2C+QDK:6SZ\VRN]N"EX)C4L>O#TKOC4P,SO)7?B[ M71<^Z6:.G&_[\;(=?7%A9UWXES6@?)4)GV0CX(Z/J_.P]`&JJ?QG[.K5('3) M_:4%,3EO?[/K[:=\P1927BK6<(4&NR/5/#$M6=`)6CY8]@RB@5,I!6QYD2G( M4O_0F.^20Y171>0\X^VN9[SJ>JFX"&:3#KRD!WMC;PNW?C&3-+6=9#]JYPJS#(;X6<%#3S$4/P@P[=*T+CD2-G=S26,``K9-:#)=8)RCSK1 M[7:\KS<=>=N>OOF\W4NA:)J:'O@^E;]'6C0KM#HL!Y":X-XXEVY:S`;\:85- M3&-C_V^^L(J MN6TKV[=(-H*^Y**X'1C<("AC+#=O3./5(BG<22^--G)&M;#MRQY;H+,":+5+ MG^\AG1(&=PJ?U8OOYC?BKRE@D'_R?U!+`P04````"`!4BPQ%ZI!!U1P&``#_ M*```$0`<`'-B9FTM,C`Q-#`V,S`N>'-D550)``.0ANI3D(;J4W5X"P`!!"4. M```$.0$``.U:6U/;.!1^WIW9_Z#-S,YT'QS'"5!(H1T*39LN$-I`E^E+1[&5 M1(,M&4F&Y-_OD6]Q'*,D%&8RF^:!L8^^\^E.^R?=;@V]>_O'[PA^AW]:%NI0XGMM=,I=J\N&_`VZP`%I MHX^$$8$5%V_0-^Q'(/ERTV4*9*ZB]P2D23=MM%-W!LBR5N#L\TBX)"?LO^^< MH\9>J]%L.#O(:=PUZY,A]'>*%;1JX5_-T\8^_'&:5TVG[33:CK-B3PJK2.8] M-2;[#>@%?JNIGU/IYLH'=\>A?#WY2F]&/;8?77Z_4>=]_,_G_J#G33]_G]Y] MOYVH?YW=3]^"OW^+V'TAV3`"/($)-'M;%28=NV M'QX>Z@^M.A(C9AY*N%"![-`NTQ3((TF\'GL; M/X>"2*")E47.R[D;^>SLR42I54D(7]YQ+Q'ONZ#/3'A*@D\',2 M,LHI=8@']CHBA8O1CP^69S]%OF MZ,]1;7D&\I&8QZLW[(5Z!03=RR0-2S#F7.R4G!#V<C;'>>\GN8+CS3450WF:#OE:._5"^5Z1K/=`2_6YE.B,/7E!19ZC7%? M4;T7$.84-)=5<_0J940YY9;OO"K+>'5B5H.:,]1:XPOP_TZ6_J,/A+^2(8H/ MDMOZO/&H)FD0ZH5,(AL+,@398!A8V>'?#W"M/@G\#**I#0?)<9;+T4@[SBBP M@&Z7Z@F-K/X;*/!^NZ#"K$?T%?SS3_ MLSH)HV]=)TL#]H5OI>/H,_ M!,>Y4(@MG.J;KGF2"ZHS[L94!A7]9F5ZEA993M-J.?6)]&:6KF/$+`SK&9'I M/<$(XV73(U94ZN@':Z:\:O_&FRM3_Y6*-O&5S"0_:*L[>3QKS-$.669%>U\7K'7W/]\-TS74\D$I?R-=BJ\U7 M8C,L3I^.:DI$,.<8]7V]-LW>XYOA-I0HRKVKN))ZD4@/EY+*FB"`A;)1%W85 M&@6!B("8JD@C/PH>A1F0`L3D8KY)@;VAC'P%K)E'U4UK&)RT#9*;#VB`):B: M=P.6>[#*$]-G<*0W'%)=2A/;\[=--3=>Y.K%+_$Z7,`.)3E$_S`)"9-ZRY_X ML1SV=`==0;P7]%#OO=*=US6LB*\XO)3=6X+9U.15F=T3=`0\L3D=8G:Q`KNI MKLX/P/B_D(A4U<.ST+JQHW+)A')6G'C.)OMXQC&[%-PEQ)./3KUEH(WU+C[3 MN>(59W3E3_(JR(W[(&>3Z-AUP0`O\V51O-309)N@7BX_AW:R_H+'_P!02P$" M'@,4````"`!4BPQ%B2$==1(6```KI@``$0`8```````!````I($``````L``00E#@``!#D!``!02P$"'@,4 M````"`!4BPQ%Y_@=I)`(``#`7```%0`8```````!````I(%=%@``&UL550%``.0ANI3=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`5(L,13/ M`Q0````(`%2+#$5/\.LWW18``/XM`0`5`!@```````$```"D@78C``!S8F9M M+3(P,30P-C,P7VQA8BYX;6Q55`4``Y"&ZE-U>`L``00E#@``!#D!``!02P$" M'@,4````"`!4BPQ%/V]G8"8/``#!U@``%0`8```````!````I(&B.@``&UL550%``.0ANI3=7@+``$$)0X```0Y`0``4$L! M`AX#%`````@`5(L,1>J00=4'-D550%``.0ANI3=7@+``$$)0X```0Y`0``4$L%!@`` 0```&``8`&@(``'Y0```````` ` end XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Issuance of Common Stock
6 Months Ended

Jun. 30, 2014

Text Block [Abstract]

4. Issuance of Common Stock
During the six months ended June 30, 2014 the Company issued 5,666,667 shares of $0.001 par value Common Stock as follows:

In January 2014 the Company issued 200,000 shares of $0.001 par value Common Stock for cash of $40,000 or $0.20 per share and was paid directly to an affiliated company for licensing rights.

In January 2014 the Company issued 600,000 shares of $0.001 par value Common Stock for R&D services valued at $96,000 or $0.16 per share.

In February 2014 the Company issued 66,667 shares of $0.001 par value Common Stock for cash of $13,333 or $0.20 per share and $3,333 was paid directly to an affiliated company for licensing rights.

In March 2014 the Company issued 10,000 shares of $0.001 par value Common Stock for services valued at $1,400 or $0.14 per share.

In March 2014 the Company issued 1,000,000 shares of $0.001 par value Common Stock for services valued at $170,000 or $0.17 per share.

On March 27, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for origination fee valued at $75,000 or $0.15 per share as part of a convertible note payable for $100,000.

On April 14, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for services valued at $100,000 or $0.20 per share.

On April 17, 2014 the Company issued 1,700,000 shares of $0.001 par value Common Stock for services valued at $323,000 or $0.19 per share.

On April 25, 2014 the Company issued 400,000 shares of $0.001 par value Common Stock for services valued at $60,000 or $0.15 per share.

On May 15, 2014 the Company issued 500,000 shares of $0.001 par value Common Stock for services valued at $80,000 or $0.16 per share.

On June 12, 2014 the Company issued 190,000 shares of $0.001 par value Common Stock for services valued at $30,400 or $0.16 per share.

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\W93'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K6%B M;&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/C5?0V]N=F5R=&EB;&5?3F]T97,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I% M>&-E;%=O7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)S$P+5$\2!A M(%=E;&PM:VYO=VX@4V5A'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)TYO/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)UEE2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)U-M86QL97(@ M4F5P;W)T:6YG($-O;7!A;GD\'0^)S(P,30\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\W93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO&-E3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\W93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R MF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR M,#`L,#`P+#`P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\W93'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'!E;G-E*3H\+W-T'0^)SQS<&%N/CPO'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\W93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS M<&%N/CPO6UE;G0@:6YT97)E'!E;G-E'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!E>'!E;G-E'0^)SQS<&%N/CPO6UE;G0@;V8@97AP96YS97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0 M'0^)SQS M<&%N/CPO'0^)SQP('-T>6QE/3-$)VUA6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2!3=6YS:&EN92!":6]P:&%R;6$L($EN8RXI('=A2!O9@T*4W5N M28C,S0[+B!4:&4@0V]M<&%N>2!W87,@9F]R;65D(&9O2!H87,@8V]N=&EN=65D#0IT;R!R86ES92!M;VYE>2!T M:')O=6=H('-T;V-K('-A;&5S(&%N9"!B;W)R;W=I;F=S+CPO<#X-"@T*/'`@ M6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA"!M;VYT:"8C,38P.VEN=&5R:6TF(S$V,#MP97)I;V0-"F5N9&5D M($IU;F4@,S`L(#(P,30@=V%S('1A:V5N(&9R;VT@=&AE(&)O;VMS(&%N9"!R M96-O2!T;R!R969L M96-T('!R;W!E"!M;VYT:"!I;G1E6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA2!H860@;W5T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQP('-T>6QE M/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2`R,#$T M('1H92!#;VUP86YY(&ES6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M2!I2!T;R!A;B!A M9F9I;&EA=&5D(&-O;7!A;GD@9F]R(&QI8V5N6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2!I6QE/3-$)V9O;G0Z(#AP="]N M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!I2!I6%B;&4@9F]R("0Q,#`L,#`P M+CPO<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)V9O;G0Z M(#AP="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2`Q-2P@ M,C`Q-"!T:&4@0V]M<&%N>2!I6QE/3-$)V9O;G0Z(#AP M="\Q,34E($-A;&EB7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^)SQP('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@5&EM M97,@3F5W(%)O;6%N+"!4:6UE28C,30V.W,@0V]M;6]N(%-T;V-K(&%T("0P+C(P#0IP97(@2!I6QE/3-$)V9O;G0Z(#AP M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#AP="\Q,34E($-A;&EB7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P<'0[(&UA65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\W93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%B;&4@*$1E=&%I;',@3F%R'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W M93'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'1087)T I7S=E-S XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. Notes Payable
6 Months Ended

Jun. 30, 2014

Notes to Financial Statements

3. Notes Payable
The Company had outstanding loans of $12,500 accruing interest at a rate of 12% and $100,000 accruing interest at 10%. At June 30, 2014 and December 31, 2013 accrued interest was $5,898 and $2,641, respectively.

X

- Details

Name: SBFM_NotesToFinancialStatementsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheet (Unaudited) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Current Assets:

Cash and cash equivalents $ 38,411 $ 31,240

Prepaid expenses 5,640 0

Total Current Assets 44,051 31,240

TOTAL ASSETS 44,051 31,240

Current Liabilities:

Current portion of note payable 282,500 12,500

Accounts payable 93,874 23,809

Interest payable 5,898 2,641

TOTAL LIABILITIES 382,272 38,950

SHAREHOLDERS' EQUITY

Preferred stock, $0.10 par value per share; Authorized 5,000,000 Shares; Issued and outstanding -0- shares 0 0

Common Stock, $0.001 per share; Authorized 200,000,000 Shares; Issued and outstanding 65,965,728 and 60,299,061 at June 30, 2014 and December 31, 2013 respectively 65,966 60,299

Capital paid in excess of par value 6,409,606 5,426,140

Accumulated other comprehensive (Loss) 0 0

(Deficit) accumulated during the development stage (6,813,793) (5,494,149)

TOTAL SHAREHOLDERS' EQUITY (338,221) (7,710)

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 44,051 $ 31,240

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

1. Nature of Operations/Activities
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

1. Nature of Operations/Activities

Mountain West Business Solutions, Inc. (“MWBS”) was incorporated August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009 MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. The financial statements represent the activity of Sunshine Etopo, Inc. from August 17, 2009 (inception) through October 15, 2009, and the consolidated activity of Sunshine Etopo, Inc. and Sunshine Biopharma Inc. from October 15, 2009 forward. Sunshine Etopo, Inc. and Sunshine Biopharma Inc. are hereinafter referred to collectively as the "Company". The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.

During the last six month period the Company has continued to raise money through stock sales and borrowings.

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s current technology before another company develops a similar technology and drug.

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 24 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

2. Unaudited Financial Information
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

2. Unaudited Financial Information

The unaudited financial information included for the six month interim period ended June 30, 2014 was taken from the books and records without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations for the six month interim period ended June 30, 2014 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2014.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)-(j)

-URI http://asc.fasb.org/extlink&oid=35737889&loc=d3e1280-108306

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section G

-Subsection 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-K (SK)

-Number 229

-Section 302

-Paragraph a

+ Details

Name: us-gaap_QuarterlyFinancialInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheet (Parenthetical) (USD $)

Jun. 30, 2014

Dec. 31, 2013

SHAREHOLDERS' EQUITY

Preferred stock, par value $ 0.10 $ 0.10

Preferred stock shares authorized 5,000,000 5,000,000

Preferred stock shares issued 0 0

Preferred stock shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock shares authorized 200,000,000 200,000,000

Common stock shares issued 65,965,728 60,299,061

Common stock shares outstanding 65,965,728 60,299,061

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2014

Aug. 12, 2014

Document And Entity Information

Entity Registrant Name Sunshine Biopharma, Inc

Entity Central Index Key 0001402328

Document Type 10-Q

Document Period End Date Jun. 30, 2014

Amendment Flag false

Current Fiscal Year End Date --12-31

Is Entity a Well-known Seasoned Issuer? No

Is Entity a Voluntary Filer? No

Is Entity's Reporting Status Current? Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 68,270,961

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2014

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: SBFM_DocumentAndEntityInformationAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Unaudited Statement Of Operations (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Income Statement [Abstract]

Revenue: $ 0 $ 0 $ 0 $ 0

General & Administrative Expenses

Accounting 32,020 1,620 37,200 5,400

Financial Consulting 60,000 64,500 326,000 684,610

Legal 169,405 75,000 214,777 24,689

Licenses & fees 70,000 5,655 153,333 325,000

Office 7,983 5,665 12,889 8,279

Merger costs 0 0 0 0

Public Relations 100,000 0 100,000 0

Research and Development 323,000 0 323,000 23,400

Stock Transfer Fee 3,105 153 4,188 1,606

Writedown of intangible assets 0 0 0 0

Total G & A 765,513 152,593 1,171,387 1,072,984

(Loss) from operations (765,513) (152,593) (1,171,387) (1,072,984)

Other (expense):

Interest expense (52,875) (375) (148,257) (5,705)

Beneficial conversion feature 0 0 0 (548,951)

Total Other (Expense) (52,875) (375) (148,257) (554,656)

Net (Loss) $ (818,388) $ (152,968) $ (1,319,644) $ (1,627,640)

Basic (Loss) per common share $ (0.01) $ 0.00 $ (0.02) $ (0.03)

Weighted Average Common Shares Oustanding 65,468,255 56,564,063 63,309,853 54,248,411

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: SBFM_FinancialConsulting

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Custom Element.

+ References

No definition available.

+ Details

Name: SBFM_Office

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_GeneralAndAdministrativeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The total expense recognized in the period for promotion, public relations, and brand or product advertising.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_MarketingAndAdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.

+ References

No definition available.

+ Details

Name: us-gaap_ProfessionalAndContractServicesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

3. Notes Payable (Details Narrative) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Notes to Financial Statements

Interest accrued $ 5,898 $ 2,641

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_InterestAccrued

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: SBFM_NotesToFinancialStatementsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

6. Financial Statements
6 Months Ended

Jun. 30, 2014

Notes to Financial Statements

6. Financial Statements
For a complete set of footnotes, reference is made to the Company’s Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission and the audited financial statements included therein.

X

- Details

Name: SBFM_NotesToFinancialStatementsAbstract

Namespace Prefix: SBFM_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for condensed financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 10

-Paragraph f

-Article 3

+ Details

Name: us-gaap_CondensedFinancialStatementsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

4. Issuance of Common Stock (Details Narrative) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Issuance of Common Stock

Shares issued 5,666,667

Par value of common stock $ 0.001 $ 0.001

X

- Details

Name: us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 31 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Unaudited Statement Of Cash Flows (USD $)
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Cash Flows From Operating Activities:

Net (Loss) $ (1,319,644) $ (1,627,640)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock issued for licenses, services, and other assets 860,800 636,310

Stock issued for payment interest on notes payable 75,000 5,086

Stock issued for payment of expenses 43,333 0

Beneficial conversion feature on note conversion 0 548,951

(Increase) Decrease in prepaid expenses (5,640) (2,030)

Increase (decrease) in accounts payable 70,065 (302)

Increase in interest payable 3,257 619

Net Cash Flows (used) in operations (272,829) (439,006)

Cash Flows From Investing Activities:

Net Cash Flows (used) in Investing activities 0 0

Cash Flows From Financing Activities:

Proceed from note payable 160,000 463,000

Note payable used to pay expenses 60,000 0

Note payable used to pay origionation fees 50,000 0

Sale of common stock 10,000 0

Net Cash Flows provided by financing activities 280,000 463,000

Net Increase (Decrease) In Cash and cash equivalents 7,171 23,994

Cash and cash equivalents at beginning of period 31,240 132,638

Cash and cash equivalents at end of period 38,411 156,632

Supplementary Disclosure Of Cash Flow Information:

Stock issued for services, licenses and other assets 593,400 576,310

Stock issued for note conversions 0 513,000

Stock issued for net deficit of MWBS 0 0

Stock issued for interest 170,000 0

Stock issued for payment of expenses 43,333 0

Loan proceeds used to pay expenses 40,000 0

Cash paid for interest $ 0 $ 0

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_LoanProceedsUsedToPayExpenses

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_NotePayableUsedToPayExpenses

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_NotePayableUsedToPayOrigionationFees

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_StockIssuedForInterest

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_StockIssuedForPaymentOfExpenses

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: SBFM_StockIssuedForPaymentOfExpenses1

Namespace Prefix: SBFM_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The gross value of stock issued during the period upon the conversion of convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

5. Convertible Notes
6 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

5. Convertible Notes
March 27, 2014 the Company issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $100,000 plus 500,000 Common shares (paid) and $20,000 (unpaid) for origination fee. This Convertible Note accrues interest at the rate of 10% per annum and is convertible at the option of the Holder into shares of the Company’s Common Stock at $0.20 per share on or before September 27, 2014. Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon Conversion, the stock may be valued at either the book value or the market value of the bonds.

May 7, 2014 the Company issued a Convertible Note to one accredited investor (as that term is defined under the Securities Act of 1933, as amended) in the aggregate amount of $500,000. The note proceeds are payable on an as needed basis. During the quarter ended June 30, 2014 $100,000 was disbursed. This Convertible Note accrues interest at the rate of 10% per annum beginning in three months from the date issued and is convertible at the option of the Holder into shares of the Company’s Common Stock at $0.20 per share on or before September 27, 2014.

Since the Note was issued at a premium no value is apportioned to the conversion feature when recording the issue per ASC 470-20-05. The debt and its interest are reported as if it were a nonconvertible debt. Upon Conversion, the stock may be valued at either the book value or the market value of the bonds.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for short-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Article 9

+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 9 85 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://sunshinebiopharma.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 00000002 - Statement - Balance Sheet (Unaudited) Sheet http://sunshinebiopharma.com/role/BalanceSheet Balance Sheet (Unaudited) false false R3.htm 00000003 - Statement - Balance Sheet (Parenthetical) Sheet http://sunshinebiopharma.com/role/BalanceSheetParenthetical Balance Sheet (Parenthetical) false false R4.htm 00000004 - Statement - Unaudited Statement Of Operations Sheet http://sunshinebiopharma.com/role/UnauditedStatementOfOperations Unaudited Statement Of Operations false false R5.htm 00000005 - Statement - Unaudited Statement Of Cash Flows Sheet http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows Unaudited Statement Of Cash Flows false false R6.htm 00000006 - Disclosure - 1. Nature of Operations/Activities Sheet http://sunshinebiopharma.com/role/NatureOfOperationsactivities 1. Nature of Operations/Activities false false R7.htm 00000007 - Disclosure - 2. Unaudited Financial Information Sheet http://sunshinebiopharma.com/role/UnauditedFinancialInformation 2. Unaudited Financial Information false false R8.htm 00000008 - Disclosure - 3. Notes Payable Notes http://sunshinebiopharma.com/role/NotesPayable 3. Notes Payable false false R9.htm 00000009 - Disclosure - 4. Issuance of Common Stock Sheet http://sunshinebiopharma.com/role/IssuanceOfCommonStock 4. Issuance of Common Stock false false R10.htm 00000010 - Disclosure - 5. Convertible Notes Notes http://sunshinebiopharma.com/role/ConvertibleNotes 5. Convertible Notes false false R11.htm 00000011 - Disclosure - 6. Financial Statements Sheet http://sunshinebiopharma.com/role/FinancialStatements 6. Financial Statements false false R12.htm 00000012 - Disclosure - 3. Notes Payable (Details Narrative) Notes http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative 3. Notes Payable (Details Narrative) false false R13.htm 00000013 - Disclosure - 4. Issuance of Common Stock (Details Narrative) Sheet http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative 4. Issuance of Common Stock (Details Narrative) false false All Reports Book All Reports Process Flow-Through: 00000002 - Statement - Balance Sheet (Unaudited) Process Flow-Through: 00000003 - Statement - Balance Sheet (Parenthetical) Process Flow-Through: 00000004 - Statement - Unaudited Statement Of Operations Process Flow-Through: 00000005 - Statement - Unaudited Statement Of Cash Flows sbfm-20140630.xml sbfm-20140630.xsd sbfm-20140630_cal.xml sbfm-20140630_def.xml sbfm-20140630_lab.xml sbfm-20140630_pre.xml true true

3. Notes Payable	6 Months Ended
3. Notes Payable	Jun. 30, 2014
Notes to Financial Statements
3. Notes Payable	The Company had outstanding loans of $12,500 accruing interest at a rate of 12% and $100,000 accruing interest at 10%. At June 30, 2014 and December 31, 2013 accrued interest was $5,898 and $2,641, respectively.

Balance Sheet (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 38,411	$ 31,240
Prepaid expenses	5,640	0
Total Current Assets	44,051	31,240
TOTAL ASSETS	44,051	31,240
Current Liabilities:
Current portion of note payable	282,500	12,500
Accounts payable	93,874	23,809
Interest payable	5,898	2,641
TOTAL LIABILITIES	382,272	38,950
SHAREHOLDERS' EQUITY
Preferred stock, $0.10 par value per share; Authorized 5,000,000 Shares; Issued and outstanding -0- shares	0	0
Common Stock, $0.001 per share; Authorized 200,000,000 Shares; Issued and outstanding 65,965,728 and 60,299,061 at June 30, 2014 and December 31, 2013 respectively	65,966	60,299
Capital paid in excess of par value	6,409,606	5,426,140
Accumulated other comprehensive (Loss)	0	0
(Deficit) accumulated during the development stage	(6,813,793)	(5,494,149)
TOTAL SHAREHOLDERS' EQUITY	(338,221)	(7,710)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 44,051	$ 31,240

Balance Sheet (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
SHAREHOLDERS' EQUITY
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	65,965,728	60,299,061
Common stock shares outstanding	65,965,728	60,299,061

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Aug. 12, 2014
Document And Entity Information
Entity Registrant Name	Sunshine Biopharma, Inc
Entity Central Index Key	0001402328
Document Type	10-Q
Document Period End Date	Jun. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		68,270,961
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2014

Unaudited Statement Of Operations (USD $)	3 Months Ended		6 Months Ended
Unaudited Statement Of Operations (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]
Revenue:	$ 0	$ 0	$ 0	$ 0
General & Administrative Expenses
Accounting	32,020	1,620	37,200	5,400
Financial Consulting	60,000	64,500	326,000	684,610
Legal	169,405	75,000	214,777	24,689
Licenses & fees	70,000	5,655	153,333	325,000
Office	7,983	5,665	12,889	8,279
Merger costs	0	0	0	0
Public Relations	100,000	0	100,000	0
Research and Development	323,000	0	323,000	23,400
Stock Transfer Fee	3,105	153	4,188	1,606
Writedown of intangible assets	0	0	0	0
Total G & A	765,513	152,593	1,171,387	1,072,984
(Loss) from operations	(765,513)	(152,593)	(1,171,387)	(1,072,984)
Other (expense):
Interest expense	(52,875)	(375)	(148,257)	(5,705)
Beneficial conversion feature	0	0	0	(548,951)
Total Other (Expense)	(52,875)	(375)	(148,257)	(554,656)
Net (Loss)	$ (818,388)	$ (152,968)	$ (1,319,644)	$ (1,627,640)
Basic (Loss) per common share	$ (0.01)	$ 0.00	$ (0.02)	$ (0.03)
Weighted Average Common Shares Oustanding	65,468,255	56,564,063	63,309,853	54,248,411

3. Notes Payable (Details Narrative) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Notes to Financial Statements
Interest accrued	$ 5,898	$ 2,641

6. Financial Statements	6 Months Ended
6. Financial Statements	Jun. 30, 2014
Notes to Financial Statements
6. Financial Statements	For a complete set of footnotes, reference is made to the Company’s Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission and the audited financial statements included therein.

4. Issuance of Common Stock (Details Narrative) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Issuance of Common Stock
Shares issued	5,666,667
Par value of common stock	$ 0.001	$ 0.001

Unaudited Statement Of Cash Flows (USD $)	6 Months Ended
Unaudited Statement Of Cash Flows (USD $)	Jun. 30, 2014	Jun. 30, 2013
Cash Flows From Operating Activities:
Net (Loss)	$ (1,319,644)	$ (1,627,640)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock issued for licenses, services, and other assets	860,800	636,310
Stock issued for payment interest on notes payable	75,000	5,086
Stock issued for payment of expenses	43,333	0
Beneficial conversion feature on note conversion	0	548,951
(Increase) Decrease in prepaid expenses	(5,640)	(2,030)
Increase (decrease) in accounts payable	70,065	(302)
Increase in interest payable	3,257	619
Net Cash Flows (used) in operations	(272,829)	(439,006)
Cash Flows From Investing Activities:
Net Cash Flows (used) in Investing activities	0	0
Cash Flows From Financing Activities:
Proceed from note payable	160,000	463,000
Note payable used to pay expenses	60,000	0
Note payable used to pay origionation fees	50,000	0
Sale of common stock	10,000	0
Net Cash Flows provided by financing activities	280,000	463,000
Net Increase (Decrease) In Cash and cash equivalents	7,171	23,994
Cash and cash equivalents at beginning of period	31,240	132,638
Cash and cash equivalents at end of period	38,411	156,632
Supplementary Disclosure Of Cash Flow Information:
Stock issued for services, licenses and other assets	593,400	576,310
Stock issued for note conversions	0	513,000
Stock issued for net deficit of MWBS	0	0
Stock issued for interest	170,000	0
Stock issued for payment of expenses	43,333	0
Loan proceeds used to pay expenses	40,000	0
Cash paid for interest	$ 0	$ 0